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STELLINGEN 
1. Celcultures geïsoleerd uit slachtmateriaal van grote landbouwhuisdieren kunnen 
een belangrijke bijdrage leveren aan het verkrijgen van essentieel inzicht in de 
aard en eigenschappen van voor de consument relevante metabolieten van 
diergeneesmiddelen. 
-dit proefschrift 
Bij het vaststellen van residutoleranties voor sulfonamides moet worden uitgegaan 
van de som van de moederstof en de N"-acetyl-metaboliet. 
-Vree et al. (1985) in Antibiotics and chemotherapy, pharmacokinetics of sulfonamides 
revisited, eds Schonfeld & Hahn, Karger, Basel, pp 5-65 
-dit proefschrift 
3. Er zijn sterke aanwijzingen dat de bijwerkingen van nitrofuranen bij zowel mens als 
dier grotendeels veroorzaakt worden door de remming van het enzymcomplex 
pyruvaat dehydrogenase. 
-Martindale, The extra pharmacopoeia (1982), The pharmaceutical press, London 
-Staley et al. (1978), Am. J. Path. 91: 531-541 
-dit proefschrift 
4. Eiwitgebonden residuen van diergeneesmiddelen kunnen niet per definitie als 
onschadelijk worden beschouwd, aangezien ook hier het venijn in de staart kan 
zitten. 
-dit proefschrift 
5. Er is onvoldoende bewijs voor de genotoxiciteit van furazolidon bij zoogdiercellen. 
-IARC monographs (1983) vol 31, pp 141-151 
6. Bij de ontwikkeling en toepassing van analysemethoden gebaseerd op immuno-
chemische technieken, kan inzicht in de biotransformatie van stoffen in belangrijke 
mate bijdragen aan het voorkomen van zowel vals-positieve als vals-negatieve 
resultaten. 
In hun onderzoek naar het lot van bolestatine, een toxine afkomstig uit de 
satansboleet (Boletus Satanas), leveren Kretz et al. onvoldoende bewijs voor de 
absorptie van het intakte eiwit in het maagdarmkanaal. 
-Kretz et al. (1991), Xenobiotica 21: 65-73 
8. Het toelatingsbeleid van pesticiden wordt door Ames et al. ten onrechte 
gebagatelliseerd. 
-Ames et al. (1990), Proc. Natl. Acad. Sei. 87: 7777-7781 
9. Bij het vaststellen van normen voor nitraat in bladgroenten moet niet worden 
uitgegaan van het N.E.L./A.D.I. principe, maar van streefwaarden die gebaseerd 
zijn op natuurlijke achtergrondswaarden. 
10. Zolang het gebruik van kunstmest in de landbouw niet afneemt, blijven alle 
pogingen om de schade aan het milieu als gevolg van het uitrijden van mest te 
verminderen, ongeloofwaardig. 
11. De rustgevende eigenschappen van waterbedden worden veelal teniet gedaan door 
het sterk opgedreven stroomverbruik. 
-Consumentengids, januari 1991 
12. ATB (All Terrain Bike) fietsers op bospaden bedreigen vooral de rust van de 
loslopende hond en zijn baas, en beschermen daardoor indirect die van het wild. 
Stellingen behorend bij het proefschrift: The use of pig hepatocytes for biotransformation 
and toxicity studies 
Laurentius A.P. Hoogenboom, 10 april 1991 
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VOORWOORD 
Zo, dit varkentje is gewassen en middels dit voorwoord wil ik nog even terugkijken 
op de wijze waarop dit is gebeurd. Daarbij wil ik de stelling verdedigen dat promoveren 
is als het met de fiets beklimmen van bergpassen. 
Wanneer je voor de eerste keer aan zo'n beklimming begint, weet je niet goed 
waaraan je begint. Je gaat af op verhalen van anderen en je wilt de uitdaging graag 
aannemen. Je weet nog niet veel over het te gebruiken verzet, laat staan over het aan 
te houden tempo. Voordat je op weg gaat verzorg je je fiets, bestudeer je het bergpro-
fiel en maak je een plan over de wijze waarop je je krachten denkt te verdelen. Je 
kiest voor jezelf een aantal mijlpalen uit, aan de hand waarvan je je gemaakte 
vorderingen wilt afmeten. Vervolgens ga je rustig aan de slag en al trappend leg je de 
eerste meters af. Na wat startproblemen gaat het steeds beter; je zit in het ritme en 
hebt dan nog alle tijd. Gaandeweg komen de eerste moeilijkheden die je nog vrij 
eenvoudig weet op te lossen, vooral als je daarbij ondersteund wordt door anderen. 
Bovendien bereik je je mijlpalen, hetgeen je motiveert om door te gaan, zeker wanneer 
je ook nog wordt aangemoedigd door andere fietsers of eventuele voorbijgangers. 
Wanneer je echter zo vlak onder de top zit, nemen de problemen toe, je komt er wat 
door te zitten. Hoe laag of hoe hoog die berg ook is, die laatste meters zijn altijd weer 
zwaar en soms vraag je je dan wel eens af waarvoor je het allemaal doet. De 
vermoeidheid is echter snel vergeten wanneer je de laatste bocht omgaat en sprintend 
het hoogste punt bereikt. En dan, onder het genot van een drankje, lijkt het al snel 
alsof het toch allemaal erg eenvoudig was en besef je dat het de moeite waard was. 
Promoveren doe je niet alleen. Daarom wil ik hierbij eenieder bedanken die op 
enigerlei wijze heeft bijgedragen aan het tot stand komen van dit proefschrift. Allereerst 
zijn dat mijn ouders die mij hebben leren fietsen en nog steeds mijn trouwste 
supporters zijn. Harry Kuiper, Louis Vroomen en het RIKILT wil ik bedanken voor de 
hulp bij het uitkiezen van een voor mij interessante bergpas en het aanleveren van het 
benodigde materiaal. Margot Huveneers-Oorsprong, Marcel Berghmans, Melle van 
Kammen en Saskia Hesse wil ik bedanken voor hun deelname in het avontuur en de 
benodigde ondersteuning. Francis Pastoor, Weimoed Clous, Antoinette van Milaan, 
Trinette van Vliet en Oreana Tomassini wil ik bedanken voor hun bijdrage aan 
bepaalde deelaspecten van het hier gepresenteerde onderzoek. Evenals Ton Ermens, 
Marcel Mengelers, Monique Ploum, Sjoerdje de Boer, Maryvon Noordam, Folke 
Dorgelo, Maike te Riele, Paulien Oosterveld, Stefania Olmo, Nicoline Fransen, Gijs 
Kleter, Olga Melis en Gera Marsman wil ik hen ook bedanken voor hun bijdrage aan 
de prettige sfeer binnen de afdeling. Francis, jouw taart staat mij nog vers in het 
geheugen. 
Bep van Veldhuizen, Bas Blaauboer, Wim Traag, Henk Keukens, Theo Polman, 
Robert Schilt, Piet Berende, Carel Funke, Walter Hazeleger en de werknemers van 
slachterij Hallers & Zonen te Ede wil ik bedanken voor de door hun ingebrachte 
deskundigheid. Professor Koeman wil ik bedanken voor zijn hulp bij het afleggen van 
de laatste meters, zowel de meters vlak voor het bereiken van de mijlpalen, de publica-
ties, als die vlak voor de top, het uiteindelijke proefschrift. Ik denk dat het verhaal 
daardoor een stuk boeiender is geworden. Tenslotte wil ik nog even stil staan bij de 
bijdrage van die mensen, die zo vaak op de achtergrond blijven maar die achter de 
schermen zorgen voor het reilen en zeilen van het instituut. Zonder een goede 
infrastructuur valt er nou eenmaal weinig te fietsen. 
Karin, jou wil ik speciaal bedanken voor het begrip en het geduld dat je steeds weer 
weet op te brengen voor mijn hobbies. Zonder jouw actieve deelname en hulp zouden 
er na de laatste bocht nog vele laatste bochten gevolgd zijn. Zo, nu voorzichtig afdalen 
en op naar de volgende berg. 
CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
The intensification in the breeding of food-producing animals during the last decades, 
has been accompanied by an increased use of veterinary drugs and growth-promoting 
agents. However, treatment of animals with drugs may result in residues of both the 
parent compound and its metabolites in edible products, which may imply a possible 
health risk for the consumer. Therefore, it is essential to obtain accurate information 
not only on the toxic properties of a drug, but also on its biotransformation, especially 
since there are numerous examples where metabolites have been shown to be 
responsible for the adverse effects of a compound. Since the kind of metabolites are 
often specific for a certain animal species, such information should preferentially be 
obtained from studies with target animals. However, experiments with large domestic 
animals are in general difficult to perform for reasons of costs, duration, housing 
facilities, and ethics, especially when the use of radiolabelled compounds is required in 
order to obtain the relevant information. In vitro models with hepatocytes isolated from 
livers of food-producing animals may offer a good alternative for at least part of the 
animal studies. 
In vitro models with isolated hepatocytes 
In recent years, there has been a large increase in the development and use of in 
vitro models, not only because of the demand of animal well-fare groups to reduce the 
use of laboratory animals, but also because of a number of scientific and financial 
advantages. This has e.g. resulted in the development of a large number of cell-lines, 
which can be used in short-term tests for screening compounds on their cytotoxic and 
especially genotoxic properties. A major disadvantage of these cell-lines is however the 
very limited biotransformation potential, and as a result the insensitivity of the cells for 
compounds that need to be activated in order to exert their toxic action. A possible 
though limited solution for this problem is the inclusion of liver homogenates and the 
required cofactors in the tests. 
For studying the biotransformation of compounds, purified enzymes and isolated 
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fractions of liver cells, like microsomes, used to be the preferred in vitro model. 
However, the disruption of the cellular structure has been shown to seriously limit the 
value of the results with respect to the in vivo situation. As pointed out below, this may 
explain the popularity of primary cultures of hepatocytes, especially since the techniques 
for their successful isolation have become available. 
Most methods used for the isolation of viable cultures of hepatocytes are based on 
the work by Howard et al. (1967), who used an enzymatic treatment of liver slices for 
the dispersion of the cells. The efficiency of the method has subsequently been 
improved by the introduction of an in situ perfusion, that is commonly used in the case 
of small laboratory animals (Berry & Friend 1969), and the perfusion of the liver with 
a buffer containing a Ca2+-chelator, like EGTA, prior to the enzymatic treatment with 
collagenase (Seglen 1976). More recently, these methods were adapted for the isolation 
of hepatocytes from liver samples obtained from larger animal species, including man 
(Reese & Byard 1981, Strom et al. 1982, Guillouzo et al. 1985). 
Advantages and disadvantages of hepatocyte cultures 
The applicability of hepatocytes for various uses has been reviewed by Fry & Bridges 
(1979), Moldéus et al. (1983), Guillouzo (1986) and Chenery (1988). In general they 
come to the major conclusions regarding the advantages and disadvantages of the 
model: 
-An important advantage of freshly isolated hepatocytes in comparison with cellular 
fractions like microsomes, is the presence of a complete set of biotransformation 
enzymes in the original cellular configuration. As a result compounds may be 
transformed by a number of subsequent metabolic steps, very sSimilar to in vivo. In 
addition, the use of expensive cofactors is superfluous, due to the intact metabolic 
functioning of the cells. 
-The intact cellular structure offers the opportunity to use hepatocytes for studying 
(toxic) effects of compounds on the functioning and viability of the cells, possibly in 
relation to the biotransformation of a compound. 
-An important advantage of hepatocytes both over the intact animal, and perfused 
organ, is that cells isolated from one liver or liver sample can be divided over a large 
number of experimental units. This is very useful for studying e.g. dose- and time-
relationships in the biotransformation or toxic effects of a compound, or for comparing 
the effects of different compounds, or for studying the interactions between a number 
of compounds. The fact that the model is easy to handle and small in volume, makes 
it very suitable for the use of radiolabelled or rare and expensive compounds. 
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-One of the major problems encountered with rat hepatocytes,' is the fact that the 
prolonged use of monolayer cultures is limited by a change in the activity of certain 
biotransformation enzymes during the ageing of the cells (for review see Paine 1990). 
Initially, this was shown for the very important group of cytochrome P-450 related 
enzyme activities, which often decrease to about 50% within 24 h. However, subsequent 
studies also reported changes, both increases and decreases, for other enzymes and 
enzymatic activities (Grant et al 1985, Croci & Williams 1985, Grant & Hawksworth 
1986, Vandenberghe 1988). Furthermore, the problem is not restricted to hepatocytes 
from rats, although in the case of human hepatocytes, the decrease in cytochrome P-450 
levels appears to be much slower (Guillouzo et al 1985, Mennes et al 1988). 
A possible solution for this problem, appeared to be the inclusion of certain 
hormones in the medium (Decad et al. 1977). Similar results were obtained by using 
medium containing nicotinamide or metyrapone, or medium free of cystine and cysteine, 
but supplemented with aminoleavulinic acid (Paine 1990). However, the application of 
such media has been a limited success since the apparently stable levels of cytochrome 
P-450 were accompanied by a selective change in the pattern of the different 
isoenzymes. A more promising approach appears to be the long-term cocultivation of 
hepatocytes with a rat epithelial cell-line, resulting in steady state levels of cytochrome 
P-450 after an initial decline (Bégué et al. 1984, Guillouzo 1986). However, the results 
of a recent study by Rogiers et al (1990), indicate that this technique does not offer 
a satisfying solution for the selective shift in the cytochrome P-450 isoenzyme patterns. 
Although this feature seriously limits the prolonged use of hepatocytes, it should be 
reminded that in general, a decline in enzyme activities will have consequences for the 
rate of conversion of a compound, but does not necessarily have to result in a change 
in metabolite patterns. 
-Due to the complexity of the hepatocyte model, cellular fractions are sometimes 
more suitable for studying a specific biotransformation step or for the detection of 
reactive intermediates. In addition, often larger quantities of a specific metabolite can 
be prepared, due to the possibility to speed up the rate of conversion by using high 
levels of not only the cofactors, but also the compound under investigation, levels that 
may be cytotoxic for intact cells. 
Toxicity end-points in hepatocyte cultures 
For studying the toxicity of compounds, a wide variety of end-points can be chosen, 
since in theory each function of the liver cell can be monitored like genetic 
mechanisms, morphological changes, metabolic functions, intracellular communication 
but also the wide variety of different enzymes involved in the biotransformation. 
However, a few end-points have gained a more general popularity. 
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Viable hepatocytes have been shown to contain enzymes capable of recognizing and 
removing adducts between xenobiotics and DNA. This so-called DNA-repair 
mechanism, has been used to develop a test for the screening of xenobiotics on their 
genotoxic properties (Williams 1977, Probst et al. 1981, Williams et al. 1989). 
A large number of so-called cytotoxicity tests has been developed to detect damage 
indicative of the death of the cells. Many references can be cited, using the leakage of 
the cytosolic enzyme lactate dehydrogenase (LDH) into the culture medium, a 
parameter that has been shown to correlate very well with the diffusion of the dye 
trypan-blue into cells with a damaged membrane (Jauregui et al. 1981). More recently 
there has been a tendency to select end-points that are more suitable for large scale 
screening on cytotoxicity. This underlies the success of the so-called MTT- and NR-tests 
(Borenfreund et al. 1988), that were originally introduced for cell-lines and subsequently 
adapted for the use with hepatocytes. The MTT-test determines the reduction of a 
tetrazolium-salt by the mitochondrial enzyme succinate dehydrogenase, the NR-test on 
the uptake of the vital dye neutral red by the lysozymes in the cell. 
An effect that in many cases may precede the death of the cell is the depletion of 
intracellular glutathione (GSH). This tripeptide is present at high concentrations in the 
cell and is involved in the detoxification of both reactive intermediates of compounds, 
as well as hydrogen peroxide, formed in the detoxification of superoxide (Babson et al. 
1981, Reed & Farris 1984, Eklow-Lâstbom et al. 1986, Jones et al. 1986). Therefore a 
decrease in GSH-levels as a result of the exposure to a certain compound may either 
be an indication for the increased formation of reactive oxygen species (oxidative 
stress), or for the formation of metabolites with nucleophilic properties, which might 
result in their binding to DNA and/or proteins. 
The type of toxic effects that can be detected, may be specific to the liver 
(hepatotoxicity), but also be of a more general cytotoxic nature. In vivo, a specific 
organotoxic effect might be largely due to toxicokinetic parameters such as absorption, 
distribution, and excretion (Ekwall & Ekwall 1988). 
The use of hepatocytes to study species-differences 
Both quantitative and qualitative differences have been reported in the biotrans-
formation of xenobiotics by different animal species (Williams 1974, Kato 1979). Initi-
ally, indications for this phenomenon came primarily from toxicity studies with small 
laboratory animals, showing species-differences in the sensitivity towards the toxic effects 
of a compound. More recently, species related differences in the biotransformation of 
compounds were shown in studies with isolated cellular fractions from livers of different 
animal species, including farmanimals (Patterson & Roberts 1970, Souhaili-El-Amri et 
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al 1986, Watkins & Klaassen 1986, Dalvi et al. 1987, Short et al. 1988). The 
development of procedures for the isolation of hepatocytes from livers of different 
species, including man, allowed the use of this model for comparative studies on the 
species related biotransformation and toxicity of xenobiotics (Table 1.1.). 
In vivo studies have revealed a large difference between rats and mice in their 
sensitivity to the hepatotoxic and carcinogenic properties of aflatoxin Bl (Croy et al. 
1983). In vitro studies showed that rat hepatocytes were more sensitive than those from 
mice, as became apparent by the death of the cells at much lower concentrations, the 
much higher levels of binding of metabolites of aflatoxin Bl to TCA-precipitable cell-
material (Decad et al. 1979, Hanigan and Laishes 1984), and the much higher levels of 
unscheduled DNA-synthesis (Steinmetz et al. 1988). Furthermore, the mycotoxin caused 
segregation of nucleolar components in rat hepatocytes, but not in cells from mice 
(Cole et al. 1986). 
In the DNA-repair study by Steinmetz et al. (1988) both monkey and mouse 
hepatocytes gave negative test-results after exposure to 2-acetyl-aminofluorene and 
benzidine, in contrast to cells from rat, hamster and man. In the case of benzo(a)-
pyrene, cells from mouse, hamster and especially the rat were shown to be relatively 
insensitive in comparison to those from the cynamolgus monkey and man. The overall 
differences in the DNA-repair response to the various test compounds as observed in 
this study between cells from monkey and man, were consistent with those obtained by 
Neis et al. (1986), using hepatocytes as activating system in the Ames test. 
With a quite different set of end-points, Blaauboer et al (1990) demonstrated a 
marked species-difference in the effect of beclofibric and clofibric acid on peroxisomal 
ß-oxidation and peroxisome proliferation, effects that could only be observed in hepa-
tocyte cultures from the rat and not in those of cynamolgus monkey and man. 
Several research groups have demonstrated that species differences in the 
biotransformation of drugs with diverse but known in vivo metabolite patterns, could 
be reproduced with hepatocytes. Gee et al. (1984) reported a good correlation between 
the results from an in vitro study and the in vivo metabolism of tolbutamide. Rat 
hepatocytes showed the highest activity but were unable to transform the sulfonylurea 
side-chain, which was the most important step performed by dog hepatocytes. In studies 
with amphetamine (Green et al. 1986), rabbit hepatocytes were shown to be much more 
active than cells from the rat, dog, monkey and man, and primarily N-hydroxylated the 
compound, whereas for rat hepatocytes the hydroxylation of the aromatic ring appeared 
to be the more important step. N-demethylation of ketitofen was shown to be the 
major metabolic route for rat and rabbit hepatocytes, in the latter case followed by 
sulfatation (Le Bigot 1987). The end-products of these steps were only found in traces 
with human hepatocytes, where the N-glucuronide and reduced ketitofen were the 
major metabolites. A similar difference was observed with diazepam (Seddon et al. 
1989), where the 4-hydroxy metabolite was observed with hepatocytes from rats, but not 
with those from monkey, dog or man, where instead N-demethylation and, with the 
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Table 1.1 List of studies using hepatocytes of different animal species to compare the biotransformation 
and/or toxicity of compounds. 
Species used 
rat, mouse 
rat, mouse 
rat, mouse, 
man 
rat, mouse, 
hamster, guinea pig 
rat, mouse, 
hamster, guinea pig 
rat, mouse, 
hamster, rabbit 
rat, mouse, hamster 
monkey, man 
monkey, man 
rat, hamster, 
guinea pig 
rat, monkey, 
man 
rat, hamster, 
rabbit, dog 
rat, rabbit, dog, 
monkey, man 
rat, rabbit, 
dog, monkey 
rat, rabbit, 
man 
rat, rabbit, dog, 
guinea pig, man 
rat, dog, 
monkey, man 
rat, dog, 
monkey, man 
Effect studied 
biotransformation 
biotransformation, 
cytotoxicity 
toxicity 
Ames test, 
DNA-repair 
biotransformation 
DNA-repair 
DNA-repair 
Metabolic activation 
Ames test 
Metabolic activation 
Ames test 
peroxisome 
proliferation 
cytotoxicity, 
biotransformation 
biotransformation 
biotransformation 
biotransformation 
biotransformation 
biotransformation 
biotransformation 
Compounds used 
aflatoxin Bl 
aflatoxin 61 
aflatoxin Bl 
2-(acetyl)-amino-
fluorene 
2-acetyl-aminofluorene 
various compounds 
various compounds 
various compounds 
benzidine, 
4-amino-biphenyl 
(be)clofibric acid 
acetaminophen 
amphetamine 
tolbutamide 
ketitofen 
diazepam 
diazepam 
temelastine 
Reference 
Decad et al 
1979 
Hanigan & 
Laishes 1984 
Cole et al 
1986 
Holme & 
S0derlund 1985 
Holme et al 
1986 
McQueen & 
Williams 1987 
Steinmetz et al 
1988 
Neis et al 
1986 
Neis et al 
1984 
Blaauboer et al 
1990 
Green et al 
1984 
Green et al. 
1986 
Gee et al 
1984 
Le Bigot et al 
1987 
Chenery et al 
1987 
Seddon et al 
1989 
Oldham et al 
1990 
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exception of the dog, 3-hydroxylation were the important steps. 
The major conclusion that can be drawn from these and other comparative studies 
listed in Table 1.1, is that in general no two animal species appear to be comparable 
in the biotransformation and sensitivity towards a toxic effect of a compound. 
Therefore, extrapolation of data obtained with cellular fractions, hepatocytes or intact 
animals from one species to another species is not possible, and stresses the need for 
the use of target-animals for risk-assessment purposes. 
Isolation and use of hepatocytes from large domestic animals 
The possible isolation and use of hepatocytes from large domestic animals has been 
subject of a number of studies. Suspension cultures of hepatocytes, isolated from liver 
samples of sheep (Démigne et al. 1986, Chow et al. 1990), goats (Aiello & Armentano 
1987a, 1987b, Aiello et al. 1989), and cows (Aiello et al. 1989), were e.g. used to study 
the gluconeogenesis from propionate and butyrate, a process that is relatively specific 
for ruminants. Monolayer cultures of pig hepatocytes, isolated by an in situ perfusion 
from livers of neonatal animals, were used to study the catabolism of lipoproteins 
(Pangburn et al. 1981, Bachorik et al. 1982), regarding the good similarity between pigs 
and men with respect to the importance of the LDL particle. In the same field of 
interest, Kwekkeboom et al. (1988, 1989) used monolayer cultures of pig hepatocytes, 
isolated from liver samples of young animals (up to 7 weeks), to investigate the 
feedback regulation of bile acid synthesis, being an important factor in the elimination 
of cholesterol from the body. Finally, suspension cultures of hepatocytes, isolated by an 
in situ perfusion from 2-15 days old piglets were used by Pegorier et al. (1982), to study 
the effects of fasting on the gluconeogenesis. 
Only recently, investigators have become aware of the opportunities to use hepato-
cytes from large domestic animals for studying the possibly species-specific biotrans-
formation and toxicity of compounds used in veterinary practice. Suolinna & Winberg 
(1985) studied the deethylation of 7-ethoxycoumarin and the conjugation of methyl-
umbelliferone by suspension cultures of bovine hepatocytes, isolated from liver samples 
obtained at the slaughterhouse from fetal or adult (1.5-2 years) animals. Shull et al. 
(1986), introduced the surgical removal of the caudate lobe of the bovine liver, and its 
subsequent use for the isolation of hepatocytes. Subsequently the biotransformation of 
7-ethoxycoumarin and the pesticide aldrin was studied in monolayer cultures. Mennes 
et al. (1988) included sheep hepatocytes in a study with rat, hamster, dog, monkey and 
human hepatocytes, in order to compare the decline of cytochrome P-450 levels in 
monolayer cultures. Recently Pool et al. (1990) used suspension cultures of pig hepato-
cytes obtained from 12 months old animals, to study the effect of a number of nitros-
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amines on the frequency of single strand breaks in the DNA. 
These studies clearly show that it is possible to isolate viable hepatocytes from large 
domestic animals. However, the possible use of these cells for biotransformation and 
toxicity studies of compounds used in veterinary practice, has not been thoroughly 
investigated. 
Scope of the study 
The main aim of the present study was to develop a method for the isolation of 
viable hepatocytes from liver samples of adult pigs, secondly, to investigate whether 
these cells can be used for biotransformation and toxicity studies, and thirdly, to 
demonstrate the value of the model, more in particular for studies on the identity and 
properties of metabolites of veterinary drugs, that might be present as residues in 
edible products. The opportunities of the model for studying the mechanisms under-
lying adverse effects in target-animals was therefore beyond the scope of this study. 
The procedure for the isolation of pig hepatocytes (Chapter 2), as well as the use 
of the cells for biotransformation (Chapters 3, 4) and toxicity studies (Chapter 5) was 
investigated in the first part of the study. For this purpose, the antibacterial drugs 
sulfadimidine and a number of nitrofurans, as well as the steroid hormone ß-nortesto-
sterone were used as model compounds. 
In the second part (Chapters 6, 7, 8), the identity and properties of metabolites of 
furazolidone were studied in more detail, as a follow-up of the studies performed in our 
laboratory by Dr Vroomen (1987). Previous in vivo studies with "C-labelled furazolid-
one, revealed that this drug is extensively biotransformed in the pig, partly resulting in 
the presence of unextractable radiolabelled compounds in the protein fraction. 
Regarding the persistence of this, possibly drug-like, material, as compared to the 
parent compound and other metabolites, special attention was paid to the identity and 
possible toxic properties of these type of metabolites. The issue of bound-residues of 
furazolidone and other drugs has since long been one of most controversial and difficult 
problems in the field of residue toxicology. 
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ISOLATION AND CULTURING OF PIG HEPATOCYTES 
Materials and Methods 
Introduction 
Hepatocytes were isolated from a piece of pig liver based on a method described 
by Seglen (1976) for the isolation of rat hepatocytes, modified for liver biopsies as 
described by Strom et al. (1982). Cells are dispersed by the subsequent treatment with 
the Ca2+-chelator EGTA and the bacterial enzyme collagenase, and purified by filtration 
and centrifugation. This chapter describes in more detail the methods used for the 
isolation, culturing and use of the cells, as well as some of our experiences with the 
methods, that might be of use to other research groups. 
Materials and methods 
Chemicals 
Williams' medium E powder, Hanks' balanced salts (HBS), fetal calf serum (FCS), 
penicillin/streptomycin, Trypan Blue solution (0.4%), and HEPES buffer were purchased 
from Flow Laboratories (Rickmansworth, U.K.), bovine insulin, bovine serum albumin 
(RIA-grade) and collagenase types I and IV from Sigma (St.Louis, U.S.A.), collagenase 
type H from Boehringer (Mannheim, F.R.G.), phenol red from Serva (Heidelberg, 
F.R.G.), and NaCl, KCl, NaOH, CaCl2.2H20, NaHC03 and EGTA from Merck 
(Darmstadt, F.R.G.). Water was purified using a water purification system (Millipore 
Q UF, Etten-Leur, The Netherlands). Tissue culture dishes were obtained from Costar 
(Badhoevedorp, The Netherlands). An oxygenator as described by Moldéus et al. (1978) 
was made at the RIKILT by M.L. Karruppannan. 
Animals 
Livers were obtained from sows, both non-pregnant and pregnant (3-12 days), and 
castrated males (Dutch Landrace x Yorkshire), with an age varying between 5 and 15 
25 
months. Animals were kept at the Department of Animal Husbandry of the Agricultural 
University in Wageningen, and had not been treated recently with veterinary drugs. 
Preparation 
Buffer solutions and media were in general prepared one or two days before the 
perfusion. For the isolation of the cells five HEPES buffered solutions were prepared. 
Buffer I contained 8.3 g NaCl, 0.5 g KCl, 2.4 g HEPES and 0.19 g EGTA per litre, 
Buffer II 8.3 g NaCl, 0.5 g KCl and 2.4 g HEPES per litre, buffer III 3.9 g NaCl, 0.5 
g KCl, 24.0 g HEPES and 0.7 g CaCl2.2H20 per litre, buffer IV 2 g BSA, 9.91 g HBSS 
and 2.4 g HEPES per litre and buffer V 9.91 g HBSS and 4.8 g HEPES. All buffers 
were brought with 5 N NaOH to pH 7.65 (at room-temperature), sterilized by filtration 
over a 0.2 iiM Sterivex filter (Millipore) and stored at 4 °C. Occasionally, buffers were 
enriched with 10 mg phenol red per litre. A sixth solution containing 9 g NaCl per litre, 
was autoclaved at 120 °C for 20 min. All glassware and steel equipment was sterilized 
at 180 °C for 4 h, plastic material was autoclaved at 120 CC for 20 min. 
A solution of collagenase in buffer III was prepared 2 h before the perfusion (200 
mg/100 ml), filtersterilized (0.45 /xM), stored at 4 °C and diluted with 300 ml 
prewarmed buffer III shortly before use. Buffers I and II were preincubated for 2 h at 
40 °C. 
Isolation and purification of hepatocytes 
Pigs were transported to a slaughterhouse in the town of Ede and killed by 
electrocution followed by exsanguination. Subsequently a caudal lobe of the liver was 
obtained (about 150 g) and washed with 0.5 litre of icy-cold NaCl-solution via the veins 
and arteries using a 50 ml syringe. The sample was then transported to the laboratory 
in 1 litre of icy-cold NaCl. At the laboratory the weight of the sample was reduced to 
about 100 g, and the sample was placed in a large Büchner funnel covered by a large 
watchglass (Figs 2.1 and 2.2A). Small pipettips (20-200 /xl) were used to connect four 
of the larger bloodvessels of the liver sample with the oxygenator (Fig. 2.2B). The 
oxygenator was furthermore connected to a peristaltic pump (run at 120 ml/min) and 
a gascylinder with 0 2 /C02 95/5 (about 2 bubbles/sec), and was placed in a waterbath 
set at 40 °C. During the perfusion the pressure within the system was kept between 40 
and 60 cm water pressure, as controlled with the open manometer. The liver sample 
was perfused with respectively 1 litre of buffer I, 1 litre of buffer II, and finally 400 ml 
of the collagenase solution for 30 min under recirculation. During this period the liver 
swell and the surrounding connective tissue started to leak. 
Subsequently the sample was disconnected from the system and placed in a beaker. 
All further handlings were performed under sterile conditions in a laminar flow cabinet 
(Clean Air, Woerden, The Netherlands). The sample was cut into small pieces using 
a pair of scissors and the suspension filtered over respectively a Büchner funnel, to 
remove the larger parts, and a 250 /im nylon filter. The filters were washed with icy-
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Fig. 2.1 Schematic presentation of the perfusion during the recirculation step with collagenase. 
The buffer is pumped by a peristaltic pump (1) via the oxygenator (2) to the liver sample (3), 
which is placed in a Büchner funnel. Oxygen is added via the oxygenator at (4) and escapes via 
the overload (5). The pressure is monitored with the manometer (6). All vessels containing buffer 
solutions, the oxygenator and the tubing are placed in a waterbath (40 °C). 
cold buffer IV. The filtrate (about 200 ml) was poured into four 50 ml centrifuge tubes 
(Costar), cooled on ice for 5 min, and centrifuged at 100 g for 4 min at 4 °C using a 
Sorvall RC-3B centrifuge. The supernatant was removed and the pellet resuspended in 
buffer V, using a glass pipet. The cells were collected again by centrifugation and 
washed twice with buffer V. Eventually the pellets were resuspended in 100 ml 
Williams' medium E and filtered through a 250 ßm nylon filter. A sample of the filtrate 
was diluted 1/1 with a solution of trypan blue, and after 5 min used to determine both 
the concentration of cells and the fraction of trypan blue excluding cells (viability) in 
a Bürker counting chamber. 
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A 
$?•'• ':&-
B 
Fig. 2.2 Equipment used for the perfusion of a sample of pig liver (A) as well as the connection 
of the sample with the oxygenator (B). 
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Cell culturing 
Unless indicated, cell suspensions were diluted to a density of 1.25-1.5 million viable 
cells per ml of Williams' medium E, supplemented with 5% FCS, 0.5
 ßg insulin per ml, 
50 IU penicillin per ml and 50
 Mg streptomycin per ml. Cells were seeded in either 60 
mm dishes (2.5 ml/dish), or in 24-multiwell dishes (0.5 ml/well of a suspension 
containing 0.6-0.75 million viable cells per ml), and incubated in an incubator at 38 °C, 
5% C02 and high humidity. After 4 h the medium was replaced by new medium. 
Appraisal 
The method described above has been successfully applied on a large number of 
liver samples. About 2.5-8 million viable cells could be isolated per gram of liver, with 
93 ± 3 % of the cells being impermeable to trypan blue, as calculated over the last 40 
samples. In the majority of the cases, isolated cells attached themselves to uncoated 
Fig. 2.3 Monolayer cultures of pig hepatocytes, 48 h after seeding. 
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tissue culture dishes and stretched within 24 h, resulting in nice monolayer cultures 
(Fig. 2.3). However, occasionally cultures were obtained with a high fraction of trypan 
blue excluding cells, but with low plating efficiency, for inapparent reasons. At this point 
age, sex and early pregnancy can apparently be ruled out as factors which prevent a 
successful isolation of the cells. On the other hand it appears that the type of collagen-
ase is crucial. With collagenase type IV (Sigma), a large amount of cells, however with 
low viability, were obtained, unable of forming monolayer cultures. No improvement 
was obtained by reducing the duration of the collagenase treatment. For a while 
collagenase type H from Boehringer was successfully applied, than with a new shipment 
of the same batch the isolation failed completely, resulting in a large number of 
ruptured cells and large losses during the washing of the cells. With collagenase type I 
(Sigma), which had been used successfully at the start of the project, the problems 
disappeared immediately. When occasionally other batches of the collagenase obtained 
from Boehringer were used, the problems returned. Although no systematic comparison 
of different types of collagenase at the same time was performed, it seems that this is 
an important factor, which might however be different for livers of other animal 
species. 
Despite these occasional problems, it is evident that viable cells can be isolated from 
liver samples of pigs on a regular base and that quantities of cells are large enough for 
large scale experiments. 
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CHAPTER 3 
THE USE OF PIG HEPATOCYTES FOR 
BIOTRANSFORMATION STUDIES OF VETERINARY DRUGS 
This chapter is based mainly on the following publication: 
Hoogenboom L.A.P., Pastoor F.J.H., Clous W.E., Hesse S.E. and Kuiper H.A. (1989). The use 
of porcine hepatocytes for biotransformation studies of veterinary drugs. Xenobiotica 19: 
1207-1219. 
completed with some data from: 
Hoogenboom L.A.P., Milaan A.J. van, Hesse S.P., Vroomen L.H.M. and Kuiper H.A. The use 
of porcine hepatocytes for biotransformation and toxicity studies of veterinary drugs. In: 
Proceedings of the 4,h congress of the European Association for Veterinary Pharmacology 
and Toxicology, Budapest, Hungary 1988 (in press). 
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THE USE OF PIG HEPATOCYTES FOR 
BIOTRANSFORMATION STUDIES OF VETERINARY DRUGS 
Summary 
Cultures of porcine hepatocytes with high viability were isolated from a liver sample by a 
simple procedure. In aging monolayer cultures the cytochrome P-450 content and 7-ethoxy-
coumarin-O-deethylase activity decreased gradually while glutathione levels increased. 
The nitrofuran, furazolidone, was rapidly transformed by suspension cultures, partly resulting 
in the formation of 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidinone. Acetylating and 
deacetylating activities towards sulphadimidine and its N4-acetyl metabolite were present in 
suspension cultures of porcine hepatocytes. Relative and absolute levels of these activities varied 
in different batches of hepatocytes. 
In aging monolayer cultures the biotransformation of furazolidone was relatively low during 
the first 24 h as compared to the next 72 h. The acetylation of sulfadimidine tended to increase 
with culture age whereas the deacetylation of the N4-acetyl metabolite decreased. 
No differences were seen in a number of enzyme activities measured in cytosolic and 
microsomal fractions isolated from different lobes of one liver. Differences between livers from 
different animals were marked. 
Abbreviations used: ECOD= ethoxy-coumarin-O-deethylase; LDH= lactate-dehydrogenase; 
GSH= reduced glutathione; DMSO= dimethyl-sulfoxide 
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Introduction 
Most foreign compounds are intensively metabolized upon administration to animals, 
and the outcome of the biotransformation process, e.g. the kind of metabolites formed, 
may vary from species to species and may also be influenced by factors like sex, age 
and nutrition (Smith et al. 1984, Souhaili-El-Amri et al. 1986, Watkins & Klaassen 
1986). Therefore, the toxicity and biotransformation of veterinary drugs should 
preferably be studied in target animals. Yet, food-producing animals are rarely used for 
this purpose since such studies are expensive, time-consuming, and require special 
technical facilities. This is particularly true in the case of experiments with radiolabelled 
compounds, often necessary for identification of unknown metabolites. 
The use of in vitro models such as cell fractions and cell cultures isolated from 
organs of food-producing animals may help to overcome some of these problems as 
pointed out by Shull et al. (1987). Specific biotransformation steps of a drug may be 
elucidated as well as the influence of other compounds or metabolic processes which 
occur in vivo (Vroomen et al. 1987a). Furthermore, the use of intact cells offers the 
opportunity to integrate biotransformation and toxicity studies. As described in Chapter 
1, the isolation and application of hepatocytes from food-producing animals has been 
reported for larger animal species, like cattle (Shull et al. 1986; Suolinna and Winberg 
1985), and sheep (Demigne et al. 1986). Furthermore, hepatocytes have been isolated 
from newborn or foetal pigs by an in situ perfusion technique and subsequently been 
used for studying fat and carbohydrate metabolism (Bachorik et al. 1982, Pangburn et 
al. 1981). As described in Chapter 2, we have now developed a method to isolate 
hepatocytes from liver samples of adult pigs. 
Aim of the present study was to investigate the value and properties of pig 
hepatocytes, both in suspension and monolayer cultures, using a number of different 
parameters. The cytochrome P-450 content, as well as the deethylation of 7-ethoxy-
coumarin was studied both in suspension and monolayer cultures, regarding the 
important role of cytochrome P-450 isozymes in biotransformation processes, and the 
reported decline of P-450 related enzymatic activities in monolayer cultures of 
hepatocytes from other animal species (Chapter 1). Intracellular glutathione (GSH) 
concentrations were measured, regarding its possible role in both the biotransformation 
of foreign compounds and in the protection against toxic effects. 
It should be stressed that studies with isolated models should always be validated by 
results from in vivo studies. Therefore, the biotransformation of two widely used 
veterinary drugs, sulphadimidine and furazolidone, were studied. In vivo studies with 
pigs have revealed that sulphadimidine is excreted mainly as its N"-acetyl metabolite 
(50%) (Hoogenboom et al. 1988, Vree et al. 1985). Furazolidone is thought to be 
metabolized by reduction of the nitro-group, partly resulting in the formation of an 
open chain cyano metabolite (Vroomen et al. 1987b). In addition to studies with 
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Suspension cultures, special attention was paid to the effect of ageing of monolayer 
cultures on the biotransformation of these compounds. 
Major causes of variation in metabolic potential between hepatocytes isolated from 
different livers are most likely due to individual differences between animals. 
Furthermore, in the case of rat livers it is well known that there are differences in 
enzyme activities between peri-venous and peri-portal hepatocytes originating from the 
same liver (Kera et al. 1987, Quistorff et al. 1986). Whether such differences are also 
reflected in hepatocyte cultures prepared from different lobes is unclear. We therefore 
studied several enzyme activities in cell fractions prepared from the four major lobes 
of a pig liver and, in addition, we compared the enzyme activities in cell fractions 
isolated from livers of six different animals. 
Materials & Methods 
Chemicals and solvents 
Williams' medium E, Hanks' balanced salts, HEPES buffer, foetal calf serum, 
penicillin/streptomycin, glutamine and trypan blue were purchased from Flow 
Laboratories (Rickmansworth, UK), Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-
tetraacetic acid (EGTA) and Folin reagens from Merck (Darmstadt, FRG), insulin, 
cytochrome C, sulphatase, collagenase type I, bovine serum albumin, diethyl 4-
nitrophenol phosphate (paraoxon), fluoro-dinitrobenzene and sulphadimidine from 
Sigma (St Louis, MO, USA), resorufin, l-chloro-2,4-dinitrobenzene and hydroxy-
coumarin from Aldrich (Brussels, Belgium), NADPH, GSH, 7-ethoxycoumarin from 
Boehringer (Mannheim, FRG) and 7-ethoxyresorufin from Pierce Chemicals (Oud 
Beijerland, The Netherlands). Tissue culture dishes were purchased from Costar 
(Badhoevedorp, The Netherlands). Furazolidone was a gift from Orphahell B.V. 
(Mijdrecht, The Netherlands) and N-acetyl sulphadimidine from ILOB-TNO (Wage-
ningen, The Netherlands). The open-chain cyano-metabolite of furazolidone was 
synthesized as described previously (Vroomen et al. 1987b). 
Animals 
Liver samples were obtained from seven to nine month old sows in early pregnancy 
(7-10 days), used in programmes of the Department of Animal Husbandry of the 
Agricultural University at Wageningen. Animals were not treated with veterinary drugs 
during a considerable period prior to slaughtering. The presented data are based on 
studies with hepatocytes isolated from livers of seventeen different animals. The results 
of each experiment were checked for reproducibility in at least one similar experiment 
using hepatocytes isolated from another liver. 
35 
Hepatocyte isolation 
Hepatocytes were isolated from a liver sample as described in Chapter 2, with one 
difference; following the treatment with collagenase, the sample was minced and the 
homogenate was diluted with 100 ml of buffer containing fresh collagenase (0.05%), 
and incubated for another 10 min at 37 °C, followed by filtration. 
Culture conditions 
For monolayer cultures, 2.5 million viable cells in 2.5 ml of medium were seeded in 
60 mm dishes. Routinely Williams E medium supplemented with 5% foetal calf serum, 
insulin (0.5 /ng/ml), glutamine (2 mM), penicillin (50 IU/ml) and streptomycin (50 
Hg/ml) was used. After four hours cells were attached and the medium was renewed. 
For suspension cultures, cells were washed and diluted to a density of 2.5 million 
viable cells per ml in Krebs/Henseleit buffer (Moldéus et al. 1978) containing 20 mM 
HEPES. Cells were preincubated for 15 minutes at 37 °C prior to the addition of the 
substrates. 
Cell-monitoring 
At various time intervals, cells in monolayer cultures were washed and removed from 
the dishes in 1 ml of either phosphate buffered saline or a specially defined P-450 
buffer, as described by Topp and van Bladeren (1986) (0.1 M sodium phosphate buffer 
pH 7.4, 0.5% (v/v) Triton X-100, 20% (v/v) glycerol, 1 mM EDTA and 1 mM dithio-
threitol). Cells collected in phosphate buffered saline were immediately frozen and 
stored in liquid nitrogen. For determination of the cytochrome P-450 content, cell 
suspensions were thawed on ice, homogenized and an aliquot of 0.4 ml was diluted with 
0.2 ml of the special P-450 buffer. The remaining cell suspension (0.6 ml) was used for 
determination of intracellular GSH. Cells collected in the special P-450 buffer were 
homogenized using a teflon pestle, and subsequently centrifuged at 14,000 g. The 
supernatant was stored in liquid nitrogen. Cytochrome P-450 levels were determined by 
the CO-difference spectrum as described by Omura and Sato (1964). No differences in 
cytochrome P-450 levels were observed due to the two methods of cell collection and 
preparation. 
Protein in cell homogenates or cellular fractions (see below) was determined by the 
method of Lowry as modified by Peterson (1977). Glutathione (GSH) was determined 
by HPLC as described by Reed et al. (1980), using an amino spheri-5 column (4.6 x 
220 mm; Brownlee, Santa Clara, USA). A 0.5 M citrate-buffer (pH 4.6) was used 
instead of the regular acetate buffer. Possible deterioration of the analytical column by 
the remaining fluoro-dinitrobenzene and its breakdown products was prevented by using 
a column switch technique in combination with an amino guard column (4.6 x 30 mm, 
Brownlee). Intracellular GSH levels were not influenced by storage of the cells in liquid 
nitrogen. 
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7-Ethoxycoumarin O-deethylase (ECOD) activity 
Cells in suspension or monolayer culture were incubated in medium containing 
different concentrations of 7-ethoxycoumarin. A concentration of 100 /LIM proved to be 
useful for monitoring monolayer cultures. Small aliquots were taken after different time 
intervals, snap-frozen and stored at -20 °C. For analysis, samples were thawed, treated 
with sulphatase/ß-glucuronidase for 1 h and diluted in glycine/NaOH buffer (pH 10.3) 
as described by Aitio (1978). Fluorescence was measured within a few minutes because 
of the instability of 7-hydroxy-coumarin at pH 10.3. All measurements were done on 
a MPF-2A fluoro-spectrophotometer (Perkin Elmer) (kex 370 nm, A.em 457 nm). The 
efficiency of the method was checked by measuring the concentrations of 7-ethoxy-
coumarin under the same conditions (Xex 330 nm; kern 390 nm). 
Biotransformation of sulphadimidine, its NA_-acetyl metabolite and furazolidone 
Cell suspensions (2.7 ml), containing 2.5 million viable cells per ml, were preincub-
ated for 15 min at 37 °C in Williams' E supplemented with 20 mM HEPES. Unless 
indicated, furazolidone, sulphadimidine or N"-acetyl sulphadimidine were added in 
DMSO (final concentration 1%). After different incubation times (0, 20, 40 and 80 min) 
aliquots of 0.2 ml were taken and snap-frozen. For analysis, samples were thawed, 
diluted with 1 ml sodium acetate buffer (0.1 M, pH 5) and extracted three times with 
2 ml ethyl acetate. The extracts were analyzed by HPLC coupled to diode array 
equipment (Hewlett Packard) as described previously (Hoogenboom et al. 1987). This 
technique allowed confirmation of the identity and purity of the metabolites both by 
their chromatographic behaviour and their UV spectra. 
In the case of monolayer cultures, the incubation medium was replaced by 3 ml of 
Williams' E supplemented with furazolidone, sulfadimidine or the N"-acetyl metabolite. 
At t=0 and t=24 h samples of 0.5 ml were taken, mixed with 0.5 ml sodium acetate 
buffer (0.1 M, pH 5) and 2 ml EtAc, and stored at -20 °C until analysis, as described 
above. The amount of drug transformed was calculated by comparing the concentrations 
before and after the incubation. 
Preparation of cellular fractions 
Whole livers or parts of livers were obtained as described and transported on ice to 
the laboratory. Livers were divided by separation of the four lobes. Lobes were 
perfused with 0.9% NaCl and homogenised under nitrogen in twice their volume of a 
1.15% KCl-solution using a Braun blender mixer. Homogenates were centrifuged for 
20 min at 9000 g (4 °C). The supernatant was centrifuged for 90 min at 105,000 g 
(4 °C), the cytosolic fraction was aspirated and the pellet was resuspended in 1.15% 
KCl. Following centrifugation, the microsomes were resuspended in 0.1 M phosphate 
buffer (pH 7.4). Both microsomal and cytosolic fractions were stored in liquid nitrogen. 
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Enzyme activities in cellular fractions 
Microsomal fraction 
Cytochrome P-450 levels were determined as described by Omura & Sato (1964). 
Ethoxyresorufin- and ethoxycoumarin-O-deethylase activities were determined using a 
direct fluorescence technique (Prough et al. 1978). Substrate concentrations were 
0.5 ßM and 100 ßM for 7-ethoxyresorufin and 7-ethoxycoumarin, respectively. NADPH-
dependent cytochrome-C-reductase activity was measured by the method of Strobel and 
Dignam (1978). UDP-glucuronyl transferase activity was determined as described by 
Vessey & Zakim (1972) using p-nitrophenol as substrate; optimal activity was obtained 
by preincubating the microsomes in 12.5 mM Tris/HCl buffer (pH 8.0) containing 0.6% 
Triton X-100 for 10 min at 20 °C. 
Cytosolic fraction 
Glutathione-S-transferase activity was measured as described by Habig and Jakoby 
(1981) using l-chloro-2,4-dinitrobenzene as substrate. Acetyl-CoA-acyltransferase activity 
was determined by incubating cytosolic fractions in 0.1 M phosphate buffer (pH 7.4) 
containing 0.16 mM sulphadimidine at 37 °C. At regular time intervals samples were 
taken and analyzed by HPLC for the N^-acetyl metabolite as described previously 
(Hoogenboom et al. 1987). GSH concentrations were determined after storage for one 
year in liquid nitrogen. GSH levels determined in three freshly homogenized and 
fractionated livers gave results in the same range as observed in stored samples. 
Results 
Using a biopsy technique, hepatocytes were isolated from livers of adult sows with 
a yield varying between 2.5 and 10 million cells per gram wet weight. The fraction of 
cells excluding trypan blue varied between 90 and 95%. Usually, cells readily attached 
themselves to uncoated culture dishes resulting in typical monolayer cultures. However, 
in three out of seventeen cases, cultures were obtained with poor plating efficiency 
despite an initial high fraction of trypan blue excluding cells. 
There was a large variation in intracellular glutathione (GSH) levels in freshly 
isolated hepatocytes (Fig. 3.1). In all cultures GSH-levels increased markedly during the 
first 48 h. Cellular levels of cytochrome P-450 decreased to about 70 and 40% within 
respectively 24 and 48 h (Fig. 3.2A). Similar results were obtained for the ECOD-
activity in aging monolayer cultures (Fig. 3.2B). ECOD-activities in suspension cultures 
at t=0 h at the same cell density of 1 million/ml, were markedly lower, i.e. 0.33 ± 0.01 
and 0.19 ± 0.00 nmol/min per mg protein (mean ± SEM; n=3) for the two batches 
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Fig. 3.1 Intracellular GSH levels in aging 
monolayer cultures of pig hepatocytes, 
isolated from livers of 4 different animals. 
Results are expressed per mg cellular protein 
(mean ± SEM; n=3). 
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Fig. 3.2 Cytochrome P-450 levels (A) and ECOD-activity (B) in aging monolayer cultures of 
hepatocytes isolated from livers of two different pigs. Cultures were started at t=0 h; medium was 
renewed at t=4 h. Results are expressed per mg total cellular protein (mean ± SEM; n=3). 
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Fig. 3.3 ECOD-activity of suspension cultures of one batch of pig hepatocytes at different (A) 
substrate concentrations and (B) cell densities. A: cell density was 0.5 million/ml; concentrations 
of 7-ethoxycoumarin were: 10 D , 30 O ,100 A , and 300 • /xM. B: substrate concentration was 
100 /LtM; cell densities were: 0.5 A , 1.0 O , and 2.5 • million/ml. Results are expressed as mean 
± SEM (n=3). 
of cells. This was not reflected in the cytochrome P-450 levels, being 0.26 ± 0.01 and 
0.22 ± 0.02 nmol/mg protein. 
Fig. 3.3 shows the ECOD-activity of freshly isolated cells in suspension at different 
concentrations of 7-ethoxycoumarin (A) and at different cell densities (B). In a similar 
experiment where cells were incubated for 30 min with 100 /xM 7-ethoxy-coumarin at 
a density of 0.75, 1.50 and 3.00 million cells per ml, ECOD-activities of respectively 
0.33 ± 0.01, 0.23 ± 0.01 and 0.15 ± 0.01 nmol/min per million cells were measured. 
Addition of 95% oxygen (carbogen) to the cultures at a cell-density of 1.5 million per 
ml resulted in an activity of 0.37 ± 0.01 nmol/min per million cells. 
Furazolidone (50 ßM) was rapidly metabolized in suspension cultures, partly resulting 
in the formation of the open chain cyano metabolite, 3-(4-cyano-2-oxobutylidene-
amino)-2-oxazolidinone (Fig. 3.4). In a second experiment, where cells, isolated from 
another liver, were incubated for 80 min with 20 ßM furazolidone either without further 
additions or in the presence of 1% DMSO or 2% BSA, respectively 38.7 ± 2.7, 
37.4 ± 0.4 and 36.3 ± 0.5 % of the drug was metabolized. 
Addition of sulphadimidine to suspension cultures resulted in the formation of low 
levels of N"-acetyl sulphadimidine. The reversed reaction was observed upon addition 
of N"-acetyl sulphadimidine to the cells. In the dose range studied, both activities 
increased proportionally with the concentration of the substrate (Fig. 3.5). Incubation 
of cells (culture 2, Fig. 3.6) with either sulphadimidine or its N"-acetyl metabolite in the 
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Fig. 3.4 Biotransformation of fura-
zolidone ( • — • ) and formation of 
the open-chain cyano metabolite 
( • — • ) by suspension cultures 
(mean ± SEM; n=3). Substrate 
concentration 10 fjM. 
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Fig. 3.5 Acetylation of sulpha-
dimidine ( • ) and deacetylation of 
N4-acetyl sulfadimidine ( • ) by 
suspension cultures at different 
substrate concentrations (mean ± 
SEM; n=3). Cells from culture no.l 
(Table 3.1) were used for this 
experiment. 
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presence of paraoxon (2.5 /ug/ml), resulted in an almost complete inhibition of the de-
acetylation reaction and a 1.3-fold increase in the amount of acetylated drug (Table 
3.1). No increase in LDH-release could be observed due to treatment with paraoxon 
(data not shown). Both the amounts of acetylated and deacetylated products were lower 
when 2% bovine serum albumine was added to the medium (Table 3.1). The presence 
of 1% DMSO resulted in a clear reduction of the deacetylation rate while the 
acetylation rate tended to increase. There was a marked variation in the acetylation and 
deacetylation activities between batches of hepatocytes prepared from different livers 
(Fig. 3.6, Table 3.1). As a result there was a clear difference in the relative activities 
of the two enzymes as shown by the deacetylation/acetylation ratio (Table 3.1). 
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Fig. 3.6 Acetylation (A) and deacetylation (B) by four different batches of porcine hepatocytes 
(Culture no. 1 • , 2 • ,3 + ,4 A ). Substrate concentrations: 360 /iM sulphadimidine and 94 ßM 
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Table 3.1 Biotransformation of sulfadimidine and its N4-acetyl metabolite by hepatocytes isolated 
from livers of six different pigs, and the influence of paraoxon, BSA and DMSO on the 
(de)acetylation rate. Activities are expressed as the fraction of drug transformed after 1 h. (mean ± 
SEM). Substrate concentrations were 360 juM (sulfadimidine) and 94 /iM (N4-acetyl sulfadimidine), 
except for culture 6 where a concentration of 20 ßM for both compounds was used. DMSO, 
paraoxon and BSA were used at concentrations of 1% (v/v), 2.5 /Jg/ml and 20 mg/ml respectively. 
Cell density was 2.5 million viable cells/ml. ND= not determined. 
Culture 
no.1 
1 
2 
2 
2 
3 
4 
5 
5 
5 
5 
6 
6 
6 
Addition 
DMSO 
DMSO 
DMSO/Paraoxon 
DMSO/BSA 
DMSO 
DMSO 
DMSO 
DMSO/BSA 
BSA 
DMSO 
DMSO/BSA 
Fraction of drug metabolized in 1 h 
Acetyl 
1.01 
0.58 
0.80 
0.39 
0.41 
0.18 
0.38 
0.23 
0.35 
0.17 
0.41 
0.27 
0.35 
ation (A) 
± 
+ 
± 
± 
± 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
0.05 
0.02 
0.00 
0.01 
0.00 
0.01 
0.03 
0.03 
0.03 
0.01 
0.08 
0.02 
0.04 
(%) 
Deacetylation (D) 
4.70 
7.21 
0.40 
0.66 
4.50 
6.39 
3.08 
8.99 
3.93 
6.88 
4.48 
9.77 
± 
+ 
+ 
ND 
+ 
± 
+ 
± 
± 
± 
± 
± 
± 
0.13 
0.32 
0.06 
0.01 
0.10 
0.08 
0.08 
0.17 
0.11 
0.08 
0.11 
0.16 
Ratio 
(D/A) 
4.6 
12.5 
0.5 
1.6 
25.0 
16.7 
13.7 
25.5 
23.8 
16.7 
16.6 
27.7 
1
 rates for cultures 1 to 4 were calculated from the data presented in Fig. 3.6. 
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Fig. 3.7. Biotransformation of furazolidone, sulfadimidine and N4-acetyl-sulfadimidine by monolayer 
cultures of different ages. Monolayer cultures were incubated in Williams' E containing 50 /UM 
furazolidone (FÜH), 250 ßM sulfadimidine ('[ÏTÏÏÏÏ1'). or 250 jltM N4-acetyl-sulfadimidine Q |) 
(0.5% DMSO) for 24 h starting 4, 28, 52 or 76 h after the seeding of the cells. 
Furazolidone, sulfadimidine and its N4-acetyl-metabolite were readily transformed by 
monolayer cultures of pig hepatocytes (Fig. 3.7). The transformation of the nitrofuran 
drug was relatively low during the first 24 h as compared to the next three periods of 
24 h. The contribution of the cyano-metabolite to the total amount of metabolites was 
calculated to be 15.5 ± 2.7, 7.7 ± 0.8, 11.9 ± 0.6 and 15.6 ± 2.0 % at the end of 
respectively interval 1 to 4. The deacetylation of N"-acetyl-sulfadimidine decreased in 
aging cultures, whereas the acetylation of the parent compound increased. 
Differential centrifugation of the 9000 g supernatant of liver homogenates at 
105,000 g resulted in the separation of a cytosolic and a microsomal fraction containing 
2/3 and 1/3 of the protein respectively. The differences in a number of enzyme activities 
in microsomal and cytosolic fractions, prepared from different lobes of one liver were 
relatively small (Table 3.2). However, with the exception of cytochrome P-450 and 
glutathione levels, larger variations were observed in enzyme activities in cytosolic and 
microsomal fractions prepared from livers of different animals. 
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Discussion 
The results presented in this chapter demonstrate the possibility of isolating viable 
hepatocytes from a liver sample obtained shortly after exsanguination of a pig. This was 
shown both by trypan blue exclusion and the ability of the cells to form monolayer 
cultures. However, in a small number of cases, cultures showed poor plating efficiency 
despite an initial high fraction of trypan blue excluding cells. This might have been due 
to the low levels of intracellular glutathione (GSH) present in freshly isolated 
hepatocytes (see Fig. 3.1). A possible relationship between low intracellular GSH levels 
and poor plating efficiency has been pointed out previously in the case of rat 
hepatocytes (Morrison et al 1985). The cause of the low initial GSH levels is unclear. 
However, extrapolation of GSH concentrations measured in the cytosolic fractions 
(Table 3.2) would result in cellular concentrations of 25-40 nmol/mg protein, considering 
that the cytosolic protein accounts for about 2/3 of the cellular protein. Comparison 
of these values with GSH levels measured in hepatocytes indicates a loss of GSH 
during the isolation of the cells. Cytochrome P-450 levels in freshly isolated hepatocytes 
were similar to those in microsomes, regarding a cytosolic/microsomal protein ratio of 
2/1 (Table 3.2). In aging monolayer cultures, cytochrome P-450 concentrations 
decreased, as has been reported for hepatocyte cultures isolated from livers of other 
species like rat and man (Grant et al. 1986, Strom et al. 1982). The cytochrome P-450 
dependent ECOD-activity was shown to decrease even more rapidly. 
Four hours after seeding, ECOD-activity in monolayer cultures was about twice as 
high as in suspension cultures of the same cell-density, at the time of seeding. The 
difference could not be explained by the small number of non-viable cells, present in 
suspension cultures, nor by a difference in cytochrome P-450 content. However, several 
other factors may influence the ECOD-activity, such as oxygen-tension, serum albumins, 
organic solvents and cell-density (Rogiers et al. 1986). In our experiments, ECOD-
activity in suspension cultures was shown to decrease with increasing cell-densities 
(Fig. 3.3B), possibly because the diffusion of oxygen into the medium can no longer 
meet the oxygen demand. This theory is supported by the observation that aeration 
with 95 % oxygen resulted in a 1.8 fold increase in the ECOD-activity. 
The nitrofuran furazolidone was readily metabolized, partly resulting in the formation 
of the open-chain cyano derivative (Fig. 3.4). The latter compound has been shown to 
be a minor metabolite in blood plasma of pigs (Vroomen et al. 1987b). In our 
experiments, the contribution of the cyano-metabolite to the overall biotransformation 
of the drug might even be overestimated, regarding the low initial GSH concentrations. 
Using rat and pig liver microsomes, Vroomen et al. (1987b) have demonstrated that the 
formation of this metabolite decreased with increasing concentrations of GSH, probably 
due to the formation of a conjugate between GSH and a reactive intermediate of 
furazolidone. Therefore, similar to the in vivo situation, little is known about the 
majority of the metabolites of furazolidone. 
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The acetylation of sulphadimidine to its N4-acetyl metabolite was slow in both 
cytosolic fractions and hepatocytes (Table 3.2, Fig. 3.5). Deacetylation of N4-acetyl 
sulphadimidine proceeded more rapidly in all batches of hepatocytes tested (Fig. 3.6). 
No differences were seen in the relative proportion acetylated or deacetylated product 
in the wide range of concentrations examined (Fig. 3.5). This indicates that in the case 
of sulphadimidine only part of the formed N"-acetyl metabolite is again deacetylated to 
the parent compound. This hypothesis is supported by the fact that inhibition of 
deacetylation by non-toxic concentrations of paraoxon resulted only in a 1.3 fold 
increase in the proportion of acetylated drug (Table 3.1). These results clearly 
demonstrate the presence of an equilibrium between two opposing biotransformation 
pathways, as discussed by Vree et al. (1985). in vivo, the N4-acetyl metabolite seems to 
be more important, as judged by the high proportion of this compound in the urine of 
pigs (Hoogenboom et al. 1988, Vree et al. 1985). This may be due to the fact that the 
acetylated compound is cleared more efficiently by the kidney. In addition the role of 
other internal or external factors cannot be excluded, as demonstrated by our 
experiments (Table 3.1). It was shown that both the amounts of acetylated and 
deacetylated product were lower in the presence of albumins. This might be explained 
by a reduction of the concentration of free drug, since it has been shown that both 
compounds bind to albumins by hydrophobic interactions (Hoogenboom et al. 1988, 
Vree et al. 1985). DMSO, which was routinely used in most experiments, appeared to 
inhibit the deacetylation activity, as has previously been reported in the case of 
cytochrome P-450 related enzyme activities like the deethylation of 7-ethoxy-coumarin 
(Rogiers et al. 1986). As a result of this inhibition, there seems to be an 
underestimation of the already high deacetylation/acetylation ratio. Fig. 3.6 clearly 
demonstrates the existence of large differences in both the absolute and relative 
acetylation and deacetylation capacities of sulphonamides by cell cultures isolated from 
livers of different animals. It is unclear, whether such differences reflect the possible 
existence of slow and fast acetylation phenotypes, which has been reported in the case 
of humans (Vree et al. 1985). 
As shown in this study, the cells can be used both as suspension cultures and as 
monolayer cultures. Monolayer cultures offered the advantage of prolonged incubation 
intervals, and allow the cells to recover from the isolation. The latter might explain the 
increase in the biotransformation of furazolidone in older cultures (Fig. 3.7). In the case 
of ethoxy-coumarin, sulfadimidine and its N"-acetyl metabolite, aging of the monolayer 
cultures clearly affected the velocity of the degradation, but it did apparently not affect 
the metabolite pattern. Looking at the formation of the cyano-metabolite, a similar 
conclusion might be drawn in the case of furazolidone, but it should be mentioned that 
the identity of more than 85% of the metabolites is unknown, which makes it difficult 
to compare metabolite patterns. 
No large differences could be observed in enzyme-activities in cellfractions isolated 
from different lobes of one liver (Table 3.2). However, variation between livers of 
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different animals was marked. The intraspecies differences observed both in cellular 
fractions and hepatocytes stress the need to investigate the reproducibility of results 
obtained with material from one liver. 
This is the first report on the use of adult porcine hepatocytes isolated from a liver 
sample for biotransformation studies. Since the known in vivo metabolites of furazolid-
one and sulfadimidine could be detected in this in vitro system, we are confident that 
the use of cell cultures prepared from pig livers and possibly other organs of food-
producing animals may largely contribute to elucidating biotransformation pathways of 
veterinary drugs, thus lowering the need to use intact animals. 
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CHAPTER 4 
THE USE OF PIG HEPATOCYTES TO STUDY THE 
BIOTRANSFORMATION OF ß-NORTESTOSTERONE BY PIGS 
Identification of glucuronidated 15a-hydroxy-norandrostenedione as 
an important in vitro and in vivo metabolite 
This chapter is based on the following publications: 
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of pig hepatocytes to study the biotransformation of ß-nortestosterone by pigs: identification 
of glucuronidated 15a-hydroxy-norandrostenedione as an important in vitro and in vivo 
metabolite. Drug Metab. Dispos. 18: 999-1004. 
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THE USE OF PIG HEPATOCYTES TO STUDY THE 
BIOTRANSFORMATION OF ß-NORTESTOSTERONE BY PIGS 
Identification of glucuronidated 15a-hydroxy-norandrostenedione as 
an important in vitro and in vivo metabolite 
Summary 
Pig hepatocytes were used to examine the biotransformation of ß-nortestosterone. Initially 
the major metabolite of ß-nortestosterone was norandrostenedione, which upon prolonged 
incubation was further transformed, primarily to the glucuronide of 15a-hydroxy-norandrost-
enedione. No differences were observed in this pattern between hepatocytes isolated from livers 
of sows or castrated male pigs. With increasing culture age the rate of formation of 
norandrostenedione did not change, contrary to a decrease in its further oxidation and 
glucuronidation. 15a-Hydroxy-norandrostenedione, primarily as its glucuronide, was identified 
in the urine of pigs injected with ß-nortestosterone. In addition norandrostenedione and the 
glucuronide of the parent compound were detected, although in much smaller amounts. 
Abbreviations used are: NOR= ß-nortestosterone; NA= norandrostenedione; 15aOH-NA= 
15a-hydroxy-norandrostenedione; PCB-138= 2,3,4-2',3',5'-polychlorbiphenyl; IS= internal 
standard; TMS= trimethyl-silyl; MOX= methoxyamine-hydrochloride; MID= multiple-ion 
detection; EtAc= ethyl-acetate 
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Introduction 
Primary cultures of hepatocytes, isolated from livers of food-producing animals, have 
been shown to be a useful model for studying the biotransformation of growth-
promoting agents and veterinary drugs (Shull et al. 1987). In previous chapters we 
described the isolation of pig hepatocytes and showed that these cells were able to 
transform the veterinary drugs sulfadimidine and furazolidone, resulting in the formation 
of compounds previously detected in vivo. Aim of the present study was to further 
demonstrate the value of this model for studying the biotransformation of xenobiotics. 
For this purpose, ß-nortestosterone (4-estren-17ß-ol-3-one) was used as a model 
compound regarding the special interest in metabolites of these type of compounds, 
that might be used for controlling their misuse. 
In the first part of the study we investigated the biotransformation of 3H-labelled 
ß-nortestosterone by monolayer cultures of pig hepatocytes, isolated from livers of both 
female and castrated male pigs. One of the main problems encountered with monolayer 
cultures of hepatocytes is the change in certain enzyme activities with increasing age 
of the cultures (Fry and Bridges 1979, Grant et al. 1985). In Chapter 3 we described 
e.g. the decrease in cytochrome P-450 levels and the cytochrome P-450 dependant 
deethylation of ethoxycoumarin (ECOD-activity) in ageing monolayer cultures of pig 
hepatocytes. Since the role of cytochrome P-450 isozymes in the oxidation of steroids 
is well established (Guengerich 1987, Waxman 1988), we investigated how this decrease 
affects the biotransformation of ß-nortestosterone and therefore limits the prolonged 
use of the model. 
In the second part of the study castrated male pigs were injected with unlabelled 
ß-nortestosterone and the urine of these animals was investigated for the presence of 
the major in vitro metabolites. 
Materials & Methods 
Materials 
[3H]ß-nortestosterone (703 GBq/mmol) was obtained from Amersham (Amersham, 
UK), ß-nortestosterone, ß-glucuronidase (Escherichia coli), and insulin from Sigma (St. 
Louis, MO, USA), 2,3,4-2',3\5'-polychlor-biphenyl (PCB-138) from Promochem (Wesel, 
FRG), methoxylamine-hydrochloride from Chrompack (Middelburg, The Netherlands), 
N,0-bis-(trimethylsilyl)-trifluoroacetamide from Pierce (Rockford, II, USA), collagenase 
(type H) from Boehringer (Mannheim, FRG), Williams' E, penicillin/streptomycin and 
fetal calf serum from Flow Labs (Rickmansworth, UK). Norandrostenedione and 15a-
hydroxy-norandrostenedione were kindly supplied by Organon (Oss, The Netherlands). 
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Isolation and culturing of hepatocytes 
Hepatocytes were isolated from livers of pigs (Dutch Landrace x Yorkshire) obtained 
from the Department of Animal Husbandry (Agricultural University, Wageningen, The 
Netherlands) as described in Chapter 2. Isolated hepatocytes were diluted to a density 
of 1.5 million viable cells per ml in Williams' medium E supplemented with 5% FCS, 
penicillin/streptomycin (50 IU and 50 jitg/ml respectively) and insulin (0.5 /ig/ml), and 
plated in 60 mm tissue culture dishes (2.5 ml/dish). Prior to the addition of ß-nortesto-
sterone, monolayer cultures were washed twice with Krebs-Henseleit medium 
supplemented with 10 mM glucose and preincubated for 30 min in this medium. 
ß-Nortestosterone was dissolved in dimethyl sulphoxide (0.5 mM) and added to the 
cultures at a final concentration of 5 /JM. For radioactivity studies, [3H]ß-nortestosterone 
was diluted with unlabelled hormone to a specific activity of 1.8 GBq/mmol. 
Animal study 
Three pigs were injected intramuscularly with 200 mg ß-nortestosterone, dissolved in 
5 ml arachid oil/benzyl alcohol (90:10 v/v). Urine samples were collected during 
different time intervals, namely before injection (blank), and 0-4, 4-8, 8-12, 12-24, 24-34 
and 34-48 h after injection, and stored at -20 °C. 
Chromatography 
For in vitro studies with [3H]ß-nortestosterone, samples were taken from the medium 
and injected on the HPLC-system either without further pretreatment or after 
incubation with ß-glucuronidase for 1 h at 37 °C. The HPLC-system was equipped with 
a PRP-1 column (250x4.6 mm I.D.; Hamilton, Reno, NV, USA) and coupled to a 
radioactivity-monitor (Berthold, Wildbad, FRG). Compounds were eluted from the 
column using a 0-22 min liniar gradient of 2-100 % acetonitrile in water. 
For identification of the major in vitro metabolite after prolonged incubation, the 
medium was extracted three times with EtAc, treated with ß-glucuronidase for 1 h at 
pH 7.0 and 37 °C, and extracted again three times with EtAc. The organic phase was 
evaporated under nitrogen and the residue dissolved in acetonitrile/water (3:7 v/v). To 
facilitate the further purification by HPLC, the system was equipped with a PRP-1 
semi-preparative column (305x7 mm I.D.; Hamilton) and coupled to a diode-array 
detector. 
Aliquots of urine (5 ml) were mixed with 5 ml methanol and evaporated to dryness 
under nitrogen. The residue was dissolved in 0.35 ml acetonitrile/ water (3:7 v/v) and 
injected on the HPLC-system described above. The fraction containing the polar 
metabolites (retention time 9-12 min) was collected, concentrated under nitrogen, mixed 
with 1 ml KPi (0.1 M, pH 7.0), treated with ß-glucuronidase (1 h, 37 °C) and extracted 
with EtAc (3x4 ml). Following evaporation of the organic solvent under nitrogen, the 
residue was dissolved in 50 ßl acetone and investigated by HPTLC and GC/MS. 
HPTLC analysis of 5 ß\ of this solution was performed with Silica-60 thin layer plates 
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(Merck, Darmstadt, FRG) which were chromatographed in two directions (eluent 
1: hexane/EtAc/ dichloromethane 10:20:20 v/v, eluent 2: chloroform/ethanol/ toluene 
45:3.5:5 v/v). Spots were developed by dipping the plates in ethanol/sulphuric acid (95:5 
v/v) for 30 sec and heating at 95 °C for 8 min. For GC/MS analysis, samples were 
investigated either with or without further derivatization as described by Tuinstra et al. 
(1983). 
For identification of norandrostenedione and unconjugated ß-nortestosterone, aliquots 
of medium or urine (5 ml) were extracted twice with EtAc (5 ml), which was 
subsequently evaporated. The residue was dissolved in 0.3 ml acetonitrile/water 3:7 (v/v) 
and 0.15 ml of this solution was injected on the HPLC-system described above. The 
fractions containing norandrostenedione and ß-nortestosterone were collected, 
evaporated to dryness and derivatized with respectively TMS or MOX, before GC/MS 
analysis. 
Identification 
'H-NMR spectra were recorded in CDC13 on a Bruker CXP-300 instrument. GC/MS 
analysis was performed on a Hewlett-Packard GC-MS instrument (HP-MSD 5970B), 
equipped with a CpSil5-CB column (25 m x 0.25 mm I.D., 0.12 ßm coating; Chrom-
pack, Middelburg, The Netherlands) using a temperature-gradient of 80 °C for 3 min 
followed by a linear increase of 15 °C/min up to 280 °C. Before derivatization PCB-138 
was added as an internal standard. For positive identification of compounds, the relative 
intensities of the M+-peak and a number of important fragment-peaks were measured, 
putting the highest intensity at 100% (Multiple Ion Detection (MID)-analysis). Two 
compounds were judged identical when the variations in the intensities of all fragment-
peaks were within 10%. The identity of norandrostenedione in the incubation medium 
was confirmed by full spectrum analysis. 
Results 
The biotransformation of ß-nortestosterone by pig hepatocytes could easily be 
studied, using a radiolabelled compound in addition to a radioactivity detector coupled 
on-line to the HPLC-system. The biotransformation of ß-nortestosterone by 24 h old 
monolayer cultures of hepatocytes isolated from the liver of a castrated male pig, 
resulted initially in the formation of a less hydrophilic compound, eluting after 21 min 
(Fig. 4.1 A), which was subsequently metabolized to more hydrophilic compounds 
(Figs 4. IB and 4.1C). Deglucuronidation of these metabolites resulted primarily in the 
formation of a compound with a retention time of about 15 min (Fig. 4. ID). A similar 
pattern was obtained with hepatocytes isolated from the liver of a sow (Fig. 4. IE). 
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Fig. 4.1. Biotransformation of ß-nortestosterone by pig hepatocytes and the influence of sex and 
culture age. 
Cells from a castrated male pig (A-D), and a sow (E,F) were incubated with ß-nortestosterone 
for 10 (A), 60 (B) or 150 (C-F) min. The medium was analyzed before (A,B,C), or after (D,E,F) 
treatment with ß-glucuronidase for 1 h, using an on-line radioactivity detector. The chromatograms 
shown were obtained with cultures aged 24 h in the case of the castrated male pig, or 4 h (E) 
and 72 h (F) for the sow. 
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Table 4.1 Influence of culture age on the biotransformation of ß-nortestosterone by pig 
hepatocytes. Hepatocytes from a sow, cultured for 4, 24, 48 or 72 h, were incubated with 
ß-nortestosterone for different time intervals. Media samples were analyzed by HPLC for the 
presence of ß-nortestosterone, norandrostenedione or polar metabolites (retention time 9 to 13 
min (Fig. 4.1)). Part of the samples, taken after 150 min, were treated with ß-glucuronidase and 
analyzed for the amount of 15o>hydroxy-norandrostenedione (mean ± SEM; n=2). 
culture 
age 
(h) 
4 
24 
48 
72 
incubation 
time 
(min) 
20 
150 
20 
150 
20 
150 
20 
150 
NOR 
22.2 
0.3 
22.6 
0.0 
24.4 
0.0 
20.7 
0.0 
± 
± 
± 
+ 
+ 
± 
± 
± 
0.9 
0.1 
0.2 
0.0 
1.1 
0.0 
0.3 
0.0 
fraction of total 
NA 
43.0 ± 
5.3 ± 
44.7 ± 
6.2 ± 
48.5 ± 
14.0 ± 
57.0 ± 
23.0 ± 
1.7 
0.9 
0.1 
0.1 
0.3 
1.1 
0.6 
0.4 
radioactivity (%) 
polar 
11.0 
62.3 
10.6 
64.8 
8.4 
55.1 
5.0 
42.5 
metabolites 
+ 
± 
+ 
+ 
± 
± 
+ 
+ 
1.3 
0.6 
0.9 
0.9 
1.2 
1.8 
0.1 
1.2 
15aOHNA 
( + D C ) 
ND 
52.5 ± 0.1 
ND 
48.1 ± 0.0 
ND 
37.5 ± 4.2 
ND 
15.9 ± 0.6 
+DC: after deconjugation; ND: not determined 
With increasing age of the latter cultures, no differences were observed in the initial 
conversion of ß-nortestosterone, whereas the subsequent formation of the polar 
metabolites clearly decreased (Fig. 4. IF, Table 4.1). 
The initially formed metabolite (RT. 21 min) coeluted on HPLC with norandroste-
nedione. Its identity was further confirmed by GC/MS analysis, following derivatization 
of the two keto-groups with MOX (Fig. 4.2), resulting in an M+ peak of 330 (272 + 
2x29). 
Using UV/VIS diode array equipment, the main deglucuronidated metabolite (RT. 
15 min) was shown to have an absorption maximum at 244 nm. The 'H-NMR spectrum 
of the purified metabolite is shown in Fig. 4.3A, as well as the effect of addition 
of CD3OD on the spectrum (insert). Decoupling experiments showed that the NMR 
signal at 4.43 ppm was coupled to the signals at 1.40, 2.12 and 3.02 ppm. The latter 
two were coupled to each other, with a coupling constant J of about 19 Hz. The 
identity of the metabolite was further investigated by GC/MS, either directly or after 
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Fig. 4.2. GC/MS analysis of the initial major metabolite of ß-nortestosterone. 
The metabolite eluting at 21 min was purified, derivatized with MOX (A) and compared to a 
reference standard of norandrostenedione (B). Spectra were recorded in full-spectrum GC/MS. 
treatment with MOX and/or TMS to derivatize keto and/or hydroxy groups respectively. 
The mass spectrum of the underivatized compound showed an M+-peak at 288 m/e 
(100%) and major fragments at 260 (27%), 147 (16%), 133 (17%) and 110 m/e (36%). 
Treatment with MOX/TMS or only TMS resulted in M+-peaks at 418 and 360 m/e. 
From these spectra the possible identity of the metabolite was thought to be 
15a-hydroxy-norandrostenedione. A reference standard of this compound was shown to 
have identical retention times on HPLC, HPTLC and GLC as the in vitro metabolite. 
NMR and mass spectra of the in vitro metabolite (A) and the standard (B) are 
compared in Figs 4.3 and 4.4 respectively. 
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Fig. 4.3. Identification of 15a-hydroxy-norandrostenedione as an in vitro metabolite by 'H-NMR. 
Spectra of the major in vitro metabolite after deconjugation (A), and a standard of 15a-hydroxy-
norandrostenedione (B). The insert in (A) shows the effect of CD3OD on the spectrum. 
For validation of the in vitro results, three castrated male pigs were injected with 
ß-nortestosterone. For one pig, all urine samples were investigated for the presence of 
15a-hydroxy-norandrostenedione, norandrostenedione and the parent compound. Based 
on the information from the in vitro experiments, glucuronides could be purified from 
the matrix by HPLC, prior to the ß-glucuronidase treatment. After extraction of the 
deconjugated metabolites with EtAc, HPTLC analysis revealed a blue spot with RF-
values of 0.33 and 0.12 in respectively the first and second direction of development, 
identical with 15a-hydroxy-norandrostenedione. The intensity of this spot, which was not 
observed in urine samples taken before intramuscular injection of ß-nortestosterone, 
was most bright in the urine sample collected between 4-8 h after administration and 
gradually decreased in samples collected at later time intervals. A similar pattern and 
time course was obtained with GC/MS analysis (Fig. 4.5, Table 4.2). 
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Fig. 4.4. Mass (MID) spectra of the purified major deconjugated metabolite of ß-nortestosterone 
generated by pig hepatocytes (A), a standard of 15a-hydroxy-norandrostenedione (B), and a 
deconjugated metabolite with the same retention time in the urine of pigs, injected with 
ß-nortestosterone (C).Compounds were derivatized with TMS, and the four major fragment-peaks 
were selected for comparison (MID). 
The identity of the compound as 15a-hydroxy-norandrostenedione was further 
confirmed by GC/MS analysis (Fig. 4.4C). The metabolite in its glucuronidated, and to 
a smaller extent in its free form, could also be detected by HPTLC in urine samples 
of two other pigs, collected 4-8 h after injection with ß-nortestosterone, but not in 
samples collected before treatment. 
The occurrence of norandrostenedione in the urine was investigated by 
GC/MS analysis. As shown in Fig. 4.5, a compound with an identical retention time as 
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Fig. 4.5. Detection by gas-chromatography (MID) of 15a-hydroxy-norandrostenedione and 
norandrostenedione in urine samples of a pig treated with ß-nortestosterone. 
Urine samples were collected before (A,C), or 4-8 h after injection with ß-nortestosterone (B,D). 
Samples were injected on HPLC and the glucuronide-fraction was incubated with ß-glucuronidase. 
Deconjugated compounds, extracted with EtAc, were derivatized with TMS and analyzed by 
GC/MS (A,B). The HPLC fraction containing norandrostenedione was collected and treated with 
MOX (C,D) before GC/MS analysis. The peaks of PCB-138 (IS) and those coeluting with 
ß-nortestosterone, norandrostenedione and 15a-hydroxy-norandrostenedione are indicated. 
norandrostenedione (16.0 min) could be detected after (D), but not before (C) 
treatment with ß-nortestosterone. Its identity was confirmed by the similarity of its mass 
spectrum with that of a reference standard as shown in Figs 4.6B and 4.6A respectively. 
The presence of a small amount of ß-nortestosterone in the urine was confirmed by 
GC/MS analysis, but only in the EtAc-extract obtained after deglucuronidation. In 
addition, in these samples a number of other spots and peaks were observed by 
HPTLC and GLC (Fig. 4.5) respectively, which were absent before treatment, and 
increased and subsequently decreased in samples collected at longer time intervals. 
These spots had not been observed after incubation of hepatocytes with ß-nortestos-
terone and were therefore not further investigated. 
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Table 4.2 Estimated concentrations of 15a-hydroxy-norandrostenedione, ß-nortestosterone and 
norandrostenedione in urine samples of a pig treated with ß-nortestosterone. 
Concentrations of conjugated 15a-hydroxy-norandrostenedione and ß-nortestosterone, and 
norandrostenedione in urine samples were estimated by GC/MS analysis. 
compound 
0-4 
interval (h after injection) 
4-8 8-12 12-24 24-34 34-48 
15aOHNA 
NOR 
NA 
3.3 
0.5 
— 
8.5 
0.6 
0.5 
4.8 
0.4 
0.5 
1.7 
0.2 
0.2 
0.1 
0.1 
Concentrations are expressed as ßg deconjugated compound/ml 
Fig. 4.6. Identification by GC/MS of 
norandrostenedione in the urine of 
pigs treated with ß-nortestosterone. 
Mass spectra of a standard of 
norandrostenedione (A), and a 
compound in the urine with similar 
retention time (B), after derivatiza-
tion with MOX. 
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Discussion 
The biotransformation of ß-nortestosterone by hepatocytes isolated from livers of a 
number of sows and castrated male pigs showed a reproducible pattern. This resulted 
initially in the formation of norandrostenedione, which was further metabolized into a 
number of polar compounds. The most important metabolite, which in its free form had 
a retention time of 15 min, was identified as 15a-hydroxy-norandrostenedione by its 
spectrometric properties (Fig. 4.7). The molecular mass of 288 of the deconjugated 
metabolite is consistent with a metabolite of norandrostenedione, containing an 
additional hydroxy group. The presence of this hydroxy and the two keto groups is 
confirmed by the GC/MS analysis after derivatization of the metabolite with TMS and 
MOX/TMS, showing M+ peaks of 360 (288 + 72) and 418 m/e (288 + 72 + 2x 29). 
Furthermore, the fragments at 110 and 147 m/e in the mass spectrum of the underiva-
tized compound, indicate that the A and B rings contain no other substituents than the 
keto group at position 3 (Zaretskii 1976). Together with the UV spectrum and the 
NMR signal at 5.85 ppm, belonging to the proton at C-4, this also confirmed the 
presence of the double bond. 
Further information on the position of the hydroxy group came from the broad 
coupling of about 19 Hz, observed in the signals at 3.02 and 2.12 ppm in the NMR 
spectrum (Fig. 4.3A). Such a broad signal has been reported to be specific for the 
protons at C-16 in steroids with a keto group at C-17 (Leibfritz et al. 1982). The 
migration of the signal of the 16a-proton from about 2.5 to 3 ppm and the coupling 
of the signal at 4.43 ppm (H-15B) with the signals at 3.02 ppm (H-16a), 2.12 ppm 
(H-16B) and 1.40 ppm (H-14), strongly suggest that the hydroxy group should be at 
position 15a. More evidence for the a-orientation of the hydroxy group at C-15 comes 
from the only limited shift of the signal belonging to the protons at the methyl group 
(0.97 ppm) as compared to that in the 'H-NMR spectrum of norandrostenedione (0.94 
ppm), which in the case of a ß-orientation would have been much larger (Bridgeman 
et al. 1970). Finally, the coupling of the proton at 15ß with the hydroxy group at 3.5 
ppm explains the extra splitting of the pattern at 4.43 ppm, which disappears upon 
addition of CD3OD. The identity of the metabolite as 15a-hydroxy-norandrostenedione 
was subsequently confirmed by the similarity of the NMR and GC/MS spectra of this 
metabolite and a reference standard (Figs 4.3 and 4.4). 
No substantial changes were observed in the metabolite pattern of ß-nortestosterone 
during the first 48 h of the cultures (Fig. 4.1, Table 4.1). In particular, no decrease was 
observed in the oxidation at C-17, which in the case of testosterone and rats was shown 
to be cytochrome P-450b related (Waxman 1988, Wood 1983). Regarding the previously 
reported decrease in cytochrome P-450 levels and ECOD-activity (Chapter 3), this may 
be an indication that other enzymes like 17ß-hydroxysteroid-dehydrogenase (Sonderfan 
et al. 1989) are involved in the oxidation of ß-nortestosterone to norandrostenedione. 
The age-dependant decrease in the oxidation of norandrostenedione at C-15 subscribes 
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Fig.4.7. Major biotransformation pathway of ß-nortestosterone in primary cultures of pig hepatocytes. 
the role of a cytochrome P-450 related activity in this conversion step. 
The results from the in vivo experiment confirm the formation of norandrostenedione 
from ß-nortestosterone and its excretion by the cells, resulting in small quantities in the 
urine (Figs 4.5D and 4.6). The subsequent hydroxylation at C-15 and the almost 
complete glucuronidation are in agreement with the in vitro results. The less significant 
glucuronidation of the parent compound was not observed in vitro. The same was true 
for a number of other compounds observed in the HPTLC and GC/MS analysis, whose 
presence seemed to be related to the treatment with ß-nortestosterone. However, it is 
unclear whether these compounds are metabolites of ß-nortestosterone or compounds 
whose elimination is increased due to the treatment with this hormone. 
The present study shows that the use of hepatocytes, preceding in vivo studies, 
facilitates the characterization and detection of important in vivo metabolites and their 
subsequent identification. In addition to these type of biotransformation studies, the use 
of hepatocytes can be helpful in the production of both standards and reference 
materials necessary for the validation of analytical methods. 
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CHAPTER 5 
THE USE OF PIG HEPATOCYTES FOR TOXICITY STUDIES 
OF VETERINARY DRUGS 
A comparative study with furazolidone and other nitrofurans 
This chapter is based on the following publication: 
Hoogenboom L.A.P., Oorsprong M.B.M., Vliet T. van and Kuiper H.A. (1991). The use of pig 
hepatocytes for toxicity studies of veterinary drugs: a comparative study with furazolidone and 
other nitrofurans. Toxicology in Vitro. 
65 
THE USE OF PIG HEPATOCYTES FOR 
CYTOTOXICITY STUDIES OF VETERINARY DRUGS 
A comparative study with furazolidone and other nitrofurans 
Summary 
The possible application of primary cultures of pig hepatocytes for cytotoxicity studies of 
veterinary drugs was investigated, using the nitrofurans furazolidone, furaltadone, nitrofurazone, 
nitrofurantoin and nitrovin. Leakage of lactate-dehydrogenase (LDH) from the cells into the 
medium could be measured at high concentrations of nitrofurantoin, nitrovin, nitrofurazone and 
acetaminophen, which was used as a positive control. After incubation of cells with high 
concentrations of all drugs intracellular LDH activities were lower than the control. The 
incorporation of MC-leucine into proteins, especially those excreted into the medium, was shown 
to be a more sensitive parameter than LDH-leakage and was decreased by all drugs. 
Intracellular GSSG-levels were increased upon exposure to all nitrofurans. However, only after 
incubation of cells with 500 ßM nitrofurantoin intracellular GSH levels were decreased. In all 
other cases GSH-levels were unchanged or even elevated upon exposure. The most sensitive 
parameter measured, was the accumulation of pyruvate and lactate in the medium upon 
treatment with all nitrofurans except nitrovin. It was shown in the case of furazolidone, that this 
effect did not disappear immediately when the exposure was terminated and in addition 
accumulated upon repeated treatment of the cells, especially at low doses. 
The results of the study clearly demonstrate that primary cultures of pig hepatocytes can be 
used for cytotoxicity studies of veterinary drugs. 
Abbreviations: DMSO= dimethyl-sulfoxide; GSH= reduced glutathione; GSSG= oxidized glutathione; 
LDH= lactate-dehydrogenase (EC 1.1.1.27); PBS= phosphate buffered saline; PCA= perchloric acid; 
TCA= trichloro acetic acid 
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Introduction 
In previous chapters we described the isolation of hepatocytes from pig livers and 
the biotransformation of sulphadimidine, furazolidone and ß-nortestosterone by these 
cells. In addition to biotransformation studies, intact hepatocytes offer the opportunity 
to study the toxic properties of xenobiotics and their underlying mechanisms, as has 
been shown with hepatocytes from rats and other laboratory animals (Fry & Bridges 
1979; Jones et al. 1986; Ratanasavanh et al. 1988). However, hepatocytes from food-
producing animals have not been used for such studies, despite the fact that procedures 
for their isolation from liver samples of calves (Shull et al. 1987), sheep (Demigne et 
al. 1986), goats (Aiello et al. 1989) and pigs (Pangburn et al. 1981; Bachorik et al. 1982) 
have become available. Since species-specific metabolites may be formed, the use of 
hepatocytes isolated from livers of farmanimals should be preferred when studying the 
toxicity of compounds used in veterinary practice. This is of particular interest regarding 
the possible presence of such metabolites as residues in animal products. 
The aim of the present study was therefore to investigate the possible use of pig 
hepatocytes for studying the toxic properties of xenobiotics, in this case a number of 
nitrofurans, like nitrofurazone, nitrofurantoin, furazolidone, furaltadone, and nitrovin 
(Fig. 5.1). Nitrofurans are widely used as antibacterial and antiprotozoal agents in 
veterinary and human practice. However, following their application in man and 
animals, a number of very diverse toxic effects like peripheral neuropathy, degeneration 
of sexual glands (Paul & Paul 1964, Cohen 1978, Ali 1989), and hepatotoxic effects 
(Sharp et al. 1980, Black et al. 1980, Takabateke & Fukuhara 1978) have been 
observed. In addition, most of these compounds have been shown to posses mutagenic 
(McCalla 1983) and carcinogenic properties (Cohen 1978). 
For studying the toxicity of nitrofurans with pig hepatocytes, LDH-release and 
protein-synthesis were selected as more general end-points of cellular damage, and 
concentrations of reduced (GSH) and oxidized (GSSG) glutathione in the cells, and of 
pyruvate and lactate in the medium as more specific endpoints. Intracellular GSH levels 
may decrease regarding the role of GSH as a protective agent either by trapping 
reactive intermediates of nitrofurans, as was shown for furazolidone (Vroomen et al. 
1987; Vroomen et al. 1988), or as a substrate in the detoxification of hydrogen-peroxide 
by GSH-peroxidase, leading to the formation of GSSG (Holtzman 1981). In mammalian 
cells nitrofurans are primarily degraded by a reduction of the nitro-group (Vroomen et 
al. 1987; Boyd et al. 1979; Jonen 1980; Wang et al. 1974), initially leading to the 
formation of a radical nitro anion. Superoxide and eventually hydrogen peroxide may 
be formed due to reoxidation of this radical nitro anion by oxygen into the parent 
compound (redox-cycling). Reactive intermediates capable of binding covalently to 
proteins, DNA or GSH (Vroomen et al. 1987; Boyd et al. 1979; Vroomen et al. 1986) 
may be formed upon further reduction of the radical nitro anion. 
A disturbance of the pyruvate metabolism has been reported after incubation of 
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Fig. 5.1. Structures of the different nitrofurans used in the experiments described in this chapter. 
bacteria (Asnis et al. 1957; Lu & McCalla 1978) and slices of various rat tissues, 
including liver (Paul et al. 1952; Paul et al. 1953) with nitrofurans. Paul et al (1956), 
observing an inhibition of a crude preparation of the pyruvate dehydrogenase complex 
from pigeon breast muscle by nitrofurazone, postulated that the inhibition may be due 
to an effect of the drug on the electron-flow through the enzyme-complex. Lim et al. 
(1986) showed that exposure of isolated mouse liver mitochondria to nitrofurantoin and 
nitrofurazone resulted in an inhibition of state 3 respiration with complex I substrates, 
and presented evidence that reactive oxygen-species were responsible for the effect. 
Regarding the importance of possible irreversible and accumulating effects with 
respect to the actual administration of nitrofurans in vivo, special attention was paid to 
the recovery of cells from the exposure to furazolidone as well as to the effect of a 
repeated treatment of cells with this compound. In addition such studies may give more 
information on the mechanisms underlying the toxic effects observed. 
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Materials & Methods 
Materials 
Furazolidone (N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidinone) and nitrovin were 
a gift from Orphahell BV (Mijdrecht, The Netherlands). Nitrofurazone (5-nitro-2-
furaldehyde semicarbazone), nitrofurantoin (N-[5-nitro-2-furfurylidene]-l-amino-
hydantoin), furaltadone (5-morpholinomethyl-3-[5-nitrofurfurylidene-amino]-2-
oxazolidinone and acetaminophen were obtained from Sigma (St Louis, MO, USA). 
Williams' E, Hanks' balanced salts, trypan blue, penicillin/ streptomycin and foetal calf 
serum were purchased from Flow Labs (Rickmansworth, UK), collagenase type H, 
GSH, GSSG and analytical testkits for the determination of pyruvate and lactate from 
Boehringer (Mannheim, FRG) and L-[U-14C]leucine (specific activity 12.65 GBq/ mmol) 
from Amersham (Amersham, UK). 
Animals 
Liver samples were taken from six to nine month old sows used for studies at the 
Department of Animal Husbandry at the Agricultural University in Wageningen. In 
most cases animals were pregnant for 10 or 40 days. Only animals known to be free 
from possible drug treatment during the past 4 weeks were used. 
Isolation and culturing of hepatocytes 
Hepatocytes were isolated from a liver sample of about 100 grams by a three-step 
perfusion technique as described in Chapter 2. About 3.5 million viable cells were 
seeded in uncoated 60 mm culture dishes and allowed to attach for 4 h before renewal 
of the incubation medium. Routinely cells were incubated and exposed in Williams' 
medium E supplemented with 5% foetal calf serum, 0.5 /xg/ml insulin, 50 IU/ml 
penicillin and 50 /xg/ml streptomycin, in a C02 incubator at 37 °C. 
Exposure of cells 
All test compounds, except furaltadone were dissolved in dimethyl-sulfoxide (DMSO) 
and added to the medium to obtain the desired drug concentration. The final DMSO 
concentration of 1% had no direct effect on the parameters measured. Furaltadone was 
dissolved in water, filtersterilized and added to the medium (10 /xl/ml) which was 
supplemented with 1% DMSO. Nitrovin was dissolved in DMSO up to the highest 
possible concentration of 5 mM and therefore not tested at levels above 50 ßM. 
Monolayer cultures of hepatocytes were exposed for 16 h, starting 26 h after plating. 
In the case of recovery experiments with furazolidone, cells were exposed to the drug, 
washed twice with medium and incubated for another 8 h without the drug. At that 
time, incubation was either terminated or continued for another 16 h after replacement 
of the medium. During the same experiment, the effect of a repeated exposure was 
investigated. Therefore cells were incubated in the presence of different concentrations 
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of furazolidone for 16 h, washed twice, incubated for 8 h without the drug and 
subsequently exposed to the same drug concentrations as during the first interval. Single 
treated cells were handled in the same way, i.e. medium renewed and washed at the 
same time-points, but only exposed during the second interval. 
At the end of the incubation period, samples of the medium were taken for 
determination of the LDH-release and the protein synthesis. Cells were washed twice 
with phosphate buffered saline (PBS), scraped from the dishes in 1 ml of PBS with a 
rubber policeman, and resuspended using a Teflon pestle. For determination of the 
intracellular LDH-activity, a 100 /xl aliquot was diluted with 400 ßl PBS containing 1% 
Triton X-100 and homogenised by ultrasonic treatment. Except for the samples used 
for the LDH-release, all samples were stored in liquid nitrogen until analysis. 
Protein synthesis 
For measurement of the protein synthesis, cells were incubated with medium 
containing "C-labelled leucine (1850 Bq/ml) and the test compounds. At the end of the 
incubation, medium and cells were collected as described. Protein was precipitated by 
addition of PCA (final concentration 3%) and the supernatant was used for 
determination of the GSH-content. The pellet was washed three times with 7% TCA 
and solubilized in 1 ml of 5% sodium-dodecyl-sulphate/0.5 N NaOH. Samples of 0.75 
ml were mixed with 3 ml scintillation cocktail (Minisolve; Zinsser Analytical, 
Maidenhead, UK) and counted in a Philips liquid scintillation counter (type PW 4700). 
In the case of cellular protein, part of the samples were used for a protein 
determination. Figures for MC-leucine incorporation into proteins present in the medium 
and in the cells were corrected for cellular protein and subsequently compared with the 
adequate controls which were set to 100%. 
Assays 
Lactate-dehydrogenase activity (EC 1.1.1.27) in medium and cells was measured as 
described by Jauregui et al. (1981). Pyruvate and lactate in the medium were measured 
with Boehringer test-kits. Absolute amounts were calculated from calibration curves with 
known amounts of lactate and pyruvate in medium. Intracellular GSH was measured 
by the method of Reed et al. (1980), using a modified HPLC-method as described 
previously (Chapter 3). Protein in cells and medium was measured by the method of 
Lowry, as modified by Peterson (1977). 
Reproducibility 
All results presented were shown to be reproducible in at least one additional 
experiment with cells obtained from a liver sample of another pig. The significance of 
the observed differences between drug treated cells and the controls was statistically 
tested using the Student's t-test. For statistical analysis of the effect of a repeated 
exposure on the pyruvate metabolism an ANOVA-analysis was used. 
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Results 
As described in Chapter 2, hepatocytes isolated from a piece of pig liver, were 
shown to posses a high viability and were able to form monolayer cultures required for 
the present studies. The decision to start the exposition of cells to the drugs after a 
24 h recovery period was based on two observations. First of all, this period allowed 
the restoration of intracellular GSH levels, which decreased markedly during the 
isolation of the cells (Chapter 3). Secondly, contrary to the cytochrome P-450 related 
biotransformation reactions, the degradation of furazolidone was shown not to decrease 
during the first 96 h of the cultures (Chapters 3 and 9). 
Table 5.1 shows the effect of acetaminophen, used as a positive control, and the 
nitrofurans on LDH-leakage, protein synthesis and intracellular glutathione-status. A 
clear visible effect could only be observed after exposure to 10 mM acetaminophen, 
where cells were no longer stretched and partly detached. Exposure to this drug 
resulted in a dose related decrease of the GSH concentration, a reduction of the 
intracellular LDH-activity and an inhibition of the protein synthesis. The relatively high 
levels of radiolabelled proteins in the medium at 10 mM as compared to 3 mM were 
probably due to cell detachment. At this dose there was an increase in the LDH-activity 
in the medium. 
Slightly increased LDH-activity in the medium was also observed at the highest dose-
levels of nitrofurazone, nitrovin, nitrofurantoin and, after correction for the decreased 
total enzyme activity on the dish, also for furazolidone. Intracellular LDH-activities were 
more clearly lowered at these concentrations of the drugs. This correlated very well 
with the reduced incorporation of "C-leucine into proteins, as measured in the cellular 
fraction (corr. coef. 0.96). At lower doses the latter effect could only be measured on 
the proteins excreted into the medium, which contributed for about 15% to the total 
amount of "C-leucine incorporation in the case of cells incubated with 1% DMSO. 
Exposure to nitrofurans resulted in an increase in intracellular GSSG at the highest 
dose levels. However, only after exposure to 500 ßM nitrofurantoin, intracellular GSH-
levels were lower than the control. In all other cases GSH-levels were similar or even 
elevated, as demonstrated by the more than twofold increase after incubation of cells 
with 15 jLtM nitrovin. 
Fig. 5.2 shows the effect of nitrofurazone, nitrofurantoin, furaltadone and furazolid-
one on pyruvate and lactate concentrations in the medium. When combined (Fig. 5.2C), 
there was a clear dose-related accumulation of these compounds up to the highest drug 
levels tested, except for nitrofurantoin, where a maximum effect was seen at 150 /*M. 
Pyruvate levels alone followed a similar pattern (Fig. 5.2A), whereas lactate levels 
seemed to reach a plateau at the higher drug concentrations (Fig. 5.2B). As a result 
there was a dose related increase in pyruvate/lactate ratio's (Fig. 5.2D), although large 
variations for the different drugs were observed. Nitrovin, tested at 15 and 50 /xM, had 
no effect on pyruvate and lactate levels (data not shown). 
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Fig. 5.2. Pyruvate (A) and lactate (B) concentrations in the medium as well as their sum (C) and 
ratio (D) after incubation of pig hepatocytes for 16 h with various concentrations of furazolidone 
(eeeee), furaltadone (eeeee), nitrofurantoin (eeeee) and nitrofurazone (eeeee). Results are 
expressed as mean ± SEM (n=3). Concentrations marked with * are statistically higher from the 
control (p<0.05). 
The reversibility of some of the effects was investigated for furazolidone. As shown 
in Table 5.2, intracellular LDH-activity was fully restored within 24 h after ending the 
exposure. The amount of radiolabelled leucine present in proteins excreted into the 
medium was still low at the highest dose-level after 24 h. However, when the figures 
of cells and medium were combined, overall protein-synthesis at the dose of 500 juM 
was 75 ± 3 and 95 ± 1% of the control after 8 and 8 + 16 h respectively. Intracellular 
GSH-levels tended to be elevated in cells after exposure to the drug, even after 24 h. 
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Table 5.2 Reversibility of œil damage due to furazolidone exposure, after a recovery period of 
eight (+8) or eight plus sixteen h (+8+16). Results shown in Tables 5.1 and 5.2 were from 
experiments performed with cells isolated from the same liver (mean ± SEM; n=3). Results 
marked with * are significantly different from the control (p<0.05). 
cone. 
(/xM) 
0 
50 
500 
0 
50 
500 
recovery 
interval 
00 
+8 
+8 
+8 
+8+16 
+8+16 
+8+16 
cellular LDH 
(U/mg protein) 
0.78 ± 0.02 
0.85 ± 0.04 
0.63 ± 0.01 * 
1.10 ± 0.00 
1.44 ± 0.08 
1.10 ± 0.03 
protein synthesis 
medium 
100 
68 
28 
100 
85 
33 
(% 
± 5 
± 0 
± 2 
± 0 
± 8 
± 4 
of 
* 
* 
* 
cells 
control) 
100 ± 
106 ± 
85 ± 
100 ± 
111 ± 
117 ± 
2 
3 
2 * 
1 
2 * 
1 * 
cellular GSH 
(nmol/mg protein) 
54.8 
70.5 
76.6 
65.5 
79.3 
75.0 
± 
± 
± 
± 
± 
+ 
3.0 
1.2 * 
4.4 * 
1.6 
1.3 * 
2.1 
In order to investigate the reversibility of the effect of furazolidone on the pyruvate 
metabolism, cells were exposed to various concentrations of the drug for 16 h, washed 
and subsequently incubated in medium without the drug for 8 h, followed by a renewal 
of the medium and an additional incubation for 16 h without the drug (Fig. 5.3). 
During the first 8 h of incubation in renewed medium, the rate of accumulation of 
pyruvate and lactate seems to be unchanged as compared to the 16 h incubation in the 
presence of the drug. After the second renewal of the medium, a substantial decrease 
in pyruvate accumulation was observed in the medium at all concentrations whereas the 
effect on lactate was still clearly present, especially at the highest dose rate. 
When cells were exposed to furazolidone for a second interval of 16 h after a 
recovery interval of 8 h, there was a clear accumulation of the effect at lower dose-
levels (Fig. 5.4). However, only a small effect of the repeated exposure was observed 
at higher concentrations. 
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Fig. 5.3. Recovery of cells from the effect of furazolidone on the pyruvate metabolism. Cells were 
exposed to 0 • , 15 • , 50 A , 150 • , or 500 + pM of the drug for 16 h. At 16 h and again 
at 24 h the medium was replaced by medium without drug. Levels of pyruvate (A) and lactate (B) 
were measured in media samples taken at 16, 24 and 40 h. Results are expressed as the mean for 
triplicate dishes (n=3). For clarity the SEM has been omitted from the figure. Concentrations 
marked with * are significantly higher than the control (p<0.05). 
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Fig. 5.4. Accumulation of pyruvate and lactate in the medium after a single (| \) or repeated 
(W%X\ exposure to furazolidone. Cells were incubated in the presence of different concentrations 
of the drug for 16 h, washed twice, incubated for 8 h without the drug and subsequently exposed 
to the same drug concentrations as during the first interval for another 16 h. In the case of a 
single exposure (| |) cells were similarly treated but only exposed during the second interval. 
Bars represent the combined average concentrations of lactate (lac) and pyruvate (pyr), both with 
their own SEM (n=3). The dose dependant differences in pyruvate and lactate concentrations, 
both separate and combined, between single and repeatedly treated cells were statistically 
significant (p<0.05; ANOVA). 
Discussion 
The present study shows that the end-points selected could easily and reproducibly 
be measured in monolayer cultures of pig hepatocytes. Therefore the model could be 
used to study the cytotoxicity of a number of widely used nitrofurans. 
Incubation of pig hepatocytes with the known hepatotoxic agent acetaminophen 
resulted in a decrease in intracellular GSH and the subsequent increase of LDH-activity 
in the medium as was previously reported for hepatocytes from rats (Hayes et dl. 1986; 
Mitchell et al. 1985) and hamsters (Boobis et al. 1986). 
Among the different end-points selected, changes in LDH-activity in the medium and 
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the cells, which are considered to be an indication for membrane-damage, could only 
be observed at high doses of the drugs. The decrease in the intracellular LDH-activity 
cannot be explained by leakage of the enzyme into the medium, and may rather be due 
to an effect of the test compounds on either the activity or the de novo synthesis of the 
enzyme. The latter theory is supported by the good correlation between the decrease 
in intracellular LDH-activity and the inhibition of the protein synthesis. Furthermore, 
synthesis of LDH by the cells during the exposure intervals was clearly demonstrated 
from the increase in intracellular LDH during the ageing of the cultures (0.62 ± 0.04 
and 1.10 ± 0.00 U/mg protein at 44 and 68 h after isolation respectively; Tables 5.1 
and 5.2). 
For testing the toxicity of the nitrofurans, the inhibition of the incorporation of MC-
leucine into cellular proteins and especially into those excreted into the medium, 
appears to be a more sensitive end-point (Table 5.1). The more pronounced effect of 
the drugs on the proteins excreted in the medium may be explained by a selective 
reduction in the synthesis of these proteins or an effect of the test compounds on their 
excretion by the cells. The results of the recovery experiment with furazolidone 
(Table 5.2) seem to support the latter hypothesis, since 24 h after withdrawal of the 
drug, the overall protein synthesis seemed to be almost restored while the amount of 
radiolabelled leucine in proteins excreted into the medium was still reduced. At this 
point it is unclear whether there is a relation between this effect and the decreased 
plasma protein levels that have been measured in the case of chickens (Ali 1984), 
turkeys (Pang et al. 1982; Simpson et al. 1979), and goats (Mustafa et al. 1987) treated 
with furazolidone. 
The increased levels of intracellular GSSG after exposure of pig hepatocytes to 
nitrofurans (Table 5.1) are indirect evidence for the detoxification of reactive oxygen 
species, generated by redox-cycling of the radical nitro-anion with oxygen. The 
formation of the radical nitro-anion was recently demonstrated in rat hepatocytes 
incubated with nitrofurazone and nitrofurantoin (Rao et al. 1988). The decreased 
intracellular GSH levels observed in the case of nitrofurantoin are in agreement with 
results reported for rat hepatocytes (Rossi et al. 1988) and perfused rat liver (Aker-
boom et al. 1982, Hoener et al. 1989). The absence of GSH-depletion after exposure 
of cells to other nitrofurans was unexpected and contradictory to the decrease observed 
after treatment of a perfused rat liver with nitrofurazone (Hoener 1988). It is possible 
that a loss of GSH caused by an increased formation of GSSG and possibly GSH-
conjugates is compensated by an adequate reduction of GSSG to GSH by GSSG-
reductase and furthermore an elevated synthesis of GSH by the cells. The active 
synthesis of GSH by these cells has already been demonstrated in chapter 3 and may 
also explain the elevated GSH-levels observed in some cases at the end of the exposure 
interval (Table 5.1) or after a recovery period (Table 5.2). The use of an incubation 
medium like Williams' E, which contains high concentrations of the amino-acids 
required for GSH-synthesis, might therefore be one of the possible explanations for the 
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discrepancies between the results of our experiments and those reported by other 
authors. 
This is the first report on a disturbance of the metabolism of pyruvate in cultured 
mammalian cells incubated with nitrofurantoin, nitrofurazone, furazolidone and furalta-
done (Fig. 5.2). This parameter turned out to be the most sensitive end-point measured 
for detecting the cytotoxicity of nitrofurans. The slow recovery of the cells from the 
damage as well as the accumulation of the effect upon repeated exposure to 
furazolidone point in the direction of an irreversible binding of furazolidone or a 
metabolite to the pyruvate-dehydrogenase complex as suggested by Paul et al. (1956). 
A similar slow recovery of the decreased glucose consumption and citrate formation was 
observed with testis tissues isolated from rats killed either during the treatment with 
nitrofurazone, nitrofurantoin or furazolidone, or after a recovery period (Paul et al. 
1953). It is of interest to investigate whether this inhibition underlies the elevated 
plasma levels of pyruvate and lactate that have been reported for man (Paul & Paul 
1964) and turkey (Ali & Bartlet 1982), although in the latter case the authors 
themselves ascribed the effect to the reduced feed intake after drug treatment. 
In comparing the different nitrofurans tested, it appears that exposure of cells to 
nitrovin results in somewhat different biological effects than the other compounds. 
Effects on LDH-activity in medium and cells, and on protein synthesis were observed 
at relatively low doses, whereas the drug appeared to have no effect on the metabolism 
of pyruvate. Furthermore, nitrovin had a striking effect on GSH-levels, as discussed 
before. Of the other four compounds, nitrofurantoin seems to have the largest impact 
on the cells, as demonstrated by the LDH-leakage, the GSH-depletion and the peak 
in the effect on the pyruvate metabolism at 150 ßM. The higher sensitivity for this drug 
may be explained by the fact that nitrofurantoin is a more potent inhibitor of GSSG-
reductase than the other compounds (Buzard & Kopko 1963, Ondarzo & Abney 1970; 
Grinblat et al. 1989). 
From the results presented above, it is clear that most of the effects observed with 
other in vitro models could be reproduced with cultures of pig hepatocytes. In general 
however, results from in vitro studies will have to be validated by in vivo studies. As 
indicated above, some of the observed effects might be related to effects that have 
been noticed after treatment of animals. However, further in vivo studies will have to 
reveal the biological significance of the various effects. In this regard, the observation 
of an accumulating inhibitory effect after repeated exposure is particularly interesting, 
since it may have consequences for the administration regime of these compounds in 
the veterinary practice. The results of the present study clearly demonstrate that 
hepatocytes isolated from a sample of pig liver, can be used for detecting and 
comparing the (hepato)toxic properties of veterinary drugs, therefore avoiding possible 
extrapolation problems due to species differences. Furthermore, these cells may be very 
useful for studying in more detail the mechanisms underlying the observed effects. 
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CHAPTER 6 
THE USE OF PIG HEPATOCYTES TO STUDY THE 
INHIBITION OF MONOAMINE OXIDASE BY FURAZOLIDONE 
This chapter is based on the following publication: 
Hoogenboom L.A.P., Tomassini O., Oorsprong M.B.M, and Kuiper H.A. The use of pig 
hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Fd Chem. 
Toxicology (in press). 
83 
THE USE OF PIG HEPATOCYTES TO 
STUDY THE INHIBITION OF MONOAMINE OXIDASE 
BY FURAZOLIDONE 
Summary 
Primary cultures of pig hepatocytes were used to examine the irreversible inhibition of 
monoamine oxidase (MAO), observed in tissues of a number of different animal species after 
oral treatment with furazolidone. The rapid biotransformation of the MAO-substrate p-tyramine 
by intact cells could effectively and irreversibly be inhibited with the known MAO-inhibitors 
iproniazid and clorgyline. Incubation of cells with ß-hydroxyethylhydrazine but also 3-amino-2-
oxazolidinone, which were previously proposed as the metabolites of furazolidone responsible 
for the in vivo effect, resulted in an irreversible inhibition of the MAO-activity. Incubation of 
cells with furazolidone also resulted in a dose related inhibition, but this effect was completely 
reversible upon withdrawal of the drug. A similar MAO-inhibition was observed after treatment 
of cells with nitrofurazone and furaltadone but not nitrofurantoin. 
The results obtained with intact cells were confirmed by studies with 13,000 g pellets of 
homogenates made from cells preincubated for 24 h with the compounds, showing an 
irreversible type of inhibition in the case of iproniazid and 3-amino-2-oxazolidinone, but not in 
the case of furazolidone. 
The present study shows that hepatocytes are capable of transforming 3-amino-2-
oxazolidinone, but not furazolidone itself, into a potent irreversible type of MAO-inhibitor. 
Abbreviations used: MAO= monoamine oxidase; AOZ= 3-amino-2-oxazolidinone; 
HEH= ß-hydroxyethylhydrazine; LDH= lactate-dehydrogenase 
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Introduction 
C H = N 
Oral treatment of human patients (Pettinger et al. 1968), and animals like poultry 
(Ali et al. 1980; Ali et al. 1982), ducklings (Ali et al. 1982), and rats (Palm et al. 1967; 
Stem et al. 1967; Yeung & Goldman 1981), with furazolidone, nowadays widely used 
as a veterinary drug, has been shown to result in the inhibition of monoamine oxidase 
activity [EC 1.4.3.4] (MAO) in tissues from these animals. Since the inhibitory effect 
was shown to accumulate upon repeated exposure and disappeared only gradually after 
termination of the treatment (Ali et al. 1980; Palm et al. 1967; Stern et al. 1967; 
Pettinger et al. 1968), it is thought to be due to the irreversible binding of a metabolite 
of furazolidone to the MAO enzyme(s). Stern et al. (1967) hypothesized that this 
metabolite might be ß-hydroxyethylhydrazine (HEH), formed by ring cleavage of 
3-amino-2-oxazolidinone (AOZ), which is 
derived from the side-chain of furazolid-
one by hydrolysis of the azomethine bond 
(Fig. 6.1). This hypothesis is supported by 
the fact that MAO-inhibition was 
observed in tissues of rats after oral 
treatment with AOZ and HEH, but not 
after treatment with nitrofurans 
containing different side-chains, like nitro-
furantoin, nitrofurazone and furaltadone 
(Palm et al. 1967; Stern et al. 1967). 
Furthermore, the proposed active 
metabolite, HEH, was shown to be a 
potent MAO-inhibitor in isolated rat liver 
mitochondria, whereas AOZ and furazol-
idone gave negative results (Stern et al. 
1967). The fact that the MAO-inhibition 
by furazolidone may be related to the 
possible transformation of its side-chain 
into a hydrazine, is of particular interest, 
since AOZ may not only be released 
from the parent compound, but also from 
protein-bound metabolites of the drug, 
which can be present as residues in 
edible tissues of farmanimals (Vroomen 
et al. 1986, 1988; Chapter 8). Since 
in chickens the MAO-inhibition was 
observed only after oral administration of 
furazolidone, but not after intramuscular 
furazolidone 
I 
H N— N 
3 -amino—2-
H N -
2 - N H -
-oxazolidinone 
I 
1 
- C H 2 - - C H 2 O H 
ß—hydroxyethylhydrazine 
Fig. 6.1. Proposed pathway for the degradation of 
furazolidone, leading to the formation of ß-hydroxy-
ethylhydrazine (Stern et al. 1967). 
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injection (Ali et al. 1982), it has been proposed that the ultimate active metabolite is 
formed in the G.I. tract, most likely by bacteria. Results from experiments with chickens 
and ducklings (Ali et al. 1980; Ali et al. 1982), where the bacterial activity was reduced 
by simultaneous treatment with neomycin, seemed to support this hypothesis, but were 
contradicted by the results of an experiment with germfree rats (Yeung & Goldman 
1981). Furthermore, both Stern et al. (1967) and Cohen (1979) showed that such a 
difference between oral and intramuscular, or intraperitoneal treatment was less obvious 
in the case of rats. 
Aim of the present study was to further investigate the MAO-inhibiting properties 
of furazolidone using intact pig hepatocytes instead of cell fractions. This approach 
offers the advantage of a model with an intact biotransformation potential, and also 
might give a better insight on the actual effect of the MAO-inhibition on the activity 
of the cell towards specific MAO substrates. Furthermore, as shown before (Chapter 
5), monolayer cultures can easily be washed and are therefore very suitable for studying 
the recovery of the cells from the observed effects, thereby supplying important 
information to explain their underlying mechanisms. 
Previously, Cohen (1979) showed that the decreased MAO-activity in brain 
homogenates of rats treated with furazolidone or HEH, was non-specific with regard 
to the A and B forms of the enzyme. Therefore, the MAO-activity was determined by 
incubating the cells with "C-labelled p-tyramine, a well known substrate for both A and 
B types of the MAO-enzymes (Houslay & Tipton 1976), followed by the selective 
extraction of the deaminated metabolites at pH 5, as described by Otsuka and 
Kobayashi (1964). Using this method, the effects of the known MAO-inhibitors 
clorgyline and iproniazid were compared with those of HEH, AOZ and furazolidone, 
as well as a number of other nitrofurans, paying special attention to the reversibility of 
the observed inhibition. 
Materials & Methods 
Chemicals 
Collagenase type H was obtained from Boehringer (Mannheim, FRG), multiwell 
tissue culture dishes from Costar (Badhoevedorp, The Netherlands), Williams' medium 
E, Hanks' balanced salts, trypan blue, penicillin/streptomycin and fetal calf serum from 
Flow Labs (Rickmansworth, UK), insulin, iproniazid, clorgyline, ß-hydroxyethylhydrazine, 
nitrofurazone, furaltadone, nitrofurantoin and p-tyramine from Sigma (St. Louis, USA). 
Furazolidone and 3-amino-2-oxazolidinone were gifts from Orphahell BV (Mijdrecht, 
The Netherlands). "C-labelled p-tyramine (spec. act. 1.63 GBq/mmol) was purchased 
from NEN (Boston, USA). 
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Animals 
Liver samples were taken from six to nine month old sows (Dutch Landrace x 
Yorkshire) used for studies at the Department of Animal Husbandry at the Agricultural 
University in Wageningen, The Netherlands. 
Isolation of hepatocytes 
Hepatocytes were isolated from a piece of pig liver by a three-step perfusion 
method, as described in Chapter 2. Cells were diluted to a density of about 0.5 million 
per ml of incubation medium, Williams' medium E supplemented with 5% fetal calf 
serum, 0.5 Mg/ml insulin, 50 IU/ml penicillin and 50 jug/ml streptomycin. Of this 
suspension 0.5 ml was seeded per well of a 24-multiwell dish. After 4 h the medium 
was replaced by 0.25 ml new medium and the cells were incubated for another 16-24 h 
before experiments were started. 
MAO-inhibition assay 
Inhibition of MAO-activity was measured as described by Otsuka and Kobayashi 
(1964). In short, cells were washed once with Williams' E and incubated with 250 ßl 
of Williams' E supplemented with the drugs dissolved in dimethyl-sulfoxide (DMSO; 
final concentration in the medium 1%). After preincubation (usually one hour), 50 ßl 
of Williams' E containing 600 ßM 14C-labelled p-tyramine (diluted to a spec. act. of 10 
MBq/mmol) was added. At the end of the incubation interval (normally 20 or 30 min) 
a sample of 200 ßl was taken, diluted with 800 ßl 0.5 M citric acid and mixed with 
2 ml toluene/ethylacetate (1:1 v/v) containing 0.6% 2,5-diphenyl-oxazole (PPO). After 
centrifugation and freezing of the water layer, the supernatant was aspirated, mixed 
with 2 ml of scintillation cocktail (Minisolve, Zinser, FRG) and counted in a Philips 
liquid scintillation counter (PW 4700). Using this method about 70% of the metabolites 
were recovered with the first extraction. 
In the case of recovery experiments cells were incubated with the drug, washed twice 
with Williams' E and incubated in 250 ßl plain medium for another 1 or 24 h, before 
the addition of the solution containing p-tyramine as described above. 
MAO-inhibition in cell homogenates was determined by incubating cells in 60 mm 
culture dishes with drugs for 24 h, washing them twice with Williams' E followed by 
another incubation without drugs for 2 h. Cells were washed twice with phosphate-
buffered saline and scraped from the dishes in 1 ml of a phosphate buffer (KPi, 0.1 M, 
pH 7.4) using a rubber policeman. Cells were disrupted by ultrasonic treatment and the 
resulting homogenates centrifuged at 13,000 g for 10 min (4 °C). The supernatant was 
aspirated and the pellet was dissolved in 1 ml KPi. MAO-activity was measured by 
adding 100 ßl of this suspension to 400 ßl of KPi (0.1 M, pH 7.4), containing 125 ßM 
14C-labelled p-tyramine (37 °C). After 30 min a sample of 200 ^1 was taken and treated 
as described above. Protein in the 13,000 g fractions was determined by the method of 
Lowry as modified by Peterson (1977). 
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Leakage of the cytosolic enzyme lactate-dehydrogenase into the medium was 
determined by the method of Jauregui et al. (1981) as described in Chapter 5. 
Calculations and statistics 
All measurements were corrected for a blanc, i.e. a sample taken at the start of the 
incubation. In most cases the fractions of p-tyramine metabolized by treated cells are 
expressed in relation to the fractions metabolized by the appropriate controls. In the 
other cases, where the results are presented as the fraction of p-tyramine metabolized 
(Fig. 6.4), a correction was made for the 70% of metabolites recovered by the method 
used. All incubations were performed in triplo and controls were included in each 
multiwell-dish. The results from all experiments were checked for their reproducibility 
in at least one other experiment with cells isolated from the liver of another pig. 
Differences observed between treated and untreated cells were tested for significance 
using the two-tailed Student's t-test. 
Results 
Using the method of selective extraction of radiolabelled metabolites, the 
biotransformation of p-tyramine by pig hepatocytes could easily be measured. After 
incubation of 4 h old monolayer cultures with 100 pM p-tyramine for 20 min, 55 ± 2% 
of the substrate was metabolized into extractable metabolites. This fraction decreased 
to 33 ± 3% and 20 ± 2% in 26 and 50 h old cultures. Therefore, the standard 
incubation time of 20 min, used when working with 24-28 h old cultures, was prolonged 
to 30 min when cells were incubated for periods of 24 h. Within a 20 min incubation 
interval, very similar amounts of p-tyramine were deaminated by 24 h old cell cultures, 
isolated from the three other pigs used for the experiments described in this study, 
being respectively 36 ± 0, 29 ± 2, and 36 ± 0%. 
Fig. 6.2 shows the biotransformation of p-tyramine both in the presence of the 
MAO-inhibitors clorgyline and iproniazid and after an additional recovery interval of 
24 h. The MAO-activity could be completely reduced by these drugs and this activity 
was only slowly restored upon withdrawal of the drugs from the medium. 
Exposure of cells for 1 h to HEH resulted in a marked inhibition of the MAO-
activity, which similar to iproniazid and clorgyline, recovered only slowly upon 
withdrawal of the agent from the medium (Fig. 6.3A). A further increase of the MAO-
inhibition was observed upon prolonged incubation in the presence of this compound, 
especially at low concentrations (Fig. 6.3B). Incubation of cells with AOZ for 1 h 
resulted only in a slight inhibition of the biotransformation of p-tyramine (Fig. 6.3C). 
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Fig. 6.2. Biotransformation of p-tyramine both in the presence of clorgyline (A) or iproniazid (B), 
or after an additional recovery interval of 24 h. 
Cells were preincubated for 1 h with the drugs (and 1% DMSO). At that time p-tyramine was 
added (| |) or cells were washed twice and incubated without drugs for 24 h prior to the 
addition of p-tyramine {WW\- Results are presented as the fraction of the control (mean ± 
SEM; n=3). The fractions of p-tyramine metabolized by the control cells were 36.0 ± 0.3 and 
25.2 ± 0.2% without or after a recovery period. For both drugs differences with the control were 
significant at all concentrations tested (two-tailed Student's t-test; p<0.05). 
However, as shown in Fig. 6.3D, there was a clear and irreversible inhibition after an 
incubation interval of 24 h. 
Incubation of cells with different concentrations of furazolidone resulted in a dose-
related decrease in the amount of extractable metabolites (Fig. 6.4). The MAO-activity 
was however completely restored after exposure of cells to the drug for 1 h followed 
by a recovery interval of 1 h (Table 6.1). Furthermore, when cells were exposed to 
furazolidone for 24 h, the inhibition that was observed after 1 h in the presence of 
500 ßM, could no longer be measured (Table 6.1). After an additional recovery period 
of 1 h there was even an increase in the amount of extractable metabolites formed by 
the cells. 
Similar to furazolidone, the biotransformation of p-tyramine by the cells was 
decreased in the presence of nitrofurazone and furaltadone but only to a minor extent 
in the presence of nitrofurantoin (Table 6.2). The good solubility of furaltadone in 
water made it possible to check the use of DMSO as a solvent for the other 
compounds. As indicated in Table 6.2, DMSO slightly decreased the MAO-activity, but 
the relative fractions metabolized, as compared to the appropriate controls, were not 
influenced by this effect of the solvent. 
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Fig. 6.3. The effect of ß-hydroxy-ethylhydrazine (A,B) and 3-amino-2-oxazolidinone (C,D) on the 
deamination of p-tyramine. 
Cells were incubated with the compounds (and 1% DMSO) for 1 (A,C) or 24 (B,D) h. At that 
time p-tyramine was added (| |) or cells were washed and incubated without the drug for 1 
{V////A\ or 24 (^^1) h prior to the incubation with p-tyramine. Results are expressed as the 
fraction of the control (mean ± SEM; n=3). Values marked with * were significantly different 
from the control (two-tailed Student's t-test; p<0.05). The fractions of p-tyramine metabolized by 
control cells were 29.2 ± 1.6, 34.4 ± 0.9, and 29.2 ± 1.6% after incubation for 1 h followed by 
recovery intervals of respectively 0, 1 and 20 h, and 31.9 ± 1.4, and 32.2 ± 0.9% after incubation 
for 24 h followed by recovery intervals of respectively 0 and 1 h. 
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Fig. 6.4. Biotransformation of p-tyramine by monolayer cultures of pig hepatocytes in the absence 
or presence of different concentrations of furazolidone. 
Cells were preincubated in medium containing 1% DMSO and 0 ( • ), 50 ( T ), 150 ( • ) or 
500 ( • ) /iM furazolidone for 1 h. At that time p-tyramine was added and samples were taken 
after another 15, 30 or 60 min. Results are presented as the mean ± SEM (n=3), unless the size 
of the symbol was larger than the SEM. At all concentrations of furazolidone and at each time 
interval, the differences with the control were statistically significant (two-tailed Student's t-test; 
p<0.05). 
In none of the experiments described in this Chapter, exposure of cells resulted in 
clear visible effects, like rounding up or detachment of cells. Furthermore, exposure to 
AOZ had no effect on levels of either intracellular or extracellular LDH-activity (data 
not shown). However, since a decreased biotransformation of p-tyramine by intact cells 
may be caused by not observable cytotoxic effects, other than a direct inhibition of the 
MAO-enzyme, some additional experiments were performed with 13,000 g pellet 
fractions of cells, homogenized after their incubation for 24 h in the presence of 
furazolidone, AOZ or iproniazid, followed by a recovery interval of 2 h. As shown in 
Table 6.3, exposure to both iproniazid and AOZ resulted in a clear decrease in the 
MAO-activity, whereas in the case of furazolidone no effect could be measured. 
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Table 6.1. The effect of a short or long preincubation with furazolidone on the biotransformation 
of p-tyramine by pig hepatocytes, and the effect of a recovery interval. 
Cells were preincubated in the presence of furazolidone for 1 or 24 h. At that time p-tyramine 
was added or cells were washed twice and incubated without drug for 1 h prior to the addition 
of p-tyramine (+rec). Results are presented as the fraction of the control (mean ± SEM; n=3). 
Values marked with * are significantly different from the control (two-tailed Student's t-test; 
p<0.05). The fractions of p-tyramine metabolized by the controls are presented in the legends of 
Fig. 6.3. 
Concentration 
(MM) 
0 
50 
500 
l h 
100.0 ± 
91.9 ± 
55.3 ± 
5.3 
6.2 
3.2 * 
24 h 
100.0 ± 
98.8 ± 
115.0 ± 
MAO 
(% 
4.3 
6.2 
3.2 
of 
-activity 
control) 
1 h + 1 h ree. 
100.0 ± 2.6 
94.9 ± 5.7 
102.9 ± 0.2 
24 h + 1 h ree. 
100.0 ± 2.6 
99.3 ± 3.5 
146.5 ± 1.8 * 
Table 6.2. The metabolism of p-tyramine in the presence of furazolidone, nitrofurazone, nitro-
furantoin and furaltadone, and the effect of the solvent DMSO. 
Cells were preincubated with different concentrations of the drugs (and 1% DMSO) for 1 h, prior 
to the incubation with p-tyramine for 20 min. The effect of the water-soluble furaltadone was also 
studied in the absence of 1% DMSO. Results are presented as the fraction of the control (mean 
% SEM; n=3). Values marked with * are significantly different from the control (two-tailed 
Student's; p<0.05). The amount of tyramine metabolized by the controls was 36.2 ± 0.3 and 40.5 
± 0.3% of the initially added dose, in the presence or absence of DMSO respectively. 
Compound Concentration MAO-activity (% of control) 
(/iM) with DMSO without DMSO 
100.0 ± 0.7 Control 
Furazolidone 
Nitrofurazone 
Nitrofurantoin 
Furaltadone 
50 
500 
50 
500 
50 
500 
50 
500 
100.0 
85.2 
42.1 
86.4 
38.3 
97.7 
94.3 
77.6 
36.1 
± 
± 
± 
± 
± 
± 
± 
± 
± 
0.9 
1.4 
0.5 
2.7 
2.7 
1.7 
1.4 
1.2 
0.2 
73.9 ± 0.9 
35.3 ± 0.2 
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Table 6.3. MAO-activity in 13,000 g pellets of cells, homogenized after incubation for 24 h in the 
presence of furazolidone, 3-amino-2-oxazolidinone (AOZ) or iproniazid, followed by a recovery 
interval of 2 h. 
Results were corrected for the amount of protein and are expressed as the fraction of the control 
(mean ± SEM; n=3). In the case of the control 45.4 ± 0.3% of the p-tyramine was deaminated. 
Values marked with * were significantly different from the control (two-tailed Student's t-test 
p<0.05) 
Compound 
1% DMSO 
Furazolidone 
AOZ 
Iproniazid 
Concentration 
(/xM) 
50 
500 
50 
500 
10 
MAO-activity 
(% of 
100.0 
92.8 
107.3 
74.9 
9.2 
4.9 
control) 
+ 
+ 
± 
± 
± 
+ 
1.1 
3.2 
4.2 
2.9 * 
0.4 * 
0.5 * 
Discussion 
The present study demonstrates that pig hepatocytes are a useful model to study the 
potency of drugs to inhibit MAO-activity. First of all it was shown that the method 
generally used for tissue homogenates (Otsuka and Kobayashi 1964), can easily be 
applied with this model with high reproducibility both within and between cell cultures 
of different animals. The specificity of the system was shown by the fact that the MAO-
related formation of extractable metabolites of p-tyramine could be completely blocked 
with the MAO-inhibitors clorgyline and iproniazid (Fig. 6.2). The slow recovery of the 
effect is in agreement with the irreversible binding of these drugs to the MAO-enzyme, 
the recovery being dependent on the de novo synthesis of the enzyme. Further evidence 
that this effect is actually due to the inhibition of the MAO-activity and not to another 
cytotoxic effect, is presented by the inhibited activity in 13,000 g pellets of cells, 
homogenized after their incubation with iproniazid (Table 6.3). The almost complete 
inhibition observed with clorgyline appears to be contradictory to the supposed 
selectivity of this compound towards type A MAO-activity (Johnston 1968), since 
p-tyramine can be metabolized by both the A and B type MAO-enzymes (Houslay & 
Tipton 1976), and since both forms have been shown to be present in pig liver (Ekstedt 
1979). However, as shown by Yang & Neff (1974), the specificity of clorgyline for 
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MAO-A is concentration dependant, since at higher dose levels it also inhibited MAO-
B activity. An additional explanation may be a higher affinity of MAO-A towards 
p-tyramine, as shown in the case of rat liver (Fowler & Tipton 1981); as a result 
p-tyramine could be selectively deaminated by the A-form at the concentrations used 
in our experiments, especially regarding a possible concentration gradient over the cell 
membrane. In our studies the inhibition by clorgyline could, however, not be 
circumvented by increasing the concentration of p-tyramine from 100 ßM up to 3 mM 
(data not shown). However, since the in vivo inhibition by furazolidone has been shown 
to be non-specific with regard to the two forms of MAO-activity (Cohen 1979), the 
possible specificity of p-tyramine should not be crucial for the outcome of the present 
study. 
The rapid and irreversible inhibition of the MAO-activity after exposure of cells to 
HEH (Figs 6.3A and 6.3B), is in agreement with the results from experiments with rats 
and rat liver mitochondria (Stern et al. 1967, Cohen 1979). The MAO-inhibition caused 
by AOZ (Figs 6.3C and 6.3D) has been demonstrated in vivo but could up till now not 
be reproduced in vitro (Stern et al. 1967). The fact that in our study the inhibition 
becomes more clear after prolonged incubation with AOZ (Figs 6.3C and 6.3D), 
supports the hypothesis that AOZ has to be transformed into an active metabolite. This 
would explain the negative results obtained with isolated mitochondria, either because 
the incubation time was to short, or because these organelles were unable to activate 
AOZ. The reduced metabolism of p-tyramine observed with 13,000 g' pellets of cells 
pretreated with AOZ (Table 6.3), further demonstrates that the effect of AOZ is 
specific. 
The dose-related inhibition of the metabolism of p-tyramine in the presence of 
furazolidone, following preincubation with the drug for 1 h (Fig. 6.4), differed in two 
ways from the MAO-inhibition observed in vivo. First of all, the inhibition disappeared 
completely upon withdrawal of the drug from the medium (Table 6.1), whereas in vivo 
only a slow recovery was observed (Ali et al. 1980; Palm et al 1967; Stern et al. 1967; 
Pettinger et al. 1968). Secondly, in contrast to the in vivo situation (Palm et al. 1967; 
Stern et al. 1967), the inhibition was also observed with the nitrofurans nitrofurazone 
and furaltadone (Table 6.2). A similar conclusion could be drawn from the results 
obtained with intact cells (Table 6.1) and cellular fractions (Table 6.3) of cells, that had 
been incubated with furazolidone for 24 h. Although apparently the inhibition in the 
presence of the drug was no longer observed, the MAO-activity in intact cells was still 
suppressed in a reversible way as shown upon withdrawal of the drug from the medium. 
The reason for the increased formation of extractable metabolites of p-tyramine at the 
highest dose-level is unclear, but may be due to the inhibition of other enzymes 
involved in the metabolism. It can however be concluded that, contrary to AOZ, 
prolonged incubation of cells with furazolidone did not result in the formation of the 
metabolites, or at least adequate amounts of them, required for a detectable 
irreversible inhibition of the MAO-activity. This cannot be ascribed to a lack of 
95 
biotransformation of the drug, since similar studies revealed that during a 24 h 
incubation interval, about 50 and 10% of the furazolidone was transformed at 50 and 
500 ßM respectively (see Chapter 7). 
The reversibility of the observed inhibition by furazolidone and the fact that the 
more cytotoxic agent nitrofurantoin (Chapter 5) had little effect, indicate that the 
inhibition is rather specific and not due to a general disruption of the cell functioning. 
Furthermore it may be ascribed to the nitrofuran-part of the drug and therefore be 
related to the reported competitive inhibition of rabbit liver monoamine oxidase by a 
number of nitro aromatic compounds, including nitrofurazone (Kimes & Carr 1982). 
This type of MAO inhibition by furazolidone has not been shown before, but its 
importance in vivo is questionable, since first of all relatively high concentrations are 
required, and secondly there is no accumulation of the effect. 
The use of pig hepatocytes in this study allowed the elucidation of the discrepancy 
between the results of previous in vivo and in vitro studies, revealing that AOZ but not 
furazolidone can be transformed by these cells into active MAO-inhibiting metabolites. 
Therefore the results are in favour of the hypothesis of Stern et al. (1967) and support 
the role of the G.I. tract in the transformation of furazolidone into active metabolites. 
However, regarding the sensitivity of the azomethine bond to acid hydrolysis (Paul et 
al. 1960; Buzard et al. 1956), this role may be limited to the release of AOZ from 
furazolidone, and its metabolites, in the stomach. Evidence for this hydrolysis has 
actually been obtained after oral treatment of pigs (Tennent & Ray 1971) and mice 
(Loserth et al. 1988) with furazolidone, and after incubation of the drug in ruminai fluid 
(Hunder et al. 1987). Since mammalian cells are apparently able to transform AOZ into 
a MAO-inhibiting metabolite, the need for a bacterial activation in the G.I. tract (Ali 
et al. 1980; Ali et al. 1982) has become questionable. 
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CHAPTER 7 
THE USE OF PIG HEPATOCYTES TO STUDY THE ROLE OF 
GLUTATHIONE ON THE BIOTRANSFORMATION AND 
TOXICITY OF FURAZOLIDONE 
This chapter is based on the following publication: 
Hoogenboom L.A.P., Kammen M. van, Huveneers-Oorsprong M.B.M. and Kuiper H.A. The use 
of pig hepatocytes to study the role of glutathione on the biotransformation and toxicity of 
furazolidone. Manuscript presented to Toxicology In Vitro for publication. 
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THE USE OF PIG HEPATOCYTES TO STUDY THE 
ROLE OF GLUTATHIONE ON THE BIOTRANSFORMATION 
AND TOXICITY OF FURAZOLIDONE 
Summary 
Incubation of monolayer cultures of pig hepatocytes with furazolidone resulted in increased 
intracellular GSSG-levels but no decreased GSH-levels. A clear decrease in GSH-levels was 
observed at higher drug concentrations when either the synthesis of GSH was blocked with 
BSO or the reduction of GSSG by BCNU. Furthermore, when cells containing 35S-labelled GSH 
were exposed to furazolidone, an increased dose-related loss of radiolabelled GSH was observed. 
The loss was balanced by increased levels in the medium of GSSG and a second compound, 
probably CySSG. The biotransformation of 14C-furazolidone by cells resulted partly in the 
formation of the open-chain cyano-metabolite as well as a large number of more hydrophilic 
unknown metabolites. No evidence was obtained for the excretion by the cells of the 
glutathione-conjugate that was previously detected in microsomal incubations. This could 
however be due to the unstable nature of the conjugate, as demonstrated by its rapid 
disappearance when added to the medium. In the presence but not the absence of cells, this 
partly resulted in the formation of the cyano-metabolite, which upon prolonged incubation was 
further metabolized into more polar metabolites. 
An increased LDH-leakage at high drug concentrations could only be observed when GSH-
levels were kept at a low level with BSO. This effect was not paralleled by an increased 
formation of protein-bound metabolites of furazolidone and of the cyano-metabolite. GSH-
depletion had no effect on the inhibition of the pyruvate metabolism by furazolidone, the most 
sensitive end-point up till now. 
No evidence was obtained for the presence of reactive thiol-conjugates of furazolidone in 
the protein fraction of cells incubated with the drug. It is concluded that GSH has an active 
role in the protection of cells against the cytotoxic effects of furazolidone related to oxidative 
stress, but that no evidence could be obtained for the formation and excretion of reactive thiol-
conjugates. 
Abbreviations used: GSH/GSSG= reduced/oxidized glutathione; PBS= phosphate buffered 
saline; BSO= buthionine-D,L-sulfoximine; BCNU= l,3-bis(2-chloroethyl)-l-nitrosourea; 
DMSO= dimethyl-sulfoxide; GSF (MSF)= glutathione (mercaptoethanol) conjugate of 
furazolidone: MSH= mercaptoethanol; LDH= Lactate-dehydrogenase (EC 1.1.1.27) 
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Introduction 
Furazolidone [N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidinone] is a widely used 
veterinary drug, belonging to the class of the nitrofurans. After oral administration to 
pigs, the drug is extensively metabolized, partly resulting in the formation of the so-
called open-chain cyano metabolite, as well as drug-derived metabolites that cannot be 
extracted from tissue macromolecules (Vroomen et al. 1986, 1987a). Both these type 
of metabolites and the cyano-metabolite could be detected after incubation of rat and 
pig liver microsomes with the drug (Vroomen et al. 1987b, 1987c). However, their 
formation was almost completely reduced in the presence of physiological 
concentrations of reduced glutathione (2-10 mM), due to the formation of a 
glutathione-conjugate (Vroomen et al. 1988). Subsequent studies revealed that the 
furazolidone derived part, the acrylonitrile-derivative, of this and other thiol-conjugates 
can be released and bind again to other thiol-group containing compounds, including 
protein, and possibly DNA (Fig. 7.1). Subsequently, it has been suggested that such 
reactive thiol-conjugates might be responsible for the formation of unextractable 
furazolidone-derived metabolites in tissues of rats, fed with muscle tissue from a piglet 
that had been treated with the drug (Vroomen et al. 1990). Regarding the potential 
health risk for the consumer of edible products containing these type of metabolites, 
it is important to obtain more information on their possible formation and presence in 
tissues of treated animals, especially considering the relative long half-life of bound 
metabolites (Vroomen et al. 1986). 
In previous chapters we described the isolation of hepatocytes from a sample of pig 
liver, and their use for studying the biotransformation and toxicity of veterinary drugs. 
Since hepatocytes are in general considered to be a more complete in vitro model than 
liver microsomes, this model was used to investigate the possible formation of thiol 
conjugates of furazolidone. Incubation of rat hepatocytes with the nitrofurans 
nitrofurantoin, nitrofurazone and nifurtimox has been shown to result in the formation 
of the radical nitro anion (Rao et al. 1988), as observed in studies with microsomes 
(Peterson et al. 1979, 1982, Docampo et al. 1981). This radical nitro anion may be 
further reduced, resulting in the formation of other reactive intermediates, or be 
oxidized by oxygen, resulting in the formation of reactive oxygen species (Fig. 7.1). In 
intact cells, GSH may be involved in the scavenging of reactive intermediates of drugs, 
but also in the detoxification of H202 (Orrenius et al. 1983, Meister & Anderson 1983). 
The GSSG produced in the latter process is normally reduced by GSSG-reductase (EC 
1.6.4.2), but can also be excreted by the cell. Such an increased excretion of GSSG and 
decrease in tissue GSH-levels has been reported for isolated perfused rat livers and 
rat hepatocytes exposed to nitrofurantoin (Akerboom et al. 1982, Hoener et al. 1989, 
Rossi et al. 1988), and nitrofurazone (Hoener 1988), and after treatment of rats 
with nifurtimox (Dubin et al. 1983). Incubation of pig hepatocytes with nitrofurazone, 
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Fig. 7.1. Proposed metabolic pathway of 
furazolidone by pig liver microsomes 
and the role of glutathione (GSH) in 
the detoxification of both reactive drug 
intermediates and oxygen radicals. 
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furaltadone, furazolidone and nitrofurantoin also resulted in increased intracellular 
GSSG, but only in the latter case this was accompanied by decreased GSH-levels 
(Hoogenboom et al. 1991). It was hypothesized that the absence of a clear effect of 
furazolidone on intracellular GSH-levels, might be due to an increased synthesis of 
GSH by the cells. In addition to more direct studies on the formation of thiol-
conjugates of furazolidone, this possibility was investigated, as well as the possible 
protective role of GSH against the toxic effects of the drug, since indirect evidence for 
the formation and role of thiol-conjugates might be obtained from such studies. 
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Materials and Methods 
Chemicals 
Collagenase type H, GSH, GSSG and NADPH were purchased from Boehringer 
(Mannheim, FRG), fetal calf serum, penicillin/streptomycin and Williams' medium E 
from Flow Labs (Rickmansworth, UK), (l,3-bis(2- chloroethyl))-l-nitrosurea) (BCNU) 
from Bristol-Meyers (Toronto, Canada), insulin and buthionine-D,L-sulfoximine (BSO) 
from Sigma (St. Louis, USA), and 35S-methionine (spec act 8 GBq/mmol) from 
Amersham (Amersham, UK). "C-Furazolidone, labelled in the nitrofuran-ring (spec act 
1.75 GBq/mmol) (Amersham, Amersham, U.K.) and furazolidone were gifts from 
Orphahell (Mijdrecht, The Netherlands). 
Hepatocyte isolation and culturing 
Pig hepatocytes were isolated from livers of 6 to 12 months old sows (Dutch 
Landrace x Yorkshire) as described in Chapter 2. Cell suspensions were diluted to a 
density of 1.25 to 1.5 million viable cells/ml of medium and seeded into 60 mm tissue 
culture dishes (2.5 ml/dish). Unless indicated, Williams' medium E supplemented with 
5% fetal calf serum, 0.5 pglml insulin, 50 IU/ml penicillin and 50 Mg/ml streptomycin 
was used for culturing the cells. 
Exposure of cells 
In most experiments, treatment with furazolidone was started with 28 h old 
monolayer cultures. In some studies, cells were pretreated for 24 h with BSO (4 mM) 
or 35S-methionine (160 kBq/ml), starting 4 h after the plating of the cells. Following 
preincubation, cells were rinsed twice with Williams' medium E and incubated in this 
medium for 1 h prior to drug treatment. Incubation of cells with furazolidone was 
started by replacement of the old medium with plain Williams' E containing the 
indicated drug concentrations. Unless indicated, this was done by the addition of 
DMSO-stock solutions of the drug (final DMSO-concentration in the medium 1%). In 
some experiments 40 /nM BCNU (from a DMSO-stock solution) or 4 mM BSO (from 
a stock solution in Williams' E) were also dissolved in the medium. 
Following exposure, media samples were collected and the cells were rinsed twice 
with PBS and scraped from the dishes in 1 ml of PBS using a rubber policeman. Cells 
were either used directly or stored in liquid nitrogen until analysis. 
Assays 
Protein-levels were measured by the method of Lowry as modified by Peterson 
(1977), and LDH-activity in medium and cells as described by Jauregui et al. (1981). 
GSH-levels were determined based on the method by Reed et al. (1980), with slight 
modifications in the HPLC-procedure as described in Chapter 3. In experiments with 
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35S-labelled GSH, fractions of 0.25 ml were collected, mixed with scintillation cocktail 
(Minisolve, Zinsser Analytical, Maidenhead, UK), and counted in a Philips liquid 
scintillation counter (type PW 4700). Pyruvate and lactate concentrations in the medium 
were determined enzymatically as described in Chapter 5. 
Biotransformation studies 
The 14C labelled open-chain cyano metabolite of furazolidone was made by 
incubation of the Ames' tester strain Salmonella typhimurium TA 100 with 50 pM 
"C-furazolidone for 1 h, and purified by extraction and HPLC as described by Vroomen 
et al (1987a). The mercaptoethanol (MSF) and glutathione (GSF) conjugates of 
furazolidone were purified from a microsomal incubation (Vroomen et al 1987b, 1988), 
and stored in a formic-acid/NaOH buffer (5 mM; pH 3.6) at -40 °C. In this way the 
conjugates were shown to be stable for at least 6 months. 
For studying the degradation of furazolidone, the cyano-metabolite and thiol 
conjugates (MSF, GSF), compounds were dissolved in Williams' E without the use of 
DMSO. However, in control experiments no effect of this solvent on the metabolite 
pattern of furazolidone could be observed. At the indicated time intervals, media 
samples of 190 p\ were taken, instantaneously mixed with 10 >LII 1% formic acid and 
injected on an HPLC system equiped with a PRP-1 column (250 x 4.6 mm I.D. 
(Hamilton, Reno, USA) and coupled to an on line radioactivity detector (LB506C; 
Berthold, Wildbad, FRG). Compounds were eluted using a linear 22 min gradient of 
formic acid/NaOH (0.1 M; pH 3.6): water: acetonitrile 50/925/25 (v/v) and formic 
acid/NaOH (0.1 M; pH 3.6): water: acetonitrile 50/650/300 at a flow rate of 0.8 ml/min. 
For exchange studies, samples of the medium were mixed with mercaptoethanol to a 
final concentration of 10 mM, incubated at room temperature for 45 min, mixed with 
1% formic acid and analyzed. For confirmation of the identity of the cyano-metabolite, 
a sample of the medium was extracted with ethyl-acetate. After evaporation of the 
organic solvent under nitrogen, the residue was dissolved in water/acetonitrile 7/3 (v/v) 
and injected on an HPLC system, equiped with an Hypersil 5 ODS column (250 x 4.6 
mm I.D.; Chrompack, Middelburg, The Netherlands) and coupled to UV/VIS diode 
array equipment (Hewlett-Packard 1040 A) (eluens water/acetonitril 8/2). The identity 
of the metabolite was also confirmed by 'H-NMR as described previously (Vroomen 
et al 1987a). 
For determination of the binding of "C-labelled metabolites of furazolidone to TCA-
precipitable material, cells were washed with PBS (2x), scraped from the dishes in 1 ml 
PBS, and mixed with TCA to a final concentration of 0.7%. The precipitate was 
collected by centrifugation, washed with ice-cold methanol (3x) and ethanol (2x), 
dissolved in 5% sodium-dodecyl-sulphate and 0.4 N NaOH, mixed with scintillation 
cocktail and counted. 
For examination of the presence of exchangeable protein-bound metabolites, cells 
were incubated with 50 /uM 14C-furazolidone (1,75 GBq/mmol) for 6 or 24 h, and the 
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protein collected and washed as described above. However, after the third clean-up 
with methanol, the protein was resuspended by ultrasonic treatment in 1.5 ml 
phosphate buffer (0.1 mM, pH 7.4) containing 10 mM mercaptoethanol. After an 
incubation interval of 1 h at room temperature, the mixture was extracted with EtAc 
(3x 2 ml). The organic phase was taken to dryness, and the residue dissolved in eluent 
and investigated by HPLC for the presence of the mercaptoethanol-conjugate 
(Vroomen et al. 1987b). The protein was precipitated with TCA and washed twice with 
methanol. The washstep and the protein fraction were counted as described above. The 
method was checked with microsomal protein, that had been incubated with MSF as 
described previously (Vroomen et al. 1988) and gave consistent results. 
Salmonella/microsome test 
The glutathione and mercaptoethanol-conjugate, made by microsomal incubations as 
described above, were tested for their genotoxic properties in the salmonella 
mutagenicity test (Maron & Ames 1983), as described previously (Vroomen et al. 1988). 
MSF and GSF were synthesized, purified and tested on the same day. Compounds were 
preincubated for 1 h at 37 °C with tester strain TA100 in the absence of S9-mix, in 
concentrations up to 5 pg per plate. Furazolidone was used as a positive control. 
Results 
The hypothesis that the previously observed lack of effect of furazolidone on 
intracellular GSH-levels (Chapter 5) could be due to an increased GSH-synthesis and/or 
an effective reduction of GSSG to GSH by the cells, was investigated by incubating 
hepatocytes with furazolidone either in the presence of BSO, an inhibitor of the GSH-
synthesis (Griffith & Meister 1979), or BCNU, an inhibitor of GSSG-reductase (Babson 
& Reed 1978). Table 7.1 shows the results of two experiments with cells isolated from 
livers of different pigs. As observed before (Chapters 3 and 5), intracellular GSH-levels 
increased during the exposure interval of 20 h, from about 30 nmol/mg protein till 
about 60 nmol/mg protein. This increase was apparently not influenced by furazolidone, 
despite the presence of elevated intracellular GSSG-levels at the highest dose-level. The 
increase in GSH-concentrations during ageing could effectively be inhibited by 
incubating the cells with 4 mM BSO. Incubation of cells with furazolidone under these 
conditions, resulted in a dose-related decrease in intracellular GSH-levels. Exposure of 
cells to BCNU (40 JUM) did not affect absolute GSH-levels. Simultaneous treatment of 
cells with BCNU and furazolidone resulted in elevated GSH-levels at the concentration 
of 50 ßM, whereas a decrease was observed at 500 ;uM (Table 7.1). 
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Table 7.1 Effect of furazolidone on intracellular GSH-levels, either in the absence or presence of 
BSO or BCNU. 
Monolayer cultures of pig hepatocytes, isolated from livers of two different pigs, were incubated 
with furazolidone for 20 h, starting 28 h after their isolation, either in the absence or presence 
of BSO (4 mM), or BCNU (40 fiM). Results are expressed as the mean ± SEM (n=3). 
Inhibitor 
t=28h 
none 
BSO 
BCNU 
[Fur] 
(MM) 
0 
50 
500 
0 
50 
500 
0 
50 
500 
experiment 1 
GSH 
29 
57 
62 
61 
25 
19 
6 
71 
111 
30 
+ 
+ 
± 
+ 
+ 
± 
+ 
± 
± 
± 
3 
5 
6 
0 
1 
1 
1 
5 
1 
3 
experiment 2 
GSH 
(nmol/mg protein) 
35 
53 
62 
54 
29 
23 
6 
55 
94 
41 
± 
± 
+ 
± 
± 
± 
± 
± 
+ 
+ 
1 
2 
1 
2 
1 
1 
1 
2 
2 
3 
GSSG 
0.4 
1.0 
1.3 
3.7 
0.6 
0.5 
0.1 
1.1 
2.0 
7.0 
± 
+ 
± 
± 
± 
± 
± 
± 
± 
± 
0.1 
0.1 
0.0 
0.5 
0.1 
0.0 
0.0 
0.1 
0.0 
1.3 
In order to exclude possible artefacts related to the use of inhibitors, like BSO and 
BCNU, the effect of furazolidone on GSH-levels was studied in hepatocytes that had 
been preincubated in the presence of 35S-methionine for 24 h, resulting in the labelling 
of the intracellular GSH. As shown in Fig. 7.2A, exposure to furazolidone resulted in 
a clear and dose-related loss of labelled GSH from the cells, despite the absence of an 
effect on absolute GSH-concentrations. Investigation of media samples collected at the 
end of the incubation interval, revealed that the label was excreted into the medium 
and could be recovered in four peaks, one of them coeluting with GSSG (see insert 
Fig. 7.2B). A second peak eluted just before the GSH-peak and might be CySSG, the 
disulfide of cysteine and GSH (Reed et al. 1980, Fariss et al. 1983). As shown in Fig. 
2B there was a dose-related increase in the levels of these two labelled compounds in 
the medium, which almost matched the loss of 35S-GSH by the cells. The increased 
levels of these compounds in the medium could also be observed in the HPLC-
chromatograms obtained by UV-detection (data not shown). 
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Fig. 7.2. The effect of furazolidone on levels and turn-over of intra-cellular GSH (A), and its 
excretion into the medium (B). 
Cells, containing 3SS-GSH, were exposed to the drug for 20 h. Before (t=28 h) and after exposure, 
levels of intracellular GSH (| |) and 35S-GSH (WÏZI) were measured (A) (mean ± SEM; n=3). 
Medium samples were pooled and investigated by HPLC (as shown for 500 ßM in insert; RT 
GSH 10.1 min). The amount of label recovered in the GSSG (§§§ü) and "CySSG" (| \) peaks 
were compared with the amount of label lost by the cells as GSH (Wfflh-
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The possible formation of thiol-conjugates of furazolidone Was investigated by 
incubating monolayer cultures with 50 ßM 14C-labelled drug (Fig. 7.3). HPLC-analysis 
of media samples taken after 7 (A), 26 (B) and 50 (C) h revealed that respectively 73, 
97 and 100% of the drug was transformed, resulting in the formation of a large number 
of more hydrophilic compounds. The open-chain cyano metabolite (retention time 
20 min) could be identified by its UV and NMR spectrum (data not shown), but was 
only present in low amounts. Incubation of cells with purified cyano-metabolite (5 ßM), 
revealed however that about 72 and 97% of this compound was transformed into more 
polar metabolites after respectively 12 and 36 h (Fig. 7.3D). The detection of GSF in 
these media samples was hampered by the presence of a number of compounds with 
similar retention time (14.7 min; see Fig. 7.4A). Therefore, samples taken after 10 and 
28 h (Fig. 7.3E) were incubated with 10 mM MSH for 45 min, allowing the possible 
exchange from GSF into MSF, which could be detected more easily. This indirect 
approach did not result in the formation of detectable amounts of MSF. The 
effectiveness of this approach was shown by the fact that MSF could easily be detected 
when a similar medium sample was enriched with GSF to a final concentration of 
0.5 ßM, prior to the incubation with 10 mM MSH (Fig. 3F). 
Subsequent experiments revealed that GSF, purified from microsomal incubations, 
was highly unstable when added to monolayer cultures, initially leading to the formation 
of two compounds eluting after about 25 min (Fig. 7.4A) and eventually more polar 
metabolites as well as the cyano-metabolite (Fig. 7.4B), as confirmed by its 
chromatographic behaviour and UV-spectrum (data not shown). Similar results were 
obtained with the mercaptoethanol conjugate of furazolidone (MSF) (Fig. 7.4C). In the 
absence of cells, GSF (Fig. 7.4D) and MSF (data not shown) also disappeared rapidly, 
but in this case no cyano-metabolite could be detected. The cyano-metabolite was 
formed when GSF was preincubated for 15 min in medium, which was subsequently 
added to the cells, indicating that this metabolite is formed from a degradation product 
of GSF. Polar metabolites but not the cyano-metabolite were formed when cells were 
incubated with GSF in medium enriched with 1 mM GSH (data not shown). 
In order to obtain further information on the possible interaction between GSH and 
furazolidone, the biotransformation and toxicity of the drug in hepatocyte cultures 
containing different levels of intracellular GSH was investigated. Cells were incubated 
with 0, 50 or 500 ßM "C-labelled furazolidone for 3 (Table 7.2) or 16 h (Table 7.3), 
after or during treatment with BSO. Pretreatment of cells with BSO, resulting in 
decreased GSH-levels, led to a marked increase in the LDH-leakage at the highest drug 
level, as compared to cultures that were not pretreated (Tables 7.2 and 7.3). 
Simultaneous treatment with BSO and furazolidone for 3 h had no effect on LDH-
leakage, despite a slight decrease in GSH-levels (Table 7.2). The incubation of cells 
with furazolidone resulted in the formation of protein-bound metabolites (Table 7.2), 
but the extent of binding decreased, rather than increased, in cultures with low 
GSH-levels. Similarly, BSO-pretreatment did not result in an increased accumulation 
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Fig. 7.3. Biotransformation of furazolidone (FUR) and its cyano-metabolite (CN) by monolayer 
cultures of pig hepatocytes. 
Cells were incubated in the presence of 50 /xM 14C-labelled furazolidone for 7 (A), 26 (B) or 50 
(C) h, or 5/iM of the cyano-metabolite for 36 h (D). The excretion of GSF by cells incubated 
with furazolidone was examined by incubating a medium sample taken at t=26 h with 10 mM 
MSH for 1 h prior to HPLC-analysis (E). As a control a similar sample was spiked with 0.5 /iM 
GSF prior to the incubation with 10 mM MSH (F). 
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Fig 7.4 Fate of GSF (A,B,D) and MSF (C) incubated in the presence or absence of cells. 
GSF or MSF was added to the medium to a final concentration of 5 ßM in the presence (A,B,C) 
or absence (D) of cells. Samples were taken after 5 (A) or 60 (B,C,D) min and analyzed by 
HPLC. 
of pyruvate and lactate after exposure of cells to 50 ßM furazolidone for 16 h, and 
actually resulted in a decrease at the highest dose level (Table 7.3). BSO-pretreatment 
had no effect on the amount of drug transformed, nor did it result in the increased 
formation of the cyano-metabolite. In addition, no effect on metabolite patterns of 
furazolidone, nor on the biotransformation of the cyano-metabolite could be observed 
(HPLC-chromatograms not shown). 
I l l 
Table 7.2 Influence of intracellular GSH-levels on LDH-release caused by furazolidone and on 
the level of binding of reactive intermediates of the drug to cellular protein. 
Cells were incubated with various doses of furazolidone for 3 h. BSO (4 mM) was added to the 
medium either before (24 h), or during the treatment with furazolidone. Results presented as 
mean ± SEM for n=3. 
Treatment 
with BSO 
none 
before 
during 
[Fur] 
(MM) 
0 
50 
500 
0 
50 
500 
0 
50 
500 
GSH 
(nmol/mg protein) 
34 
34 
27 
4 
3 
1 
25 
27 
16 
± 
± 
± 
± 
± 
± 
+ 
+ 
± 
2 
2 
1 
1 
0 
0 
2 
1 
1 
LDH 
(% 
1.8 
1.9 
2.3 
5.3 
6.0 
63.7 
1.7 
1.6 
2.5 
-leakage 
of total) 
± 
+ 
+ 
± 
± 
± 
± 
± 
± 
0.1 
0.1 
0.1 
0.3 
0.6 
1.6 
0.2 
0.1 
0.2 
Covalent Binding 
(nmol/mg protein) 
0.12 
0.35 
0.12 
0.25 
0.13 
0.34 
+ 
+ 
+ 
+ 
+ 
± 
0.01 
0.02 
0.01 
0.01 
0.01 
0.02 
1
 GSH-levels at t=0 were 28 ± 1 and 5 ± 1 nmol/mg protein for cells preincubated without and 
with BSO respectively. 
The possible presence of reactive protein-bound metabolites in cells exposed to 
furazolidone was investigated by incubating the washed protein in the presence of 10 
mM mercaptoethanol for 1 h. Although part of the label could be released and 
extracted with EtAc, no MSF could be detected in these extracts (detection limit 
0.25%) (Table 7.4). With the same method, the acrylonitrile derivative could be 
released from microsomal protein, that had been incubated with MSF, as described 
previously by Vroomen et al. (1988). 
Both GSF and MSF, purified from microsomal incubations were tested twice in the 
salmonella mutagenicity test in doses up till 5 /xg/plate, but their mutagenicity could not 
be confirmed. In all four tests, furazolidone gave a clear positive result at a dose of 10 
Mg/plate, similar to those reported previously (Vroomen et al. 1988). In all cases the 
reversibility of the thiol-bond was confirmed by incubation of MSF or GSF with GSH 
or MSH respectively. 
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Table 7.3. Influence of intracellular GSH-levels on the LDH-release and the accumulation of 
pyruvate and lactate in the medium following incubation of cells with furazolidone, as well as on 
the biotransformation of the drug and the formation of the cyano-metabolite. 
Cells were incubated with various doses of furazolidone for 16 h. Pretreatment of cells with BSO 
(4 mM) for 24 h was either stopped 1 h before or continued during the treatment with 
furazolidone. Results presented the mean ± SEM for n=3. 
Treatment [Fur] GSH LDH-leakage Pyruvate+ Furazolidone [Cyano] 
with BSO Lactate metabolized 
(/iM) (nmol/ (% of total) (mM) (%) (/xM) 
mg protein) 
none 
before 
before 
and during 
0 
50 
500 
0 
50 
500 
0 
50 
500 
66 
68 
72 
15 
7 
4 
10 
5 
+ 
+ 
± 
± 
± 
± 
+ 
+ 
ND2 
6 
8 
4 
2 
1 
0 
2 
1 
1.6 
1.5 
1.7 
1.0 
1.2 
43.8 
1.9 
2.0 
86.5 
+ 
± 
± 
± 
± 
± 
+ 
+ 
+ 
0.1 
0.1 
0.1 
0.1 
0.1 
6.8 
0.2 
0.2 
3.2 
0.8 
2.8 
3.9 
0.7 
3.0 
2.4 
0.4 
3.0 
2.4 
± 
± 
± 
± 
+ 
± 
+ 
± 
± 
0.1 
0.1 
0.1 
0.1 
0.1 
0.2 
0.0 
0.1 
0.1 
51 
7 
52 
6 
52 
3 
+ 
± 
± 
+ 
+ 
+ 
2 
1 
2 
1 
4 
2 
1.8 ± 0.1 
2.0 ± 0.1 
1.3 ± 0.1 
1.8 ± 0.1 
1.8 ± 0.2 
3.1 ± 0.7 
1
 GSH-levels at t=0 were 53 ± 2 and 17 ± 2 nmol/mg protein for cells preincubated without or with 
BSO respectively. 
2
 not detected 
Table 7.4. Exchange of protein-bound metabolites of furazolidone with mercaptoethanol. Cells 
were incubated with 50 ßM furazolidone for 6 or 24 h. 
Cellular protein was washed with methanol and incubated with MSH (10 mM) at pH 7.4 for 1 h. 
Following extraction with EtAc, the protein was precipitated and washed twice with methanol. The 
EtAc-extract was analyzed by HPLC and the fraction coeluting with MSF was collected ("MSP). 
Incubation 
time (h) protein 
Radioactivity in fractions (% of total) 
methanol EtAc "MSF 
6 
24 
91.6 
87.2 
93.3 
93.0 
6.3 
9.8 
5.6 
6.0 
2.2 
3.0 
1.0 
1.0 
ND 
ND 
ND 
ND 
1
 ND: not detected. Detection limit 0.25% 
2
 100% matches 3.9 and 3.8, and 3.5 and 3.8 nmol at 6 and 24 h respectively. 
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Discussion 
This study shows that pig hepatocytes are capable of biotransforming furazolidone 
into the open chain cyano-metabolite, a large number of unknown more hydrophilic 
metabolites (Fig. 7.3), and protein-bound metabolites (Table 7.2). The transformation 
of the cyano-metabolite into more hydrophilic metabolites, shows that it is not an end-
metabolite, as concluded from studies with cellular fractions (Abraham et al. 1984, 
Tatsumi et al. 1981, Vroomen et al. 1987b, 1987c). The relatively low levels of this 
intermediate in the plasma of pigs treated with furazolidone (Vroomen et al. 1987a) 
may therefore as well be due to its further degradation rather than to its low formation. 
As hypothesized before (Chapter 5), the exposure of pig hepatocytes to furazolidone 
results in a loss of intracellular GSH, which is however compensated by an increased 
synthesis of GSH. This is demonstrated both by the dose-related decrease in GSH-levels 
in the presence of BSO (Table 7.1), as well as the dose-related loss of 35S-labelled GSH 
in the absence of an effect on absolute GSH-levels (Fig. 7.2A). The increased synthesis 
of GSH may underly the almost doubled GSH-levels observed in cells after combined 
treatment with 50 jxM furazolidone and 40 /xM BCNU (Table 7.1), and after treatment 
with nitrovin (Chapter 5). The active synthesis of GSH by hepatocytes is well 
documented (Meredith & Reed 1982, Orrenius et al. 1983), and was previously shown 
in ageing monolayer cultures of pig hepatocytes (Chapter 3). However, an increased 
synthesis of GSH by cells in response to the effect of xenobiotica has only been 
described after exposure of human fibroblasts to diethyl-maleate (Bannai 1984). 
Regarding the sometimes doubled GSH-levels, it appears that the effect cannot be 
explained by feed-back regulation of the synthesis of GSH, but may also be due to an 
additional increase in the uptake of one of the precursors of GSH-synthesis, as shown 
in the case of fibroblasts (Bannai 1984). 
At least part of the increased loss of GSH can be ascribed to the formation and 
excretion of GSSG, formed in the detoxification of reactive oxygen species (Fig. 7.1). 
First of all, increased GSSG-levels were measured in cells exposed to high 
concentrations of the drug (Table 7.1). Secondly, about 40% of the 3SS-labelled GSH 
lost by the cells, was recovered in the medium as GSSG (Fig. 7.2B), considering the 
fact that only 50% of the GSSG is derivatized with the method of Reed et al. (1980). 
Thirdly, when the adequate reduction of GSSG was further impaired by simultaneous 
incubation of the cells with BCNU, GSH-levels could no longer be completely restored 
at the highest furazolidone level. Finally, the fact that GSH primarily protected the cells 
against membrane damage at high concentrations of furazolidone (Tables 7.2 and 7.3) 
supports the role of GSH in the detoxification of reactive oxygen species (Fig. 7.1). 
From the results presented in Fig. 7.2B, it appears that the remaining part of the 
GSH-loss is balanced by increased levels of CySSG in the medium, which, according to 
Farris and Reed (1983), can be ascribed to the excretion of GSH by the cells and its 
subsequent exchange with the cystine in the medium. A similar increased loss of GSH 
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has been reported after treatment of rats with nifurtimox (Dubin et al. 1983), and to 
a lesser extent after exposure of perfused rat livers to nitrofurantoin (Hoener et al. 
1989) and nitrofurazone (Hoener 1988). The mechanism behind this effect remains 
unclear, since it is apparently not due to an increased membrane-leakage, as shown by 
the results presented by Dubin et al. (1983), and those in Tables 7.2 and 7.3. 
The failure to detect a glutathione conjugate of furazolidone in samples of the 
incubation medium (Fig. 7.3), might be related to its unstability under these conditions 
(Fig. 7.4). Nevertheless, the excretion of such a conjugate by the cells seems unlikely 
since an almost tenfold reduction in intracellular GSH did not result in increased levels 
of protein bound metabolites (Table 7.2), as in the case of microsomal incubations 
(Vroomen et al. 1987b, 1987c). The formation of GSF cannot entirely be excluded by 
this observation, since the conjugate may act as a carrier of reactive metabolites within 
the cell, exchanging its furazolidone-derived part with cellular proteins (Vroomen et al. 
1988). However, this would have to result in the formation of stable protein-adducts, 
since the furazolidone-derived part of protein bound metabolites was no longer 
exchangeable with mercaptoethanol (Table 7.4). The fact that, contrary to studies with 
microsomes (Vroomen et al. 1987b, 1987c), decreased GSH-levels did not result in the 
increased formation of the cyano-metabolite, might be explained by the formation of 
this metabolite from a compound, formed by the spontaneous degradation of the thiol-
conjugates in the medium (Fig. 7.4). However, since GSF is apparently not excreted by 
the cells (see above), the indirect formation of the cyano-metabolite from GSF should 
occur within the cell, which seems unlikely considering the high intracellular GSH-levels 
(5-10 mM), and the fact that low levels of GSH (1 mM) in the medium prevented the 
formation of the cyano-metabolite from GSF or MSF completely. In summary, the 
excretion but also the formation of a glutathione-conjugate of furazolidone by the cells 
appears to be highly questionable. 
The fact that GSH protects the cells primarily against effects related to oxidative 
stress, like membrane-damage, supports the conclusions from previous studies with 
nitrofurantoin (Boyd 1980, Rossi et al. 1988). However, from the present study it is also 
evident that even in GSH-depleted cells (Table 7.2), high concentrations of furazolidone 
are required for these type of effects. Therefore, disturbance of cellular functions, 
possibly due to the binding of reactive intermediates of the drug to cellular proteins, 
appear to be of more relevance under these conditions, especially since they may 
accumulate upon repeated exposure. An example of such an effect is the inhibition of 
the pyruvate metabolism by relatively low levels of furazolidone (Chapter 5), an effect 
that appears to be due to the binding of a metabolite of furazolidone to the pyruvate 
dehydrogenase complex (Paul et al. 1953, Paul & Paul 1964). 
In summary, the present study clearly demonstrates that exposure of cells to 
furazolidone results in an increased loss and subsequent synthesis of cellular GSH. At 
least part of this loss could be ascribed to the increased formation of GSSG and 
possibly GSH, but no evidence could be obtained for the formation of a glutathione 
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conjugate of furazolidone. The presence of exchangeable thiol conjugates in the protein 
fraction could not be demonstrated, nor could the genotoxic potential of these type of 
compounds (Vroomen et al. 1988) be confirmed. However, given the relatively high 
bioavailability of bound residues of furazolidone (Vroomen et al. 1990) and the 
mutagenic and carcinogenic potential of the parent compound (McCalla 1983, Food and 
Drug Administration 1976), further investigations on the toxic potency of bound 
residues are required. 
In addition this study demonstrates that pig hepatocytes are a very suitable model 
for this type of mechanistic studies, especially regarding the great opportunities to 
integrate biotransformation and toxicity studies. 
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CHAPTER 8 
THE USE OF PIG HEPATOCYTES TO STUDY THE NATURE 
OF PROTEIN-BOUND METABOLITES OF FURAZOLIDONE 
A new analytical method for their detection 
This chapter is based on the following publication: 
Hoogenboom L.A.P., Kammen M. van, Berghmans M.C.J., Koeman J.H. and Kuiper H.A. The 
use of pig hepatocytes to study the nature of protein-bound metabolites of furazolidone. Fd 
Chem. Toxicology (in press). 
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THE USE OF PIG HEPATOCYTES TO STUDY THE NATURE 
OF PROTEIN-BOUND METABOLITES OF FURAZOUDONE 
A new analytical method for their detection 
Summary 
The biotransformation of furazolidone, both in vivo and in vitro, results in the formation of 
so-called bound metabolites. Following the incubation of pig hepatocytes with 14C-furazolidone, 
a dose and time related increase in the formation of bound metabolites was observed. After 
withdrawal of the drug from the medium, levels decreased gradually to about 50% within 36 h. 
Using a newly developed method, it was shown that in the case of cells and liver microsomes 
at least 70% of the bound residues still contains the 3-amino-2-oxazolidinone (AOZ) side chain 
of furazolidone. With liver samples of piglets that had been treated orally with the drug for 10 
days, followed by withdrawal periods of 2 h or 10 days, fractions of releasable AOZ were 
respectively 23 and 15%, equivalent to levels of respectively 3.83 and 0.26 /ig furazolidone per 
gram of tissue. 
The release of the AOZ side-chain of furazolidone from at least part of the bound 
metabolites, finally proves their drug-related nature and subscribes the requirement for both 
adequate withdrawal periods and useful control methods. The relative simplicity of the newly 
developed method makes it an ideal tool for this purpose. 
Abbreviations: AOZ= 3-amino-2-oxazolidinone; NPAOZ= 3[[(2-nitrophenyl)methylene]-
amino]-2-oxazolidinone; EtAc= ethyl-acetate; NBA= 2-nitrobenzaldehyde 
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Introduction 
The biotransformation of veterinary drugs by the animal may lead to the formation 
of so-called bound metabolites, next to more readily excreted metabolites (Baer et al. 
1977; Rico and Burgat-Sacaze 1984; Lu et al 1988). This has been demonstrated in 
studies with radioactive labelled compounds, where part of the label could not be 
extracted from the tissues, and was therefore assumed to be associated with tissue 
macromolecules such as DNA or proteins. As a result the rate of clearance of these 
type of metabolites from the body may depend on the turnover of tissue proteins and 
be relatively low. Long withdrawal periods will be required in the absence of 
information on the identity and properties of bound residues, especially in the case of 
parent compounds with genotoxic and carcinogenic properties. However, in most cases 
the control on their maintenance will be difficult, due to the absence of adequate 
analytical methods. 
Aim of the present study was to 
further investigate the nature of protein-
bound metabolites of the antibacterial 
drug furazolidone. Vroomen et al. (1986) 
showed that, following the oral treatment 
of piglets with MC-labelled furazolidone, 
the parent compound itself had a short 
plasma half-life (1 h) and could not be 
detected in tissues, even when an animal 
was killed within two hours after the last 
treatment. However, radiolabelled 
compounds with unknown identity were 
present at high concentrations in all 
tissues and could only partly be extracted 
with water and organic solvents. During 
a withdrawal period of 14 days, levels of 
both total and bound radiolabelled 
compounds decreased, but could still be 
detected in all tissues at /ig per gram 
levels. 
Using pig liver microsomes, strong 
evidence was obtained that the binding of 
metabolites to protein was due to the 
formation of a reactive site in the nitro-
furan-part as a result of the reduction of 
the nitro-group (Vroomen et al. 1987), 
leaving the 3-amino-2-oxazolidinone 
O N- " 
2 
3-
ƒ V 
~ - C H = N — 
0 ^ N 
furazolidone 
1 N HCl 
H „ N N v 
/ \ 
oAa} 
-amino-2-oxazolidinone 
2-nitro-benzaldehyde 
C H = N -
3[[(2-nitrophenyl)methylene)-
ammo]-2-oxazolidmone 
Fig. 8.1. Mechanism behind the proposed method 
for the release and detection of 3-amino-2-oxazol-
idinone (AOZ) released from furazolidone and 
metabolites. 
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(AOZ) side-chain unaltered (see Fig. 7.1). Therefore, we developed a new method for 
the release of the AOZ side-chain under mild acid conditions and its subsequent 
detection after its derivatization with 2-nitrobenzaldehyde to 3[[(2-nitrophenyl)-
methylene]-amino]-2-oxazolidinone (NPAOZ) (Fig. 8.1). For studying the formation and 
identity of bound metabolites, the use of pig hepatocytes was preferred above 
microsomes, since this in vitro model has been shown to be more suitable for studying 
the biotransformation and toxicity of furazolidone (Chapter 7). 
Materials and methods 
Materials 
2-Nitrobenzaldehyde was purchased from Aldrich Chemicals (Milwaukee, USA), 
Collagenase type I and insulin from Sigma (St. Louis, USA), NADPH and porcine 
pepsin (2500 U/mg) from Boehringer (Mannheim, FRG), Williams' medium E, fetal calf 
serum and penicillin/streptomycin from Flow Labs. (Rickmansworth, UK). 3-Amino-2-
oxazolidinone, furazolidone and [14C]furazolidone labelled in the nitrofuran ring 
(1.75 GBq/mmol) were gifts from Orphahell BV (Mijdrecht, The Netherlands). 
[MC]Furazolidone labelled in the oxazolidinone part (27 MBq/mmol) was a gift from 
Norwich Eaton Pharmaceuticals Inc. (Norwich, New York, USA). All other chemicals 
used were of reagent grade. 
Synthesis of 3[[(2-nitrophenyl)-methylene]-amino]-2-oxazolidinone (NPAOZ) 
For the synthesis of NPAOZ, 10.2 mg of 3-amino-2-oxazolidinone (AOZ) was 
incubated with 15.2 mg of 2-nitro-benzaldehyde (NBA) in 40 ml 0.1 N HCl for 1 h at 
room-temperature. The reaction product was extracted with 40 ml of EtAc, taken to 
dryness under nitrogen and redissolved in 4 ml acetonitrile/water 1/1. The product was 
further purified on a semi-preparative Lichrosorb RP-18 column (250 x 10 mm I.D.; 
Hibar), eluted with acetonitrile/water 4/6 (v/v) at a flow-rate of 2.5 ml/min. The 
collected fractions were taken to dryness, redissolved in 10 ml water and extracted with 
10 ml EtAc, which was subsequently evaporated. The identity of the product was 
confirmed by 'H-NMR-analysis, dissolved in CDC13, using a Bruker CXP-300. Signals 
and interpretation: 8.26 (dd), 8.05 (dd), 7.66 (dt) and 7.53 (dt) ppm: protons at the 
phenyl-ring; 8.21 (s) ppm: proton at the azomethine-bond; 4.59 (dd) and 3.98 (dd) ppm: 
protons in the oxazolidinone-ring. 
Hepatocyte isolation and culturing 
Hepatocytes were isolated from liver samples of 5-9 month old sows (Dutch 
Landrace x Yorkshire) as described in Chapter 2. Cells were plated in 60 mm culture 
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dishes at a density of 1.25 million per ml (2.5 ml/dish) using Williams' medium E 
supplemented with 5% fetal calf serum, 0.5 /ng/ml insulin, 50 IU/ml penicillin and 50 
/ig/ml streptomycin. After 4 h the medium was renewed and routinely cells were 
incubated for another 16-24 h before exposure to furazolidone. 
Exposure of cells 
Exposure of cells was started by replacement of the medium with Williams' E 
containing 25 or 50 /LIM furazolidone. An adequate amount of a stock solution of the 
MC-labelled drug in acetone was taken to dryness under nitrogen and the drug was 
redissolved in the medium, that was subsequently sterilized through a 0.2 jum filter. In 
some cases furazolidone was added from a stock solution in dimethyl sulfoxide (DMSO) 
to a final solvent concentration in the medium of 1%. Furazolidone labelled in the 
nitrofuran-ring was diluted with unlabelled drug to a specific activity of 33 MBq/mmol 
as checked by HPLC. 
Following the incubation of cells with 14C-furazolidone, the medium was aspirated 
and 1 ml was extracted with 2 ml of EtAc (3x). The extract was analyzed by HPLC as 
described in Chapter 3, and the HPLC-fraction containing the parent compound was 
collected and assayed for the amount of radiolabel, similar to aliquots of the EtAc-
fraction and the remaining water phase. Cells were either washed twice with Williams' 
E and incubated for another 12 to 70 h, or washed three times with phosphate buffered 
saline (PBS) and scraped from the dishes in 1 ml PBS using a rubber policeman. 
Protein was precipitated with 2 ml of icy-cold methanol, collected by centrifugation, 
than washed with 2 ml of respectively methanol (2x), ethanol (2x) and diethyl-ether 
(2x), and redissolved in sodium-dodecyl-sulphate/NaOH (5%/0.4N). Part of this solution 
was counted for the amount of radioactivity and part was used for a protein 
determination, using the method of Lowry as modified by Peterson (1977). 
The amounts of radiolabel present in the EtAc-extract and remaining water-layer of 
the medium, and the label present in the redissolved cellular protein and various 
solvents, used to wash the protein, were combined. The fraction of drug metabolized 
was calculated from the amount of radiolabel present in the HPLC-fraction containing 
the furazolidone, as compared to this overall amount of radiolabel. Both the total 
recovery of radiolabel and the recovery of the parent compound varied between 90 
and 95%. 
Microsomal Incubation 
Microsomes, prepared from the liver of a sow (Chapter 3), were incubated with 
50 /xM ["Cjfurazolidone, labelled in the AOZ side chain, under anaerobic conditions 
as described by Vroomen et al. (1987). Standard conditions were: 1 mM NADPH, 
3 mM MgCl2, 0.1 M potassium phosphate buffer (pH 7.4), and 1.5 mg protein per ml. 
After bubbling of the mixture with argon on ice, and preincubation at 37 °C for 2 min, 
the reaction was started by adding 10 Mg/ml of a DMSO stock solution of furazolidone 
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(5 mM). After an incubation period of 10 min, the protein was precipitated with 
methanol and washed with methanol (2x), ethanol (2x) and diethyl-ether (2x). 
Liver samples 
Liver samples were obtained from two male piglets (initial age and weight: 5 weeks, 
6 kg), that had been treated orally with furazolidone, labelled in the AOZ side-chain, 
for 10 days (75 mg/day), followed by a withdrawal period of either 2 h or 10 days, as 
described by Vroomen et al. (1986). The tissues had been stored at -40 °C for six years 
with occasional thawing. For the experiments, samples of about 1 g were frozen in 
liquid nitrogen, pulverized and washed with 6 ml of respectively methanol (3x), ethanol 
(2x) and diethyl-ether. 
Release and detection of 3-amino-2-oxazolidinone (AOZ) 
Following extraction with organic solvents, pellets containing the protein of cells, 
microsomes or livers were resuspended in water using ultrasonic treatment. Aliquots of 
these suspensions were mixed with 2-nitrobenzaldehyde (from a stock solution of 50 
mM in DMSO) and HCl, and subsequently incubated in a waterbath at the indicated 
temperature and incubation time. Typical conditions were 2 ml of incubation mixture 
containing 5-10 mg protein in 0.1N HCl and 0.5 mM NBA, incubated for 20 h at 37 °C. 
In one experiment pepsin was added to a final concentration of 1 mg/ml. Following 
incubation, samples were extracted twice with 2 ml EtAc. The combined organic phases 
were evaporated under nitrogen at 40 °C in about 45 min. The excess NBA was 
eliminated by redissolving the residue in 2 ml EtAc, and evaporation of the organic 
phase. The residue was redissolved in 0.25 ml acetonitrile/water 1/1 (v/v) and analyzed 
by HPLC, using a C18-spher column (250x4.6 mm I.D., Chrompack, The Netherlands) 
and acetonitrile/water 3/7 (v/v) as eluent (1 ml/min). Compounds were detected at 
275 nm (Spectroflow 783, Applied Biosystems), and the fraction containing NPAOZ was 
collected, mixed with scintillation cocktail (Minisolve, Zinsser, FRG) and counted in a 
Philips liquid scintillation counter (type PW 4700). For some experiments the HPLC-
system was coupled to an on-line radioactivity detector (LB 506C; Berthold, FRG) or 
diode-array equipment (HP1041A; Hewlett Packard). The identity of the reaction 
product was confirmed by comparison with the standard of NPAOZ. 
Following the extraction with EtAc, the protein in the remaining incubation mixture 
was precipitated and washed with methanol and redissolved in sodium-dodecyl-
sulphate/NaOH (5%/0.4N). Both the protein fraction and washfractions as well as 50 ml 
of the EtAc-fraction redissolved in acetonitrile/water were mixed with scintillation 
cocktail and counted. Levels of released AOZ were calculated as the fraction of the 
radioactivity present in the NPAOZ-peak as compared to the combined radioactivity 
present in the EtAc, protein and wash fractions. 
All solutions containing NPAOZ were protected from the light as much as possible, 
regarding suspected light sensitivity of this compound. 
125 
Results 
As shown in Table 8.1, the biotransformation of furazolidone by monolayer cultures 
of pig hepatocytes at different ages, resulted in the formation of protein-bound 
metabolites. At the end of the incubation period, 3-4% of the metabolites could not be 
extracted from the protein fraction by subsequent treatment with methanol, ethanol or 
diethylether, and were therefore regarded as protein-bound. The capacity of the 
cultures to metabolize the drug was relatively low during the first 24 h after the 
isolation of the cells, as compared to the next 72 h. This was partly reflected in the 
levels of bound metabolites, reaching an optimum in cells incubated during the second 
interval of 24 h. During this interval there was a dose-related increase in the amount 
of bound metabolites up to the concentration of 150 pM, accompanied by a decrease 
in the fraction of drug that was transformed. Insulin, penicillin, streptomycin and fetal 
calf serum, which were omitted from the medium in further experiments, did apparently 
not affect the biotransformation of the drug (Table 8.1). 
Table 8.1. Biotransformation of furazolidone by monolayer cultures of different ages, and the 
formation of bound metabolites. Following an incubation period of 24 h in Williams' E containing 
5% fetal calf serum, penicillin/streptomycin, insulin and the indicated levels of furazolidone, 
concentrations of the parent drug in the medium and of protein bound metabolites in the cells 
were determined. Results are expressed as the mean ± SEM (n=3). 
Concentration 
(MM) 
Culture Age 
(h) 
Drug metabolized 
(% of initial) 
bound metabolites 
(nmol/mg protein 
50 4-28 57.7 2.9 0.36 0.02 
15 
50 
50 ' 
150 
500 
50 
50 
28-52 
28-52 
28-52 
28-52 
28-52 
52-76 
76-100 
87.1 ± 1.0 
80.5 ± 1.1 
81.0 ± 3.5 
55.4 ± 2.2 
16.9 ± 0.0 
81.0 ± 1.3 
73.5 ± 3.4 
0.30 ± 0.01 
0.70 ± 0.05 
0.69 ± 0.08 
1.48 ± 0.01 
1.36 ± 0.02 
0.49 ± 0.04 
0.53 ± 0.04 
Cells were incubated in Williams' E without any other additions. 
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Fig. 8.2. Time related formation and loss of bound metabolites in monolayer cultures of pig 
hepatocytes incubated with furazolidone. 
Cells isolated from livers of two different animals were incubated in medium containing either 50 
(A) or 25 (B) ßM [14C]furazolidone, labelled in the nitrofuran part ( A ) or the amino-
oxazolidinone part ( • ) of the molecule. After 12 h, cells in the remaining dishes were washed 
and incubated in normal medium. The medium in these dishes was renewed at 24 and 48 h. 
Results are expressed as the mean ± SEM (n=3). 
When hepatocytes were incubated for different time intervals (1-12 h) in the 
presence of 50 ßM furazolidone, labelled in either the nitrofuran or amino-
oxazolidinone part of the molecule, there was a clear time-related increase in the levels 
of protein-bound metabolites (Fig. 8.2A). Similar results were obtained in a second 
experiment (Fig. 8.2B) where cells, isolated from the liver of another pig, were 
incubated in the presence of 25 ßM of the drug. When the exposure interval was ended 
after 12 h by replacement of the medium, levels of bound metabolites decreased 
gradually to respectively 40% (50 ßM) and 57% (25 ßM) after 36 h. Although levels 
of bound residues tended to be somewhat higher for the drug labelled in the nitro-
furan-ring, the time-related increase and subsequent decrease was very similar for both 
types of labelled drug. 
A new method was developed for the release and detection of the AOZ side-chain 
of furazolidone, as presented in Fig. 8.1. Incubation of AOZ in 0.1N HCl in the 
presence of 2-nitrobenzaldehyde resulted in the quick formation of a compound 
identified as NPAOZ, which could be extracted with EtAc, and analyzed by HPLC. 
When the same method was applied on washed protein of hepatocytes that had been 
incubated with furazolidone labelled in the AOZ side-chain, a radioactive labelled 
compound coeluting with NPAOZ (Fig. 8.3A and B), and with identical UV-spectrum 
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Fig. 8.3. Detection of 3-amino-2-oxazolidinone 
released from protein of hepatocytes 
incubated with furazolidone. Cells were 
incubated with 50 ßM furazolidone labelled 
with 14C in the oxazolidinone side-chain. 
Washed protein was incubated in 0.1N HCl at 
37 °C in the presence of NBA for 24 h, and 
extracted with EtAc. The extract was analyzed 
by HPLC using detection by UV at 275 nm 
(A), radioactivity (B), or diode-array (C). 
In the latter case the UV-spectrum ( ) 
was compared with that of a standard of 
NPAOZ ( ). 
(Fig. 8.3C) could be detected in the EtAc-extract. Unlabelled NPAOZ was formed 
when using protein of cells that had been incubated with furazolidone labelled in the 
nitrofuran-ring (data not shown). NPAOZ was also formed when the method was 
applied on furazolidone, its cyano-metabolite or protein of microsomes, that had been 
incubated with furazolidone (data not shown). 
When the same method was used for liver samples of piglets that had been treated 
with furazolidone, labelled in the AOZ side-chain (Vroomen et al. 1986), radiolabelled 
NPAOZ could easily be identified, not only with a sample from the animal killed 2 h 
after the last treatment but also with a sample of the animal killed after a withdrawal 
period of 10 days (Fig. 8.4). 
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Fig. 8.4. Detection of 3-amino-2-oxazolidinone released from protein of livers from animals treated 
with furazolidone. Piglets were treated orally with furazolidone labelled with "C in the AOZ side-
chain for 10 days and killed either 2 h (A-C) or 14 days (D-E) after the last treatment. Liver 
samples of 1 gram were washed and incubated with NBA in the presence of 0.1N HCl. NPAOZ 
was extracted and analyzed by HPLC as described under Fig. 8.3. 
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Fig. 8.5. Effect of incubation time, HCl 
concentration and temperature on the 
release of 3-amino-2-oxazolidinone 
from protein of microsomes (V////Ä). 
cells (| |) or liver samples ( H ^ ) . 
Washed protein was incubated in the 
presence of 0.5 mM NBA and IN HCl 
at 37 °C for 24 h, unless indicated. 
Incubation time (A), HCl-concentration 
(B) and temperature (C) were 
subsequently varied. Incubation 
mixtures contained 2.3,1.7 and 14.6 mg 
of protein from microsomes, cells 
and liver respectively, containing 
respectively 1.1, 1.7 and 0.7 nmol of 
bound metabolites per mg protein. The 
liver used was obtained from the 
animal killed 2 h after the last 
treatment with furazolidone. Results 
are expressed as the mean ± SEM 
for n=2. 
Further experiments were conducted to search for optimum conditions for the assay, 
with respect to the amount of label that could be released as NPAOZ (Fig. 8.5). As 
shown in Fig. 8.5A, there was a time related increase in the fraction of bound residues 
that could be hydrolysed to A O Z in the case of protein from microsomes and cells, up 
to a maximum of about 60% at 24 h (0.1N HCl; 37 °C; 24 h). With liver samples, only 
20% of the bound radioactivity could be released as NPAOZ. Following an additional 
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incubation of the extracted protein for another 24 h, some additional NPAOZ was 
formed, resulting in maximum total levels of about 75, 80 and 25% for respectively 
microsomal, cellular and liver protein. Reduction of the concentration of HCl 
(Fig. 8.5B) led to a decrease in the levels of NPAOZ, whereas almost no NPAOZ 
could be detected in the absence of HCl. Increasing the incubation temperature was 
especially beneficial in the case of microsomes (Fig. 8.5C), but with cellular and liver 
samples the effect was less clear. Addition of pepsin to an incubation mixture with a 
liver sample (37 °C, 0.1N HCl, 24 h) resulted in.a release of 26% of NPAOZ as 
compared to 24% in the absence of the enzyme, whereas as a result of the treatment 
with pepsin, the fraction of label detected in the methanol-precipitable fraction after 
the incubation period decreased markedly from 41% to 9%. Incubating a liver sample 
with 0.05, 0.5 or 5 mM NBA (0.1N HCl, 37 °C), resulted in a dose-related increased 
release of NPAOZ from 9 to 22%, and 26% respectively. However, in the latter case 
the large amount of NBA could no longer be effectively removed and therefore 
disturbed the UV-detection. In the absence of NBA about 62% of the label could be 
recovered in the precipitable protein fraction, as compared to 56% after incubation 
with 0.5 mM NBA, indicating that the release of AOZ from the protein is not caused 
by NBA. 
Optimum conditions were used to determine the amount of total and bound 
residues, as well as the amount of releasable side-chain in liver samples of piglets killed 
at day 0 and day 14 of the withdrawal period (Table 8.2). For a comparison, a blanc 
liver sample was spiked with protein from hepatocytes incubated with [14C]furazolidone, 
equivalent with an overall binding of 67 pmol/mg protein. From these results it appears 
that the almost 50x dilution of cellular protein with liver protein does not affect the 
release of AOZ. As shown before, the fraction of bound metabolites in the liver 
samples that can be released does not exceed 25% and is even lower in the liver of the 
animal killed at day 14. However, absolute amounts of releasable AOZ reached levels 
of almost 4 jug furazolidone equivalents per gram of tissue just after the last treatment, 
and although markedly decreased, amounts equivalent with 0.25 ßg of furazolidone 
could still be released as AOZ from one gram of tissue following the withdrawal period. 
Discussion 
The results of the present study show that pig hepatocytes are a useful model to 
study the formation and identity of protein-bound metabolites of veterinary drugs, 
especially considering the often required use of radiolabelled compounds for these type 
of studies. The time and dose related formation of bound metabolites, following the 
biotransformation of furazolidone by hepatocytes (Table 8.1, Fig. 8.2), is in agreement 
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Table 8.2. Levels of total, bound and AOZ-related residues in livers of piglets treated with 
furazolidone for 10 days, and killed after withdrawal periods of 0 and 14 days. 
Liver samples (0.5 g) were homogenized, washed with organic solvents, and incubated in 0.1N HCl 
for 24 h in the presence of NBA As a control, cells, that had been incubated with furazolidone 
were treated similarly either in the absence or presence of 0.5 g blanc liver. Results are expressed 
as absolute amounts for duplicate determinations (single for total residues). Levels of bound 
residues were 490 and 68 pmol per mg of protein for liver samples of animals killed at day 0 
(2 h) and day 14 respectively. 
Sample Total Bound NPAOZ released 
(nmol)1 (nmol)1 (nmol)1 (% of bound) 
Liver day 0 
Liver day 14 
Liver+cells 
cells 
62.49 
(28.12) 
5.53 
(2.49) 
8.51 
8.73 
36.9 ± 0.0 
(16.59) 
4.0 ± 0.0 
(1.79) 
4.5 ± 0.1 
4.0 ± 0.0 
8.5 ± 0.0 
(3.83) 
0.6 ± 0.0 
(0.26) 
2.4 ± 0.0 
2.4 ± 0.1 
23.1 ± 0.1 
14.6 ± 0.5 
53.3 ± 0.7 
59.7 ± 3.2 
1
 numbers between brackets are levels expressed as ßg furazolidone equivalents per gram of tissue. 
with previous result from both in vivo and in vitro studies with microsomes (Vroomen 
et al. 1986, Vroomen et al. 1987). Furthermore, the decrease in the levels of bound 
metabolites during the recovery period (Fig. 8.2), most likely due to the turn-over of 
cellular protein, indicates that this in vitro model can also be used to study the identity 
of metabolites that are released from the protein and may be similar to those present 
as extractable residues in tissues during the withdrawal period. 
The fact that, similar to previous studies (Chapter 3), the biotransformation of 
furazolidone did not decrease during the first 100 h of the cultures (Table 8.1), as 
observed with cytochrome P-450 related enzyme activities (Chapters 3 and 4), is in 
agreement with the results from studies with pig liver microsomes, showing that 
cytochrome P-450 enzymes are not involved in the degradation of this drug (Vroomen 
et al. 1987). The similar time course in both the formation and degradation of bound 
metabolites, as observed with the two differently labelled furazolidone preparations (Fig. 
8.2), indicates that the two parts of the molecule are not separated from each other 
and supports the hypothesis that the bound metabolites still closely resemble the 
general structure of the parent compound. The latter conclusion is supported by the 
release and detection of the AOZ side-chain from metabolites bound to cellular protein 
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(Fig. 8.3). The effectiveness of the newly developed method for the release and 
detection of AOZ is demonstrated by the similarity in the HPLC retention time and 
UV-spectrum of the reaction product formed during incubation of protein-bound 
metabolites with HCl and NBA, and NPAOZ. Final proof comes from the fact that this 
product was only radiolabelled when furazolidone, used for the incubation of the cells, 
was labelled in the AOZ side-chain and not when labelled in the nitrofuran-part. 
Under currently optimal conditions, evidence was obtained that at least 75-80% of 
the bound residues in the case of microsomes and cells, and 15-25% in the case of 
livers of treated animals, still posses the intact AOZ side-chain. It seems unlikely that 
the differences observed between hepatocytes and microsomes on one hand, and livers 
from treated animals on the other hand, may simply be due to the efficiency of the 
method. A more likely explanation for this discrepancy may be a difference in the 
nature of part of the bound metabolites. First of all, part of the drug and/or its 
metabolites might be completely metabolized in vivo, possibly at other sites than the 
liver, followed by the use of the label for the synthesis of endogenous compounds, 
including amino acids and proteins. On the other hand, regarding the acid-lability of the 
azomethine bond in the furazolidone molecule (Buzard et al 1956, Paul et al 1960), 
part of the drug may have been hydrolysed in the stomach and the released AOZ 
subsequently been transformed into a compound, capable of binding to tissue 
macromolecules. Evidence for the cleavage of the azomethine-bond in vivo has been 
presented by Tennent and Ray (1971), and Loserth et al (1988). Furthermore, the 
subsequent formation of a reactive metabolite from AOZ appears to underly the 
irreversible type of inhibition of mono-amine oxidase (MAO) activity by furazolidone, 
as observed in tissues of a number of different animal-species, including man (Palm et 
al 1967, Stern et al. 1967, Pettinger et al. 1968, Ali and Bartlet 1982). Strong support 
for this hypothesis was supported by the MAO-inhibition observed in both rats (Stern 
et al. 1967), as well as pig hepatocytes (Chapter 6) exposed to AOZ. 
There is now substantial evidence that at least part of the bound metabolites of 
furazolidone still contains the AOZ side-chain, and that the conditions for the release 
of AOZ closely resemble those in the stomach. Therefore, the toxic properties of AOZ 
should be further investigated, especially considering the fact that ß-hydroxyethyl-
hydrazine has been postulated to be an intermediate in the activation of AOZ into a 
MAO-inhibiting compound (Stern et al 1967, see Fig. 6.1), and considering the 
mutagenic (Bos et al 1983) and possible carcinogenic (Innés et al 1969) properties of 
the latter compound, and the carcinogenic potency of many other hydrazines (Moloney 
and Prough 1983). Furthermore, the release of AOZ from protein-bound metabolites 
in the stomach, and its subsequent transformation into a reactive metabolite capable 
of binding covalently to protein, might underly the formation of bound metabolites as 
observed in rats, that had been fed with meat from a piglet treated with furazolidone 
(Vroomen et al 1988a). This explanation offers a good alternative for the theory that 
the bound residues in the rat are due to the the release and absorption of reactive 
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thiol-conjugates from the protein of the piglet, which can subsequently bind to the 
protein of the rat (Vroomen et al. 1988b), a mechanism for which no support could be 
obtained in previous studies with pig hepatocytes (Chapter 7). 
In the absence of better information on the properties of AOZ, that can be used for 
determining maximum tolerance levels, the presence of bound residues of furazolidone 
in edible products should be reduced as much as possible. Previously, a withdrawal 
period of 30 days was set in the Netherlands for pigs treated with furazolidone 
(Anonymous 1987), based on the genotoxic and carcinogenic properties of the parent 
compound (Klemencic & Wang, 1978; McCalla, 1983; Food and Drug Administration, 
1976), and the lack of information on the identity and biological properties of protein 
bound metabolites. The results presented in this study support the use of such long 
withdrawal periods (Table 8.2.). The relatively simple method presented in this paper 
may now be helpful in further establishing and controlling adequate withdrawal periods. 
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SUMMARY AND CONCLUDING REMARKS 
The three main objectives of this study were, (1) to investigate the possibility to 
isolate viable hepatocytes from liver samples of pigs, (2) to study their use for 
biotransformation and toxicity studies, and (3) to demonstrate the value of this model, 
in particular in the field of residue toxicology. 
The main result from this study was the fact that hepatocytes can be successfully 
isolated from samples of pig livers obtained at the slaughterhouse, and that the cells 
retained a high viability as demonstrated by parameters like the exclusion of trypan 
blue. Furthermore, the cells were able to attach themselves to untreated culture dishes, 
and to form monolayer cultures, which could be kept alive for at least seven days. 
Even more important was the fact that the cells retained the capability of biotrans-
forming xenobiotics into metabolites that were also observed in vivo. 
Initial studies with suspension cultures (Chapter 3) demonstrated that these cells 
were capable of biotransforming a number of different substrates by very diverse 
pathways, like the deethylation of 7-ethoxy-coumarin and subsequent glucuronidation 
of the product 7-hydroxy-coumarin, the acetylation of sulfadimidine and deacetylation 
of N"-acetyl-sulfadimidine, and the transformation of furazolidone, partly resulting in the 
formation of the open chain cyano-metabolite. In vivo the N"-acetyl metabolite of 
sulfadimidine has been shown to be the only significant metabolite. In the case of 
furazolidone, the only in vivo metabolite identified sofar, is the cyano-metabolite, 
although similar to in vitro it appears to be formed in relatively small amounts. 
In comparison with suspension cultures, monolayer cultures have a number of 
additional advantages, such as the extra viability criterium of the ability of cells to form 
a monolayer, the longer survival of the cells, and the physical separation between the 
cells and the culture medium. However, by the results from studies with hepatocytes 
from other animal-species, it was shown that the prolonged use of monolayer cultures 
is often limited by a decrease in the activity of certain biotransformation enzymes 
(Chapter 1). Therefore, special attention was paid to the possible existence and impact 
of this phenomenon in monolayer cultures of pig hepatocytes, by incubating cells with 
the substrates described above. There was a decrease in absolute levels of cytochrome 
P-450, and in the cytochrome P-450 related deethylation of 7-ethoxy-coumarin. In the 
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case of the N4-acetylation of sulfadimidine, an increase in the activity was observed, 
which was paralleled and possibly caused by a decrease in the reverse activity, i.e. the 
deacetylation of the N"-acetyl metabolite. Furazolidone was converted relatively slowly 
during the first 24 h of the monolayer cultures, as compared to the next 72 h, where 
little variation was observed. Therefore, the effect of ageing apparently varies from one 
compound to another, which may be a strong argument for the use of freshly isolated 
cells. However, a recovery period may allow the cells to recover from the isolation 
procedure. It was e.g. shown that intracellular levels of reduced glutathione (GSH) were 
sometimes very low in freshly isolated cells, but increased rapidly during the first 
24-48 h of the cultures (Chapters 3, 5 and 7). Since GSH has an important role in 
protecting the cells against the adverse effects of many xenobiotics (see also Chapter 7), 
freshly isolated cells may be oversensitive to the toxic properties of certain drugs. 
Further experiments were therefore primarily performed with monolayer cultures, after 
a 24 h recovery period. 
In the case of the anabolic steroid ß-nortestosterone, a substantial change in the 
metabolite pattern, due to the ageing of the cells, was only observed after 72 h 
(Chapter 4). This compound was rapidly oxidized by the cells, initially resulting in the 
formation of norandrostenedione, which was than hydroxylated and glucuronidated at 
its C-15 position. No differences were observed between cells from female and 
castrated male pigs, which is consistent with the "feminizing" effect of castration. In the 
absence of essential information on the in vivo biotransformation of this compound, 
three pigs were injected with the hormone. The fact that the two main metabolites 
could subsequently be identified in the urine of these pigs, clearly demonstrates the 
value of the model for the identification of important metabolites. 
The high viability of the cells made the model very useful for toxicity studies. In 
Chapter 5, a number of different cellular functions were chosen as end-points to study 
and compare the effects of five different nitrofuran drugs. These parameters, i.e. the 
leakage from the cells of the cytosolic enzyme lactate dehydrogenase (LDH), due to 
membrane damage, the incorporation of "C-leucine into newly synthesized proteins, the 
intracellular levels of reduced and oxidized glutathione, and the metabolism of pyruvate, 
could all be measured easily and reproducibly. Using these parameters, clear similarities 
but also differences were observed between the drugs. At the highest dose levels there 
was a small but significant increased leakage of LDH, especially in the case of 
nitrofurantoin. With all drugs, this was accompanied by a decrease in intracellular 
LDH-levels, that could only partly be accounted for by the loss into the medium. This 
might be explained by the decreased incorporation of ,4C-labelled leucine into proteins 
after exposure to all nitrofurans. This inhibiting effect was especially clear on the 
proteins excreted into the medium. Furthermore, incubation with all nitrofurans resulted 
in an increase in intracellular levels of oxidized glutathione (GSSG), which is in 
agreement with the fact that reduction of the nitro-group of these drugs may result in 
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redox-cycling and the subsequent formation of H202 (Fig. 7.1). Somewhat unexpected 
was the fact that, with the exception of nitrofurantoin, there was no decrease in 
intracellular GSH levels. The most sensitive, and possibly most specific parameter, was 
the inhibition of the pyruvate metabolism by all nitrofurans, except nitrovin, as 
concluded from the accumulation of pyruvate and lactate in the medium. In a more 
detailed study with furazolidone, it was shown that the cells recovered only very slowly 
from the latter effect, which is consistent with previous results from in vivo studies. 
These and some of the other effects, might underlie some of the many adverse effects 
reported in both human and animal patients treated with these type of drugs, like e.g. 
the increased plasma levels of pyruvate and lactate. However, in general such in vivo 
information was too limited to completely validate the model at this point, and further 
in vivo studies should be carried out for this purpose. Nevertheless, the study 
demonstrates the value of the model for studying the toxicity and underlying 
mechanisms of xenobiotics. 
In Chapter 6, another specific toxic effect of furazolidone observed in vivo but not 
in vitro, i.e. the inhibition of the enzyme monoamine oxidase (MAO), was studied in 
more detail. In this study, intact cells were used instead of homogenates for measuring 
the MAO-inhibition, thereby offering the advantage of the presence of an intact 
biotransformation potential. Using p-tyramine as a substrate for the MAO-enzymes, the 
effect of the known inhibitors clorgyline and iproniazid could easily be measured. 
Incubation of hepatocytes with furazolidone resulted in a thusfar unknown reversible 
MAO-inhibition. However, the irreversible inhibition reported in in vivo studies, was 
only observed after incubation of cells with 3-amino-2-oxazolidinone (AOZ), the side 
chain of furazolidone, and the proposed metabolite ß-hydroxyethylhydrazine (Fig. 6.1). 
The time-related increase in the MAO-inhibition by 3-amino-2-oxazolidinone, indicated 
that the compound must be transformed into a metabolite capable of inactivating 
MAO-enzymes irreversibly, possibly by covalent binding. The results from this study are 
in support of the hypothesis of Stern et al, with regard to the role of the side-chain in 
the MAO-inhibition observed in vivo. 
The great perspectives of the model in the field of residue toxicology are further 
demonstrated in Chapters 7 and 8, where the different features of the model were used 
to obtain more information on the identity and properties of the protein-bound 
metabolites of furazolidone. As a follow-up of the microsomal studies performed by 
Vroomen et al, the role of glutathione in the biotransformation and toxicity of this drug 
was further investigated (Chapter 7). Using "C-labelled furazolidone, the drug was 
shown to be extensively transformed by monolayer cultures, resulting in the formation 
of the cyano metabolite, a large number of more hydrophilic compounds, and protein-
bound metabolites. These results are in agreement with previous in vivo studies, and 
confirm the value of the model. 
Similar to the studies described in Chapter 5, furazolidone had apparently no effect 
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on intracellular GSH-levels. However, both by inhibition of the GSH-synthesis and by 
labelling of the intracellular GSH with 35S, it could be demonstrated that exposure of 
cells to furazolidone actually resulted in an increased loss of intracellular GSH, but that 
this effect was compensated for by an increased GSH synthesis. The increased GSH 
loss was accompanied by increased medium concentrations of GSSG and a second 
compound, most likely formed after excretion of GSH by the cells. However, no 
evidence could be obtained for the formation and excretion of the glutathione-conjugate 
of furazolidone that was previously detected in microsomal incubations. Similarly, the 
presence of unstable protein-bound thiol conjugates could not be demonstrated. 
Therefore, it seems unlikely that these type of metabolites are responsible for the 
previously observed high bioavailability of protein-bound metabolites in rats, that had 
been fed with muscle tissue of a piglet treated with furazolidone, as well as the 
subsequent formation of protein-bound metabolites in tissues of those rats. 
An alternative explanation for this observation was given in Chapter 8, where the 
time- and dose-related formation of protein-bound metabolites of furazolidone in pig 
hepatocytes was studied in more detail. Furthermore, by using 14C-furazolidone, either 
labelled in the nitrofuran or in the oxazolidinone part of the molecule, strong 
indications were obtained for the presence of both parts of the parent drug in protein-
bound metabolites. Therefore, a new method for the detection of these type of 
compounds was developed, based on the release and detection of the 3-amino-2-
oxazolidinone side-chain of furazolidone. Using this relatively simple method it was 
demonstrated that at least 75% of the metabolites bound to protein of hepatocytes still 
contained this side-chain, showing for the first time that at least part of these 
metabolites resemble the original structure of the parent compound. With the same 
method 3-amino-2-oxazolidinone could be released from 15-25% of the protein-bound 
metabolites present in liver samples from piglets treated with 14C-furazolidone, even 
after a storage period of seven years at -40 °C. 
The difference between in vivo and in vitro studies, with respect to the fraction of 
bound metabolites from which AOZ can be released, might be ascribed to the role of 
the stomach in the in vivo biotransformation of furazolidone. The acid hydrolysis of the 
azomethine bond of furazolidone may result in the release of 3-amino-2-oxazolidinone 
(Fig. 9.1), which is subsequently absorbed and metabolized into a compound, possibly 
via ß-hydroxyethylhydrazine (Fig. 6.1), capable of binding covalently to proteins (type I). 
As pointed out in Chapter 6, there are strong indications that this mechanism underlies 
the irreversible type of MAO-inhibition. The bound metabolites observed in vivo would 
therefore partly be related to the formation of a reactive intermediate from the side-
chain (type I), and partly to intermediates containing an intact AOZ side-chain, because 
they are formed by the reduction of the nitro-group (type II), as shown in Fig. 7.1. In 
the case of incubation of furazolidone with microsomes and hepatocytes at pH 7, it 
seems likely that the formation of bound metabolites can be ascribed to the latter type 
of reactive intermediates (type II). Since AOZ can only be released from this type of 
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Fig. 9.1 Schematic presentation of the possible mechanisms underlying the formation of bound 
residues of furazolidone in the target animal and possible fate of bound metabolites in the 
consumer of products containing such residues. 
metabolites, this difference could explain the discrepancy with in vivo. At this point it 
cannot be excluded that a similar mechanism, i.e. the acid hydrolysis of the azomethine 
bond and subsequent biotransformation of AOZ, is responsible for the high 
bioavailability of bound residues and the formation of new bound metabolites as 
observed in rats after consumption of meat from pigs treated with furazolidone. 
This is the first time that, based on experimental data, strong indications are 
obtained for the fact that bound residues of a compound may still exert a toxic action, 
once orally absorbed by the consumer. Therefore, the presence of such protein-bound 
residues should be reduced as much as possible, and adequate analytical methods, such 
as presented in this study, should be developed in order to control this. It should be 
mentioned, that the possible toxic potential of bound-metabolites of other compounds, 
depends very much on the structure and properties of those compounds, and should 
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therefore be considered from one case to another. In general these results subscribe 
the importance of including metabolites in the risk-assessment of compounds used in 
veterinary practice. 
The results of the present study clearly demonstrate the large potential of in vitro 
models with hepatocytes from large domestic animals. Regarding the high costs and 
special requirements that go along with in vivo studies with larger animals, the use of 
such in vitro models may eventually not only result in a reduction in the number of 
animals used for experiments, but even more, offer an improved chance to obtain the 
more detailed information on the species-related biotransformation and toxicity of 
xenobiotics, as requested more and more by regulatory authorities. In general, the use 
of such models may therefore contribute to the development of new drugs with a 
minimal health risk for the consumer and less adverse effects for the animal. 
Furthermore, this study shows that knowledge on the identity and nature of 
metabolites, may result in the development of new analytical methods, that can be used 
to control the sound use of drugs and growth-promoting agents in veterinary practice. 
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De drie hoofddoelstellingen van deze studie waren, (1) het onderzoeken van de 
mogelijkheid om levensvatbare hepatocyten te isoleren uit een stuk varkenslever, (2) 
het bestuderen van de mogelijkheden van dit model voor biotransformatie en 
toxiciteitsonderzoek en (3) het aantonen van de waarde van dit soort modellen, met 
name voor residu-toxicologisch onderzoek. 
Een essentieel resultaat van dit onderzoek is het feit dat het mogelijk is om 
hepatocyten te isoleren uit een stuk varkenslever verkregen via het slachthuis en dat 
deze cellen een hoge levensvatbaarheid bezitten, zoals onder meer blijkt uit de trypaan 
blauw exclusie test. Verder bleken de cellen in staat om zich te hechten aan 
onbehandelde weefselkweekplaten en zodoende monolayers te vormen die tenminste 
gedurende een periode van zeven dagen in leven konden worden gehouden. 
Nog belangrijker was het feit dat de cellen hun vermogen behielden om xenobiotica 
om te zetten in metabolieten die ook bij in vivo studies zijn aangetroffen. 
Inleidende studies met suspensie cultures (Hoofdstuk 3), lieten zien dat de cellen in 
staat waren om een aantal verschillende stoffen om te zetten langs zeer verschillende 
biotransformatie routes, zoals de deëthylering van 7-ethoxy-coumarine en glucuronidering 
van het hierbij gevormde 7-hydroxy-coumarine, de acetylering van sulfadimidine en 
deacetylering van N4-acetyl-sulfadimidine en de biotransformatie van furazolidon, 
gedeeltelijk resulterend in de vorming van de cyano-metaboliet. Uit in vivo studies met 
sulfadimidine is gebleken dat de N"-acetyl metaboliet de enige metaboliet van betekenis 
is. In het geval van furazolidon is de enige geïdentificeerde in vivo metaboliet de cyano-
metaboliet, die echter net als in vitro in relatief kleine hoeveelheden gevormd lijkt te 
worden. 
In vergelijking met suspensie cultures hebben hepatocyten in monolayer cultures een 
aantal aanvullende voordelen. Zo vormt het vermogen van de cellen om een monolayer 
te vormen een extra criterium voor de kwaliteit van de cellen, kunnen de cellen 
gedurende een aantal dagen in leven worden gehouden en is er sprake van een 
duidelijke scheiding tussen de cellen en het kweekmedium. Echter, uit studies met 
hepatocyten van andere dieren is gebleken dat de mogelijkheden voor het langdurige 
gebruik van monolayer cultures veelal worden beperkt door de achteruitgang van de 
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activiteit van bepaalde bij de biotransformatie betrokken enzymen (Hoofdstuk 1). 
Daarom is bij varkenshepatocyten ook aandacht besteed aan het bestaan en de 
mogelijke consequenties van dit verschijnsel, door bestudering van de biotransformatie 
van eerder genoemde stoffen. Er werd een achteruitgang waargenomen in de absolute 
gehaltes van het cytochroom P-450 en de daaraan gerelateerde deèthylering van 
7-ethoxy-coumarine. In het geval van de N4-acetylering van sulfadimidine, werd er een 
toenemende activiteit gevonden, die mogelijk verklaard kan worden uit de achteruitgang 
in de tegengestelde reactie, namelijk de deacetylering van de N"-acetyl metaboliet. 
Furazolidon werd relatief langzaam omgezet gedurende de eerste 24 uur, in vergelijking 
met de volgende 72 uur, waar nauwelijks enige variatie werd waargenomen. 
Samenvattend kan gezegd worden, dat het effect van het ouder worden van de cultures 
varieert per stof, hetgeen ervoor pleit om zo mogelijk vers geïsoleerde cellen te 
gebruiken. Echter, het inlassen van een zekere wachtperiode biedt de cellen de 
gelegenheid om zich te herstellen van de isolatie. Zo is in deze studie gebleken dat het 
intracellulaire gehalte van het gereduceerde glutathion (GSH) in vers geïsoleerde cellen 
veelal erg laag was en vervolgens sterk toenam gedurende de eerste 24 tot 48 uur na 
het in kweek brengen van de cellen (Hoofdstukken 3, 5 en 7). Gezien de belangrijke 
rol van GSH bij de bescherming van de cel tegen de schadelijke effecten van vele 
xenobiotica, waaronder furazolidon (zie Hoofdstuk 7), zouden vers geïsoleerde cellen 
weleens overgevoelig kunnen zijn voor zulke stoffen. Daarom werd ervoor gekozen om 
experimenten uit te voeren met 24 uur oude monolayer cultures. 
Bij studies met het anabole steroïd hormoon ß-nortestosteron, werd o.i.v. de leeftijd 
van de cultures, pas een wezenlijke verandering in het metabolietpatroon waargenomen 
na 72 uur (Hoofdstuk 4). Deze stof werd door de cellen relatief snel geoxideerd tot het 
norandrosteendion, dat vervolgens werd gehydroxyleerd en geglucuronideerd op de C-15 
plaats. Er werden geen verschillen waargenomen tussen cellen geïsoleerd van levers van 
zeugen en borgen, geheel in overeenstemming met het zogenaamde "feminizing" effekt 
van castratie. Omdat de voor validatie benodigde informatie omtrent de biotransformatie 
van ß-nortestosteron bij varkens ontbrak, werden drie dieren behandeld met deze stof. 
Het feit dat de twee hoofdmetabolieten vervolgens konden worden aangetoond in de 
urine van deze dieren bevestigt de waarde van dit model bij het opsporen en 
identificeren van belangrijke metabolieten. 
Mede dankzij de hoge levensvatbaarheid van de cellen bleek het model uitermate 
geschikt te zijn voor toxiciteitsstudies. In de experimenten beschreven in Hoofdstuk 5 
werden een aantal functies van de cellen uitgekozen, waarmee vervolgens de effekten 
van vijf verschillende nitrofuranen werden bekeken en vergeleken. Deze eindpunten, 
namelijk de lekkage van het cytosol enzym lactaat-dehydrogenase (LDH) door 
beschadiging van de celmembraan, de inbouw van 14C-leucine in nieuw gesynthetiseerde 
eiwitten, de intracellulaire concentraties van gereduceerd en geoxideerd glutathion en 
het pyruvaat metabolisme, konden allen op eenvoudige en reproduceerbare wijze worden 
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gemeten. Bij de effekten van de diverse nitrofuranen op deze eindpunten konden zowel 
overeenkomsten als verschillen worden waargenomen. Bij de hoogste concentraties was 
er een kleine maar significante verhoging in de LDH-lekkage meetbaar, vooral in het 
geval van nitrofurantoïne. Bij alle stoffen ging dit gepaard met verlaagde LDH-activiteit 
in de cellen, die echter niet volledig kon worden toegeschreven aan het verlies naar het 
medium. Dit zou ten dele verklaard kunnen worden door de verlaagde eiwit-synthese, 
die bij blootstelling aan alle nitrofuranen werd waargenomen. Overigens was het 
remmend effekt vooral duidelijk wanneer gekeken werd naar eiwitten die werden 
uitgescheiden in het medium. Na blootstelling aan alle nitrofuranen werd er een 
verhoging van de intracellulaire gehaltes aan geoxideerd glutathion (GSSG) gemeten, 
geheel overeenkomstig het feit dat de reductie van de nitrogroep van dit soort stoffen 
veelal leidt tot een zogenaamde redox-cycling en daaraan gepaard de vorming van 
waterstofperoxyde (Fig. 7.1). Daarmee in tegenspraak lijkt de waarneming dat er, met 
uitzondering van nitrofurantoïne, geen verlaging van de GSH niveaus optrad. De meest 
gevoelige en wellicht meest specifieke parameter was de remming van het pyruvaat 
metabolisme door alle nitrofuranen, behalve nitrovin, zoals afgeleid uit de ophoping van 
pyruvaat en lactaat in het medium. In een meer gedetailleerde studie met alleen 
furazolidon, bleek dat de cellen zich slechts langzaam herstelden van dit effect, hetgeen 
uit de literatuur ook bekend was uit in vivo studies. Dit effekt zou evenals sommige van 
de andere gemeten effekten ten grondslag kunnen liggen aan een aantal van de vele 
bijwerkingen die zijn waargenomen bij zowel mensen als dieren na behandeling met 
nitrofuranen, zoals de verhoogde plasma niveaus van pyruvaat en lactaat. Echter, over 
het algemeen was die informatie te beperkt om het model volledig te valideren en 
verdere in vivo studies zouden hiervoor moeten worden uitgevoerd. Desalniettemin 
bevestigt deze studie de waarde van het model voor het bestuderen van de toxiciteit 
van stoffen en de onderliggende werkingsmechanismen. 
In Hoofdstuk 6 werd een ander specifiek effect van furazolidon bestudeerd, namelijk 
de remming van het enzym monoamine oxidase (MAO), zoals waargenomen bij mensen 
en dieren. Bij deze studie werden voor het meten van de MAO-remming intakte cellen 
gebruikt in plaats van weefselhomogenaten, hetgeen het voordeel biedt dat er een 
volledig metaboliserend systeem aanwezig is. Met gebruik van p-tyramine als substraat 
voor MAO-enzym(en), kon de remming door bekende remmers als clorgyline en 
iproniazide eenvoudig worden gemeten. Incubatie van cellen met furazolidon leidde tot 
een tot nog toe onbekende volledig omkeerbare MAO-remming. Echter, het irreversibele 
type remming, zoals beschreven in vivo, werd alleen waargenomen na blootstelling van 
de cellen aan 3-amino-2-oxazolidinon (AOZ), de zijketen van furazolidon en 
ß-hydroxyethylhydrazine, een veronderstelde metaboliet bij dit proces (Fig. 6.1). De 
tijdsafhankelijke toename in de MAO-remming door 3-amino-2-oxazolidinon, suggereerde 
dat deze verbinding eerst moet worden omgezet in een metaboliet die in staat is om 
de MAO-enzymen irreversibel te remmen, mogelijk door covalente binding. Daarmee 
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ondersteunen de resultaten van dit onderzoek de hypothese van Stern et al. (Fig. 6.1), 
waarin de zijketen van furazolidon verantwoordelijk wordt gehouden voor het 
irreversibele type MAO-remming. 
De grote voordelen van het model voor residu-toxicologisch onderzoek werden verder 
aangetoond in Hoofdstuk 7 en 8, waar de diverse mogelijkheden van het model werden 
benut om meer inzicht te verkrijgen in de identiteit en eigenschappen van eiwit-
gebonden metabolieten van furazolidon. Als vervolg op de microsomale studies 
uitgevoerd door Vroomen et al, werd in eerste instantie gekeken naar de invloed van 
glutathion op de biotransformatie en toxiciteit van furazolidon (Hoofdstuk 7). Met 
behulp van 14C gelabeld furazolidon kon worden aangetoond dat de afbraak van de stof 
door de cellen resulteert in de vorming van de cyano metaboliet, een groot aantal meer 
polaire metabolieten en eiwit-gebonden metabolieten. Deze resultaten zijn geheel in 
overeenstemming met die van in vivo studies en bevestigen nogmaals de experimentele 
waarde van het model. 
Zoals eerder waargenomen (Hoofdstuk 5), had furazolidon ogenschijnlijk geen invloed 
op de intracellulaire GSH concentratie. Door remming van de GSH-synthese alsmede 
door labeling van GSH met 35S, kon echter worden aangetoond dat blootstelling van 
cellen aan furazolidon wel degelijk leidde tot een verlies van GSH, maar dat dit verlies 
door de cellen werd gecompenseerd middels een verhoogde synthese van GSH. Het 
verhoogde verlies van GSH ging gepaard met verhoogde medium concentraties van 
GSSG en een tweede stof, mogelijk gevormd na uitscheiding van GSH door de cellen. 
Echter, de vorming en uitscheiding van het glutathion-conjugaat dat eerder werd 
gevonden bij microsomale incubaties, kon niet worden bevestigd. Zo werd er ook geen 
enkel bewijs gevonden voor de aanwezigheid van instabiele eiwitgebonden thiol-
conjugaten. Daardoor lijkt het onwaarschijnlijk dat dit soort metabolieten verantwoorde-
lijk is voor de eerder waargenomen hoge biologische beschikbaarheid van eiwit-gebonden 
metabolieten in ratten, die waren gevoerd met vlees van een met furazolidon behandeld 
big, alsmede de vorming van gebonden metabolieten in die ratten. 
Op grond van de resultaten beschreven in Hoofdstuk 8 werd er een alternatieve 
verklaring opgesteld voor bovengenoemde waarneming. Daarin werd allereerst een dosis-
en tijdsafhankelijke vorming van eiwit-gebonden metabolieten van furazolidon gevonden. 
Daarbij werden er door gebruik te maken van twee verschillend gelabelde preparaten 
van furazolidon (14C-label in nitrofuraan- of in oxazolidinonring) duidelijke aanwijzingen 
verkregen voor de aanwezigheid van beide gedeelten van de moederstof in dit type 
metabolieten. Naar aanleiding hiervan, werd er een nieuwe methode ontwikkeld voor 
het aantonen van gebonden metabolieten van furazolidon, gebaseerd op het vrijmaken 
en detecteren van de 3-amino-2-oxazolidinon zijketen. Met behulp van deze relatief 
eenvoudige methode kon vervolgens worden aangetoond dat tenminste 75% van de 
metabolieten die gebonden waren aan het eiwit van hepatocyten, deze zijketen bevatte, 
waarmee voor de eerste keer werd aangetoond dat in elk geval een deel van de 
gebonden metabolieten een zekere mate van verwantschap vertoont met de moederstof. 
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Fig. 10.1 Schematische weergave van het mechanisme dat mogelijk ten grondslag ligt aan de 
vorming van gebonden residuen van furazolidon in het doeldier en de mogelijke lotgevallen van 
gebonden residuen na opname door de consument. 
Met diezelfde methode kon de zijketen ook worden vrijgemaakt van 15-25% van de 
gebonden metabolieten in levermonsters van biggen, behandeld met furazolidon, zelfs 
na opslag gedurende zeven jaar bij -40 °C. 
De verschillen tussen in vivo en in vitro studies, voor wat betreft de fracties gebonden 
metabolieten waarvan de zijketen kan worden vrijgemaakt, kunnen wellicht worden 
toegeschreven aan de rol van de maag bij de biotransformatie van furazolidon in het 
dier; door zure hydrolyse van de azomethine band in het furazolidon-molecule zou 
3-amino-2-oxazolidinon kunnen worden gevormd (Fig. 10.1), dat vervolgens wordt 
geabsorbeerd en omgezet, mogelijk via het ß-hydroxyethylhydrazine (Fig. 6.1), in een 
stof die zich kan binden aan eiwitten (type I). Zoals beschreven in Hoofdstuk 6 zijn er 
sterke aanwijzingen dat dit mechanisme ten grondslag ligt aan de irreversibele MAO-
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remming. De gebonden metabolieten in vivo zouden derhalve deels kunnen worden 
toegeschreven aan een reactieve verbinding afkomstig van de zijketen (type I) en deels 
aan reactieve verbindingen gevormd door reductie van de nitro-groep (type II), waarbij 
dus de zijketen intakt blijft (zie Fig. 7.1). In het geval van incubaties van furazolidon 
met microsomen en hepatocyten bij pH 7, lijkt het waarschijnlijk dat er slechts sprake 
is van de vorming van het laatste type gebonden metabolieten (type II). Aangezien 
alleen van deze metabolieten de AOZ zijketen kan worden vrijgemaakt, zou hiermee 
het verschil met in vivo verklaard kunnen worden. Het kan niet worden uitgesloten dat 
een soortgelijk mechanisme, namelijk de zure hydrolyse van de azomethine band en het 
activeren van het daarbij vrijkomende AOZ, verantwoordelijk is voor de hoge biologische 
beschikbaarheid van gebonden residuen en de hernieuwde vorming van gebonden 
metabolieten in ratten, gevoerd met vlees van een met furazolidon behandelde big. 
Dit is de eerste keer dat aan de hand van concrete resultaten aannemelijk kan 
worden gemaakt dat gebonden metabolieten van een stof nadelige effecten kunnen 
veroorzaken na opname door de consument. Derhalve is het van groot belang om de 
aanwezigheid van dergelijke residuen zoveel mogelijk te beperken en om analytische 
detectie methoden te ontwikkelen voor de controle hierop, zoals beschreven in dit 
proefschrift. Daarbij moet erop gewezen worden dat de potentiële toxiciciteit van 
gebonden residuen van andere stoffen sterk afhankelijk zal zijn van de structuur en 
eigenschappen van die stoffen en derhalve van geval tot geval bekeken dient te worden. 
Met deze studie wordt wel nog eens het belang van het betrekken van metabolieten 
in de risico-beoordeling van in de landbouw gebruikte stoffen onderstreept. 
Samenvattend kan gesteld worden dat de resultaten van dit onderzoek de vele 
mogelijk-heden laten zien van in vitro modellen met hepatocyten van grote landbouw-
huisdieren. Gezien de hoge kosten en speciale voorzieningen die verbonden zijn aan 
studies met grotere dieren, zal het gebruik van dit soort in vitro modellen niet alleen 
leiden tot een reductie van het aantal voor experimenten gebruikte dieren, maar ook 
de mogelijkheden vergroten om de gedetailleerde gegevens te verzamelen omtrent de 
voor dit soort dieren specifieke biotransformatie en toxiciteit van stoffen, zoals die meer 
en meer gevraagd wordt door overheidsinstanties. In het algemeen kunnen dergelijke 
modellen bijdragen tot de ontwikkeling van nieuwe middelen met een minimaal risico 
voor de consument en weinig bijwerkingen bij het doeldier. 
Zoals verder uit deze studie blijkt, kan een beter inzicht in de identiteit en 
eigenschappen van metabolieten, tevens leiden tot de ontwikkeling van nieuwe 
analytische methoden voor de controle op een goede toepassing van hulpstoffen in de 
dierlijke produktiesector. 
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